



Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada

Marco Solmi, Christoph U. Correll, Tommaso Boldrini, Jean M. Addington, Edgar Barbezat, Stella Bassetto, Andreas Bechdolf, Dan Devoe, Joseph Firth, Paolo Fusar-Poli, Ary Gadelha, Renan Göksal, Matcheri Keshavan, Eoin Killackey, Nikolaos Koutsouleris, Gabriele Lo Buglio, Mirko Manchia, Patrick McGorry, Jai Shah, Helen J. Stain, Philip G. Tibbo, Thomas Hastings, Howard C. Margoless, Nicola Otter, Eduard Vieta, Liang-Jen Wang, Scott W. Woods, Lakshmi N. Yatham, Alison R. Yung, Muhammad Omair Husain, Peter Falkai, Michael Berk & Andre F. Carvalho

To cite this article: Marco Solmi, Christoph U. Correll, Tommaso Boldrini, Jean M. Addington, Edgar Barbezat, Stella Bassetto, Andreas Bechdolf, Dan Devoe, Joseph Firth, Paolo Fusar-Poli, Ary Gadelha, Renan Göksal, Matcheri Keshavan, Eoin Killackey, Nikolaos Koutsouleris, Gabriele Lo Buglio, Mirko Manchia, Patrick McGorry, Jai Shah, Helen J. Stain, Philip G. Tibbo, Thomas Hastings, Howard C. Margoless, Nicola Otter, Eduard Vieta, Liang-Jen Wang, Scott W. Woods, Lakshmi N. Yatham, Alison R. Yung, Muhammad Omair Husain, Peter Falkai, Michael Berk & Andre F. Carvalho (2026) Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada, *The World Journal of Biological Psychiatry*, 27:6, 509-552, DOI: [10.1080/15622975.2026.2651738](https://doi.org/10.1080/15622975.2026.2651738)

To link to this article: <https://doi.org/10.1080/15622975.2026.2651738>



© 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



[View supplementary material](#)



Published online: 27 May 2026.



[Submit your article to this journal](#)



Article views: 1985



[View related articles](#)



[View Crossmark data](#)



[Citing articles: 1 View citing articles](#)



REVIEW ARTICLE



Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada

Marco Solmi^{a,b,c,d†} , Christoph U. Correll^{d,e,f†}, Tommaso Boldrin^{g,h†}, Jean M. Addingtonⁱ, Edgar Barbezat^{c*}, Stella Bassetto^{j,k}, Andreas Bechdolf^{l,m,n}, Dan Devoe^o, Joseph Firth^{p,q}, Paolo Fusar-Poli^{r,s,t}, Ary Gadelha^u, Renan Göksal^v, Matcheri Keshavan^w, Eoin Killackey^{x,y}, Nikolaos Koutsouleris^{z,aa,ab}, Gabriele Lo Buglio^{a,c} , Mirko Manchia^{ac,ad,ae}, Patrick McGorry^{x,y}, Jai Shah^{af,ag}, Helen J. Stain^{ah}, Philip G. Tibbo^{ai,aj,ak}, Thomas Hastings^{al,am}, Howard C. Margolese^{ag,an} , Nicola Otter^{ao}, Eduard Vieta^{ap}, Liang-Jen Wang^{aq} , Scott W. Woods^{ar} , Lakshmi N. Yatham^{as}, Alison R. Yung^{at,au}, Muhammad Omair Husain^{av,aw}, Peter Falkai^{ax,ay,az}, Michael Berk^{at} and Andre F. Carvalho^{at}

^aSCIENCES lab, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ontario, Canada; ^bDepartment of Mental Health, The Ottawa Hospital, Ontario, Canada; ^cOttawa Hospital Research Institute (OHRI), Ottawa; ^dDepartment of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; ^eDepartment of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, USA; ^fDepartment of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, USA; ^gDepartment of Psychology and health sciences, Pegaso Telematic University, Naples, Italy; ^hDepartment of Psychiatry, Faculty of Medicine, University of Ottawa, Ontario, Canada; ⁱDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada; ^jSocial and Cognitive Neuroscience Lab (ScnLab), Mackenzie Presbyterian University, Brazil; ^kInstitute of Psychiatry, University of São Paulo, Brazil; ^lDepartment of Psychiatry, Psychotherapy, and Psychosomatics incorporating FRITZ am Urban and soulspace, Vivantes Hospital am Urban and Vivantes Hospital im Friedrichshain, Berlin, Germany; ^mDepartment of Psychiatry and Psychotherapy, CCM, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; ⁿGerman Center for Mental Health (DZPG), Berlin-Potsdam site, Germany; ^oDepartment of Psychology, Mount Royal University; ^pDivision of Psychology and Mental Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; ^qNICM Health Research Institute, Western Sydney University, Westmead, Australia; ^rDepartment of Brain and Behavioral Sciences, University of Pavia, Italy; ^sEarly Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, UK; ^tOutreach and Support in South-London (OASIS) service, South London and Maudsley (SLaM) NHS Foundation Trust, UK; ^uSchizophrenia Program (PROESQ), Department of Psychiatry and Psychological Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo-SP, Brazil; ^vDepartment of Developmental Psychology and Socialization, University of Padova, Padova, Italy; ^wDepartment of Psychiatry, Harvard Medical School Department of Psychiatry at Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, USA; ^xOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia; ^yThe University of Melbourne, Melbourne, Australia; ^zMax Planck Institute for Psychiatry, Ludwig-Maximilian-University, Munich, Germany; ^{aa}Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany; ^{ab}Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; ^{ac}Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari; ^{ad}Unit of Clinical Psychiatry, Department of Medical Specialties, University Hospital Agency of Cagliari; ^{ae}Department of Pharmacology, Dalhousie University, Halifax, Canada; ^{af}Douglas Research Centre, Montreal, Canada; ^{ag}Department of Psychiatry, McGill University, Montreal, Canada; ^{ah}Professor of Psychology, TIPS Centre for Clinical Research in Psychosis, Stavanger, Norway; ^{ai}Department of Psychology and Neuroscience, Dalhousie University, Halifax, Canada; ^{aj}Department of Psychiatry, Dalhousie University, Halifax, Canada; ^{ak}Nova Scotia Health Authority, Halifax, Canada; ^{al}Department of Psychiatry, McMaster University, Hamilton, Canada; ^{am}Department of Psychiatry, University of Toronto, Toronto, Canada; ^{an}McGill University Health Centre, Montreal, Canada; ^{ao}EPI Canada, Canada; ^{ap}Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; ^{aq}Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung city, Taiwan; ^{ar}Department of Psychiatry, Yale University New Haven Connecticut, USA; ^{as}Mood Disorders Centre, University of British Columbia, Vancouver, Canada; ^{at}Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health, Australia; ^{au}School of Health Sciences, University of Manchester, UK; ^{av}Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada; ^{aw}Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; ^{ax}Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany; ^{ay}Max Planck Institute of Psychiatry, Munich, Germany; ^{az}German Center for Mental Health (DZPG), Partner site Munich/Augsburg, Augsburg, Germany

CONTACT Marco Solmi msolmi@toh.ca SCIENCES lab, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ontario, Canada

[†]These authors have contributed equally to this work and share first authorship

^{*}lived experience board member of the hatching ideas lab

Supplemental data for this article can be accessed online at <https://doi.org/10.1080/15622975.2026.2651738>.

© 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

ABSTRACT

Objective: To prepare evidence-based guidelines on psychosis prevention.

Methods: We reviewed evidence on risk factors for/age at onset of psychosis, tools to assess clinical high-risk of psychosis (CHR-P), transition rates, risk calculation/ethical considerations around risk communication, CHR-P biological/clinical correlates, efficacy/cost-effectiveness of interventions/psychosis prevention services. The World Federation of Societies of Biological Psychiatry framework was used to grade evidence regarding interventions/services, elaborating guidelines with evidence-/consensus-based clinical recommendations to prevent psychosis in CHR-P subjects.

Results: At the service organisation level, (i) psychosis indicated prevention services might be implemented in close collaboration with early intervention services for psychosis to minimise duration of untreated illness, (ii) intake age criteria should be between 14 to 35, (iii) services should allow access to persons with cannabis use disorder. At the assessment and risk communication level, in clinical settings: (iv) staff in mental health services should be trained in administering/rating CHR-P assessment tools, (v) administer them, (vi) be trained in using/interpreting risk calculators, and (vii) in communicating risk, (viii) only use validated risk calculators, keeping a human-to-human interaction. Also, (ix) prevention services should assess comorbid mental disorders. At the intervention level: (x) staff should offer treatment for abstinence from cannabis, (xi) offer evidence-based treatment for comorbid mental disorders, and (xii) offer treatment for CHR-P based on patient preference, following the 'first do no harm' principle.

Conclusions: Prevention services should be implemented, including interventions for cannabis use, reducing the duration of untreated psychosis, and treating comorbid mental disorders.

ARTICLE HISTORY

Received 10 October

2025

Revised 17 March 2026

Accepted 19 March 2026

KEYWORDS

Clinical guidelines;
psychosis; prevention;
clinical high risk for
psychosis; schizophrenia

1. Background

Psychotic disorders, such as schizophrenia, are associated with considerable burden (Solmi, Seitidis, et al. 2023) and reduced life expectancy compared with the general population (Correll et al. 2022) due to suicide, but most frequently as a result of co-occurring physical conditions (Stubbs et al. 2016; Correll et al. 2017). The reduced life expectancy in people with schizophrenia is aggravated by the low quality of physical healthcare that people with schizophrenia receive (Solmi, Firth, et al. 2020; Solmi, Fiedorowicz, et al. 2021). In the absence of early interventions, schizophrenia often has a chronic course, severely impacting patients' functioning and their families' environment (Kahn et al. 2015). Effective treatments for schizophrenia are available, with antipsychotics being the cornerstone of treatment at all stages of the disease (Solmi et al. 2017; Correll, Rubio, et al. 2018; McCutcheon et al. 2025). Well-evidenced psychosocial interventions should augment pharmacological treatment, in particular within early intervention services (Correll, Galling, et al. 2018). These include family interventions (for the early stages of schizophrenia), as well as cognitive behavioural therapy (CBT), cognitive remediation therapy, and individual placement and support (Solmi, Croatto, et al. 2023). While considered a new treatment modality, brain stimulation is also effective for schizophrenia, yet they are not first-line treatments (Rosson et al. 2022). Lifestyle interventions are increasingly becoming accepted and recommended (Gurusamy et al. 2018; Stubbs et al. 2018; Firth et al. 2020). Despite

the several treatment options, none of these are disease-modifying. Hence, interventions that prevent or delay the onset of schizophrenia are needed, especially considering that the duration of untreated psychosis has been associated with poorer medium and long-term outcomes (Howes et al. 2021).

While prevention has been largely implemented in other branches of medicine, it is only recently being applied to mental health care (Arango et al. 2018; Kotlicka-Antczak et al. 2020; Fusar-Poli, Correll, et al. 2021; Estradé et al. 2022). Within mental health, many studies have focused on the indicated prevention of psychosis, mainly in subjects presenting psychotic symptoms that do not meet the intensity or duration criteria for a Diagnostic and Statistical Manual of Mental Disorders (DSM)- or International Classification of Diseases (ICD)- defined psychotic disorder. The presence of subthreshold psychotic symptoms has been defined as an ultra-high or clinical high-risk (UHR/CHR) state, and has been introduced more than 25 years ago in Melbourne, Australia (Yung et al. 2005). Currently, evidence on the possibility of preventing psychosis with specific interventions has been conflicting (Mei et al. 2021; Fusar-Poli, Radua, et al. 2022), and has mainly focused on subjects meeting criteria for CHR of psychosis (CHR-P), who comprise the majority of those ultimately developing a psychotic disorder (Shah et al. 2017; Benrimoh et al. 2024).

The following guidelines provide a comprehensive overview on risk factors for psychosis, the definition and tools to assess CHR-P status, its biological

correlates and comorbid mental disorders, the literature around risk of transition from CHR-P to psychosis and around additional outcomes in CHR-P. We also reviewed literature around individual randomised controlled trials (RCTs) testing interventions to prevent psychosis, (network) meta-analyses pooling results of these RCTs, and finally observational or simulation studies reporting on the clinical and cost-effectiveness outcomes of psychosis prevention services. Recommendations for the indicated prevention of psychosis in subjects meeting CHR-P criteria were made, based on consensus, on the evaluation of RCTs and evidence regarding psychosis prevention services according to the World Federation of Societies of Biological Psychiatry (WFSBP) guidance for preparing clinical guidelines (Hasan et al. 2019).

2. Methods

We summarised available evidence adopting several strategies including meta-umbrella, umbrella, systematic reviews, or relying on previous systematic evidence synthesis recently completed, on a set of a-priori selected clinically relevant areas related to prevention of psychosis. Starting from the literature knowledge of authors, we identified relevant reviews, and updated the search to 19/09/2024 if the most updated evidence synthesis publication was published before September 2022 (more than two years old), prioritising meta-umbrella over umbrella and systematic reviews, and following the same methodology of the most updated review (e.g. an updated umbrella review for

(meta-) umbrella reviews, an updated systematic review for systematic reviews). We chose September 2022, i.e. two years, for feasibility considerations given the breadth of this evidence synthesis. Where no previous evidence synthesis was available, we conducted one, with three exceptions. First, we did not update reviews that included over 100 epidemiologic studies, since we anticipated that adding few studies would have not been likely to materially change results. Second, we did not conduct systematic reviews to identify the most frequently used psychometric tools to assess CHR-P, given the robust expertise of the authors on this subject (i.e. the tools are already known). Third, we did not conduct a systematic review for ethical considerations around the risk in assessing and communicating risk in psychosis prediction, since the subject would not easily lend itself to quantitative evidence syntheses. Instead, we leveraged the report of a recent workshop completed by experts in the area, well representing the multifaceted set of considerations around ethics and risk prediction. We then graded evidence following the WFSBP guidelines for clinical guidelines development (Hasan et al. 2019).

The a-priori list of topics, search keys, study selection flows, as well as methodological framework used for guideline preparation are detailed in the [supplementary material](#), and in [Table 1](#). The approach followed to review literature on each specific area is summarised below, including the criteria grading credibility of the evidence on risk factors ([Table 2](#)). Finally, each recommendation reached a consensus among co-authors as detailed below.

Table 1. World Federation of Societies of Biological Psychiatry grading system, and grades of recommendations.

Grades of recommendation are based on a synthesis of: i. Level of evidence (see Table 10), and ii. Acceptability (criteria for grading adapted and modified from (AWMF 2012; GRADE 2017), rated 'strong', 'limited', and 'weak'. Acceptability criteria are factors considered are risk-benefit ratio (e.g. adverse effects, interactions), cost-benefit ratio, applicability in the target population, ethical and legal aspects, preferences of service users, practicability.					
The algorithm of evaluating the acceptability to develop GoRs from LoEs is detailed below, for positive and negative recommendations.					
Recommendations for using the intervention			Recommendations for using the intervention		
Strong	1	'A' LoE and GOOD acceptability	Strong	1	Strong negative evidence (LoE -A)
Limited	2	'A' LoE and MODERATE acceptability OR 'B' LoE and GOOD acceptability	Limited	2	Limited negative evidence (LoE -B)
Weak	3	'A' LoE and POOR acceptability OR 'B' LoE and MODERATE/POOR acceptability OR 'C' LoE and GOOD/MODERATE/	Weak	3	Weak negative evidence (LoE -C)
No recommendation possible	4	Insufficient evidence (LoE D) to give recommendations	No recommendation possible	4	Insufficient evidence (LoE D) to give recommendations

Legend. GoR: grade of recommendation; LoE: level of evidence.

Table 2. Risk factors and biomarkers with significant association with psychosis reported in meta-analyses and umbrella reviews, and their credibility according to established criteria (Ioannidis 2009; Fusar-Poli and Radua 2018; Solmi, Dragioti, Croatto, Radua, Borgwardt, Carvalho, Demurtas, Mosina, Kurotschka, Shin, et al. 2021; Solmi, De Toffol, et al. 2023).

Risk factor	k	Association odds ratio	Credibility
<i>Individual medical, psychiatric, psychological factors</i>			
Ultra-high-risk state for psychosis	9	9.32 (4.91–17.32)	Convincing
Cannabis use	18	1.71 (1.47–2.00)	Highly suggestive/Convincing
Poor olfactory identification ability	55	5.26 (NA-NA)	Highly suggestive
Trait anhedonia	44	4.41 (NA-NA)	Highly suggestive
Low premorbid IQ	16	2.13 (NA-NA)	Highly suggestive
Childhood social withdrawal	15	2.91 (NA-NA)	Suggestive
Tobacco use	17	2.34 (1.65–3.33)	Suggestive
Non-right handedness	41	1.58 (1.35–1.86)	Suggestive
Neurological soft signs	8	27.59 (NA-NA)	Weak
Poor olfactory memory ability	2	20 (NA-NA)	Weak
Neuroticism	8	8.76 (NA-NA)	Weak
Epilepsy	4	7.84 (2.87–21.40)	Weak
Harm avoidance	7	5.92 (NA-NA)	Weak
Poor self-directedness	7	5.88 (NA-NA)	Weak
Heavy cannabis use	2	5.17 (3.64–7.36)	Weak
Poor olfactory discrimination ability	8	5.00 (NA-NA)	Weak
Poor extraversion	8	5.00 (NA-NA)	Weak
Poor olfactory hedonic ability	10	4.00 (NA-NA)	Weak
Psychotic-like experiences	4	3.84 (2.55–5.79)	Weak
Poor conscientiousness	7	3.45 (NA-NA)	Weak
Hearing impairment	3	3.15 (1.25–7.95)	Weak
Poor olfactory detection ability	18	3.12 (NA-NA)	Weak
High Self-transcendence	7	3.03 (NA-NA)	Weak
Poor motor function pre-onset of psychosis	4	2.78 (NA-NA)	Weak
Antisocial and externalising behaviour	3	2.39 (NA-NA)	Weak
Poor agreeableness	6	2.38 (NA-NA)	Weak
Delay in walking unsupported	5	2.37 (NA-NA)	Weak
Poor cooperativeness	7	2.33 (NA-NA)	Weak
Hypoalgesia	9	2.31 (NA-NA)	Weak
Poor reward dependence	7	2.17 (NA-NA)	Weak
Poor openness	7	2.04 (NA-NA)	Weak
Delay in standing unsupported	4	1.58 (NA-NA)	Weak
Poor persistence (trait of temperament)	7	1.54 (NA-NA)	Weak
Traumatic brain injury	8	1.49 (1.09–2.05)	Weak
Delay in sitting unsupported	4	1.41 (NA-NA)	Weak
Total A-B ridge count	13	1.32 (NA-NA)	Weak
Delay in holding head up	3	1.26 (NA-NA)	Weak
<i>Biomarkers</i>			
High Serum C-reactive protein	15	2.96 (1.75–5.01)	Suggestive
Low serum brain-derived neurotrophic factor	17	2.94 (1.61–5.55)	Suggestive
High Serum interleukin 6	29	2.61 (1.55–4.40)	Suggestive
High Plasma MDA	4	42.88 (3.15–583.91)	Weak
Low plasma TAS	3	16.67 (6.25–50.00)	Weak
High Serum IL-8	4	10.57 (1.81–61.82)	Weak
High Serum malondialdehyde	17	9.60 (3.27–28.19)	Weak
Low serum 25(OH)D	6	8.33 (2.78–25.00)	Weak
Low serum NGF	8	7.14 (1.18–50.00)	Weak
High Serum DPA	14	7.10 (3.42–14.75)	Weak
High Serum S100B	19	5.81 (3.03–11.17)	Weak
High Serum IL-1 β	11	5.45 (2.09–14.19)	Weak
Impaired glucose tolerance	7	4.55 (2.10–9.84)	Weak
Low serum Zink	9	4.35 (1.33–14.29)	Weak
High Serum prolactin	12	4.26 (1.92–9.45)	Weak
High Serum sIL-2R	9	3.55 (2.00–6.32)	Weak
High Serum LA	16	3.45 (1.67–7.13)	Weak
High Plasma TBARS	12	3.20 (1.51–6.78)	Weak
High Serum glutamate	10	3.17 (1.46–6.90)	Weak
High Serum AA	19	3.16 (1.84–5.43)	Weak
High Serum TNF- α	24	2.80 (1.50–5.21)	Weak
Low Serum ADH	11	2.78 (1.30–5.88)	Weak
High Serum DHA	18	2.52 (1.19–5.35)	Weak
High Serum IL-1RA	4	2.46 (1.07–5.63)	Weak
High Serum TGF- β	6	2.23 (1.29–3.84)	Weak
Low plasma uric acid	4	1.89 (1.13–3.12)	Weak
Serum homocysteine (Per 5 mmol/l increase)	8	1.68 (1.25–2.25)	Weak
Insulin resistance	8	1.68 (1.09–2.59)	Weak
High Serum serine	19	1.66 (1.04–2.66)	Weak
High Serum leptin	28	1.62 (1.14–2.30)	Weak
High Serum morning cortisol	42	1.60 (1.16–2.21)	Weak

(Continued)

Table 2. Continued.

Risk factor	k	Association odds ratio	Credibility
Unsaturated fatty acids supplementation	9	0.59 (0.39–0.89)	Weak
<i>Pregnancy factors</i>			
Famine	3	1.61 (1.51–1.71)	Convincing
Any famine or nutritional deficiency	13	1.40 (1.17–1.68)	Suggestive
Herpes simplex type 2 infection	5	1.35 (1.16–1.58)	Suggestive
Diabetes in pregnancy	2	10.12 (1.84–55.72)	Weak
Polyhydramnios	3	3.05 (1.15–8.06)	Weak
Maternal stress	4	2.40 (1.15–5.01)	Weak
Premature ruptured membranes	4	2.29 (1.38–3.80)	Weak
Threatened premature delivery	2	2.05 (1.02–4.10)	Weak
Pre-pregnancy and pregnancy maternal obesity	4	1.99 (1.26–3.14)	Weak
Uterine atony	3	1.93 (1.35–2.76)	Weak
Suboptimal number of antenatal care visits	4	1.83 (1.42–2.36)	Weak
Antepartum haemorrhage	14	1.63 (1.12–2.38)	Weak
Foetal hypoxia	6	1.63 (1.11–2.40)	Weak
Maternal hypertension	7	1.40 (1.10–1.78)	Weak
Toxoplasma infection	4	1.30 (1.04–1.62)	Weak
Unspecified maternal infection	9	1.27 (1.06–1.53)	Weak
<i>Maternal and paternal factors</i>			
Maternal psychosis	6	7.61 (6.29–9.21)	Highly suggestive
Any maternal psychopathology	9	4.60 (2.74–7.73)	Highly suggestive
Any paternal psychopathology	5	2.73 (2.33–3.19)	Highly suggestive
Three or more previous pregnancies	10	1.30 (1.16–1.45)	Suggestive
Maternal age < 20 years old	22	1.17 (1.07–1.27)	Suggestive
Parental severe mental illness	9	5.94 (2.99–11.79)	Weak
Parental communication deviance	19	5.80 (3.99–8.44)	Weak
Paternal age > 45 years	4	2.36 (1.35–4.11)	Weak
Maternal affective disorder	3	2.26 (1.09–4.70)	Weak
Low paternal socio-economic status	9	1.30 (1.02–1.65)	Weak
Paternal age > 34 years old	13	1.28 (1.06–1.55)	Weak
Maternal age 30–34 years old	20	1.05 (1.01–1.09)	Weak
<i>Ethnicity or migration-related factors</i>			
Black-Caribbean ethnicity in England	9	4.87 (3.96–6.00)	Convincing
Ethnic minority in low ethnic density area	5	3.71 (2.47–5.58)	Highly suggestive
Second-generation immigrant	26	1.68 (1.42–1.92)	Highly suggestive
North-African immigrants in Europe	12	2.22 (1.58–3.12)	Suggestive
Ethnic minority in high ethnic density area	5	2.11 (1.39–3.20)	Suggestive
First-generation immigrant	42	2.10 (1.72–2.56)	Suggestive
Black African ethnicity in England	4	4.72 (3.30–6.77)	Weak
Asian ethnicity in England	6	2.83 (1.59–5.05)	Weak
Other white ethnicity in England	3	2.62 (1.35–5.10)	Weak
Mixed ethnicity in England	3	2.19 (1.08–4.44)	Weak
<i>Foetal growth and gestational age</i>			
Birth weight < 2 kg	14	1.84 (1.53–2.22)	Convincing
Birth weight < 2.5 kg	25	1.53 (1.31–1.78)	Convincing
Small for gestational age	12	1.40 (1.25–1.57)	Convincing
Birth weight 2.5–2.999 kg	17	1.23 (1.15–1.31)	Convincing
Minor physical anomalies	14	5.30 (NA-NA)	Highly suggestive
Congenital malformation	10	2.31 (1.29–4.13)	Weak
Small head circumference	2	1.41 (1.00–1.97)	Weak
Premature birth	24	1.35 (1.12–1.62)	Weak
Birth length < 49 cm	8	1.17 (1.05–1.32)	Weak
<i>Labour season, labour complications, and delivery complications</i>			
Unspecific obstetric complications	21	1.52 (1.19–1.94)	Weak
Winter (Nordic countries)	11	1.05 (1.03–1.08)	Suggestive
Winter to spring (Nordic countries)	27	1.04 (1.02–1.06)	Suggestive
Incubator or resuscitation	8	2.12 (1.29–3.47)	Weak
Asphyxia state	9	1.93 (1.30–2.88)	Weak
Definite obstetric complication*	9	1.83 (1.21–2.77)	Weak
<i>Individual infections</i>			
Toxoplasma IgG	42	1.82 (1.51–2.18)	Suggestive
Chlamydia psittaci	2	29.05 (8.91–94.96)	Weak
Human endogenous retrovirus type W	5	19.78 (6.50–60.22)	Weak
Chlamydia pneumoniae	3	6.02 (2.86–12.66)	Weak
Herpes simplex type 2 infection	6	1.44 (1.14–1.81)	Weak
Borna disease virus	21	1.36 (1.09–1.70)	Weak
<i>Individual or environmental stress</i>			
Adult stressful events	13	3.11 (2.31–4.18)	Highly suggestive
Childhood adversities	34	2.80 (2.34–3.34)	Highly suggestive
Any psychological trauma	25	2.66 (1.99–3.56)	Highly suggestive
Childhood trauma	23	2.49 (1.86–3.33)	Highly suggestive
Urbanicity	8	2.39 (1.63–3.51)	Suggestive
Sexual abuse	2	12.24 (3.92–38.17)	Weak

(Continued)

Table 2. Continued.

Risk factor	k	Association odds ratio	Credibility
Adult negative life events	6	5.34 (3.84–7.43)	Weak
Disadvantaged group	3	2.27 (1.21–4.27)	Weak
<i>Risk factors for transition to psychosis within subjects at clinical high risk for psychosis</i>			
Attenuated positive symptoms	49	2.563 (NA – NA)	Highly suggestive
Poor global functioning	49	1.69 (NA – NA)	Highly suggestive
Negative symptoms	49	2.68 (NA – NA)	Suggestive
Disorganised/cognitive symptoms	18	2.48 (NA – NA)	Weak
General symptoms	21	2.27 (NA – NA)	Weak
Unemployment	7	1.81 (1.31–2.5)	Weak
Right handedness	16	1.60 (1.04–2.46)	Weak
Stress/trauma	11	1.15 (1.04–1.26)	Weak
Male sex	66	1.18 (1.03–1.34)	Weak
Total symptoms	29	1.74 (NA–NA)	Weak

Legend. 25(OH)D, 25-Hydroxyvitamin D; AA, Arachidonic Acid; ADH, Vasopressin; DHA, Docosahexaenoic Acid; DPA, Docosapentaenoic Acid; IL-1 β , Interleukin-1 Beta; IL-1RA, Interleukin-1 Receptor Antagonist; IL-8, Interleukin-8; LA, Linoleic Acid; MDA, Malondialdehyde; NGF, Nerve Growth Factor; S100B, S100 Calcium-Binding Protein B; sIL-2R, Soluble Interleukin-2 Receptor; TAS, Total Antioxidant Status; TBARS, Thiobarbituric Acid Reactive Substances; TGF- β , Transforming Growth Factor Beta; TNF- α , Tumour Necrosis Factor Alpha. When two meta-analyses reported on the same risk factor, we included the one with the largest number of studies, *, according to Lewis-Murray Obstetric Complications Scale. Edited from (Belbasis et al. 2018; Radua et al. 2018; Davies, Segre, et al. 2020; Oliver, Reilly, et al. 2020; Arango et al. 2021; Gao et al. 2022; Solmi, De Toffol, et al. 2023).

2.1. Risk factors for psychosis in the general population and in individuals at CHR-P

For risk factors for psychosis, we considered a meta-umbrella review published before September 2022 that systematically reviewed the literature on risk factors for mental disorders (Arango et al. 2021), and updated it, also searching for meta-analyses reporting on risk or protective factors for psychosis in any population, including also those meeting CHR-P criteria, and grading the credibility into convincing, highly suggestive, suggestive, weak, or no significant association based on quantitative criteria accounting for several types of bias, as already extensively applied in previous works (Bortolato et al. 2017; Dragioti et al. 2019; Kim et al. 2019; Solmi, Veronese, et al. 2020; Arango et al. 2021; Solmi, Civaradi, et al. 2021; Solmi, Dragioti, Arango, et al. 2021; Solmi, Dragioti, Croatto, Radua, Borgwardt, Carvalho, Demurtas, Mosina, Kurotschka, Thompson, et al. 2021; Solmi, Radua, et al. 2021). The criteria to grade the credibility of the evidence are detailed in the eMethods section. Modifiable factors with convincing evidence were considered as potential outcomes in the recommendation section.

2.2. Definition of CHR-P, and assessment tools

We described the structure of the two most frequently used tools to measure CHR-P status, namely the Comprehensive Assessment of At-Risk Mental State (CAARMS) (Yung et al. 2005), and Structured Interview for Prodromal Symptoms (SIPS) (Miller et al. 2003), their subscales and symptom domains, the criteria of each tool for different CHR-P subgroups, and differences with the brief psychotic disorder listed in the Diagnostic and Statistical Manual of Mental Disorders

5-Text Revision (DSM-5-TR) (APA 2022). In addition, given the emerging international partnerships and ongoing harmonisation efforts in the field, we conducted a systematic review to identify articles on international statements and consortia introducing novel psychometric tools for measuring CHR-P status. The tools to assess CHR-P based on basic symptoms were also mentioned given their longstanding historical relevance and their potential role in future research. Regarding the prognostic accuracy of psychometric instruments to assess the risk of psychosis, we identified a systematic review with meta-analysis published in September 2022.

2.3. Biological correlates of clinical high risk of psychosis

We conducted a meta-umbrella review reporting on the biological factors associated with CHR-P status. In addition, we conducted an umbrella review of previous meta-analyses and large consortium brain imaging studies to identify overall and regional structural, functional, metabolic, and electric differences between the brain of subjects with CHR-P and healthy controls.

2.4. Comorbid mental disorders of clinical high risk of psychosis

A subgroup among authors of these guidelines conducted a systematic review of the prevalence of comorbid mental disorders in CHR-P that has been published after September 2022 (Solmi, Soardo, et al. 2023) and included over 100 studies. Hence, no additional evidence synthesis was conducted for this subject. For the scope of these guidelines, we report the pooled prevalence of concomitant mental disorders in

subjects meeting criteria for CHR-P status, to inform the assessment and care to be offered in services for prevention of psychosis. We also descriptively report the impact of concomitant mental disorders on functioning in CHR-P status, on transition to psychosis after meeting CHR-P criteria. Finally, we describe the course over time of the prevalence of comorbid mental disorders after meeting CHR-P criteria at baseline.

2.5. Age at onset of psychosis, epidemiology of transition from clinical high risk of psychosis to psychosis, psychosis prediction models, and ethical considerations in estimating and communicating risk to inform clinical implementation of psychosis prevention

Meta-epidemiological evidence on the age at onset of psychosis and transition rates from CHR-P to psychosis should inform the age threshold to access psychosis prevention services, clinical decision-making, and resource allocation. A subgroup among authors of these guidelines recently conducted large scale (i.e. more than 100 epidemiologic studies included) meta-analyses on age at onset of mental disorders (Solmi, Radua, et al. 2022), and on the risk of transition to psychosis in subjects with CHR-P status over time (Salazar de Pablo, Davies, et al. 2021; Salazar de Pablo, Radua, et al. 2021). Hence, no additional evidence synthesis was conducted for this subject. Also, we updated a systematic review reporting on prediction and prognosis models with a proper internal or external validation in mental health research (Salazar de Pablo, Studerus, et al. 2021), narrowing our focus on CHR-P status and prediction of psychosis onset. Finally, we included the published report of a previous workshop specifically focusing on ethical considerations around risk estimates and communicating risk of transition to psychosis (Fusar-Poli, Manchia, et al. 2022).

2.6. Randomised controlled trials to prevent psychosis

Given that umbrella reviews miss including individual RCTs that have been published after the most updated systematic reviews (Mei et al. 2021; Zheng et al. 2022), we also conducted a PRISMA 2020 (Page et al. 2021)-compliant systematic review of RCTs for prevention of psychosis. Recent RCTs might change the conclusions based on previous (network) meta-analyses. Given the rapid expansion of this research field, our

systematic review also included ongoing RCTs and those without available results, highlighting evolving trends. We searched Embase, PsycInfo, MEDLINE, CINAHL, and clinical trials.gov up to September 19th, 2024. The search key is reported in eTable 1. Inclusion criteria were RCTs including subjects with CHR-P status according to explicit criteria. No restrictions were applied to the specific instrument used to define CHR-P, the type of intervention or control condition, and outcome of interest. We extracted author-defined primary and secondary outcomes. The primary outcome of this systematic review was transition to psychosis, in order to inform the guidelines for the indicated prevention of psychosis.

2.7. Meta-analyses and network meta-analyses of randomised controlled trials to prevent psychosis

We updated a previous umbrella review of (network) meta-analyses that included RCTs in subjects with CHR-P (Fusar-Poli, Davies, et al. 2019) conducted by a subgroup of the authors, following the PRIOR guidance (Gates et al. 2022). Inclusion criteria were systematic reviews with (network) meta-analyses of RCTs including subjects with CHR-P status according to explicit criteria. No restrictions were applied to the specific instrument used to define CHR-P, the type of intervention or control condition, and outcome of interest. We extracted author-defined primary and secondary outcomes. The primary outcome of this umbrella review was transition to psychosis, in order to inform the guidelines for the indicated prevention of psychosis.

2.8. Studies comparing psychosis prevention services with other services, and cost-effectiveness of psychosis prevention services

We updated a systematic review of cohort studies comparing clinical outcomes of psychosis prevention services versus other services (Sizer et al. 2022).

We conducted a PRISMA 2020 (Page et al. 2021) compliant systematic review on cost-effectiveness of psychosis prevention services. Inclusion criteria were cohort studies or simulated cohort studies focusing on cost-effectiveness of psychosis prevention services. No restrictions were applied to the specific instrument used to define CHR-P status, the type of control service, outcome of interest, and cost-effectiveness analysis. We extracted author-defined primary and secondary outcomes.

2.9. Clinical recommendations development

The recommendations were developed based on the available evidence and circulated to the panel for voting on a 5-point Likert scale (1=completely disagree to 5=completely agree). Consensus was defined as at least 80% of panel members rating 4 or 5. Feedback on the whole guidelines was also collected *via* email. Recommendations not reaching consensus were planned to be revised and resubmitted for voting until consensus was achieved.

3. Results

3.1. Literature review

3.1.1. Risk factors for psychosis in the general population and in individuals at CHR-P

Regarding risk factors for schizophrenia, Table 2 reports on their effect size, and the credibility of evidence (Table 2). A meta-umbrella review (Arango et al. 2021) pooled evidence from umbrella reviews mapping risk factors of all mental disorders, including schizophrenia (Belbasis et al. 2018; Radua et al. 2018). We updated that meta-umbrella review. The study selection flow is reported in eFigure 1. Studies excluded after full-text assessment, with reason for exclusion, are reported in eTable 2. We identified recent umbrella reviews on psychological trauma, unsaturated fatty acids and cannabis use association with a range of mental disorders, including schizophrenia (Gao et al. 2022; Hogg et al. 2023; Solmi, De Toffol, et al. 2023), as well as a meta-analysis on prenatal and perinatal factors associated with schizophrenia published after the two former (meta-) umbrella reviews (Davies, Segre, et al. 2020; Gao et al. 2022; Solmi, De Toffol, et al. 2023), as well as one on risk factors within those meeting CHR-P criteria (Oliver, Reilly, et al. 2020). Across meta-analyses, several factors have been nominally significantly associated with psychosis, yet most meta-analytic evidence did not meet convincing or highly suggestive credibility according to established quantitative criteria (Ioannidis 2009; Fusar-Poli and Radua 2018; Solmi, Dragioti, Croatto, Radua, Borgwardt, Carvalho, Demurtas, Mosina, Kuratschka, Shin, et al. 2021). In more detail, as shown in Table 2, 146 factors were nominally associated with risk of psychosis, and specifically 37 were individual medical, psychiatric, psychological factors, 32 biomarkers, 16 related with pregnancy, 12 maternal and paternal factors, 10 ethnicity or migration-related factors, nine dealt with foetal growth and gestational age, six with labour season, labour complications, and delivery complications, six

with individual infections, eight with individual or environmental stress and finally 10 risk factors were identified within subjects at CHR-P. Overall, only eight factors were supported by convincing evidence, namely UHR (OR = 9.32, 95%CI 4.91–17.32), black-Caribbean ethnicity in England (OR = 4.87, 95%CI 3.96–6.00), famine during pregnancy (OR = 1.61, 95%CI 1.51–1.71), birth weight below 2 kg (OR = 1.84, 95%CI 1.53–2.22), 2.5 kg (OR=1.53, 95%CI 1.31–1.78), 3 kg (OR = 1.23, 95%CI 1.15–1.31), and small for gestational age at birth (OR = 1.40, 95%CI 1.25–1.57), plus cannabis use in sensitivity analyses restricted to prospective studies. Additionally, in population-based studies, 14 factors met highly suggestive criteria, including childhood adversities in sensitivity analyses restricted to prospective studies (Arango et al. 2021; Solmi, De Toffol, et al. 2023). Finally, within CHR-P subjects no specific risk factor for transition to psychosis met convincing criteria.

Importantly, only three risk factors for schizophrenia-spectrum disorders had transdiagnostic salience across other mental disorders, according to TRANSD (Fusar-Poli, Solmi, et al. 2019) criteria. These are childhood adversities (shared with borderline personality disorder, and bipolar disorder), any psychological trauma (shared with bipolar disorder and anxiety disorder) and tobacco smoking (shared with opioid use disorder) (Arango et al. 2021), suggesting psychosis has some specific environmental risk factors compared with other disorders with only partial overlap.

3.1.2. Definition of CHR-P, and assessment tools

The UHR concept, now more frequently defined as CHR-P, was introduced more than 25 years ago in Melbourne, Australia (Yung et al. 2005) (Table 3). Whilst the concept of ‘prodrome’ has prompted researchers to look for an ‘at-risk’ status with symptoms before the onset of schizophrenia, the concept of ‘risk’ status is different from ‘prodromal’ status. Whilst ‘prodrome’ is a retrospective and deterministic construct (i.e. the period before schizophrenia onset can only later be recognised as a prodrome). In contrast, ‘risk’ is a probabilistic one (i.e. those at risk have a certain probability of developing psychosis over time), that inherently implies the possibility of prevention. Hence, the concept of ‘risk’ also calls for caution in communicating and treating CHR-P status, as a substantial proportion – indeed, the majority – of individuals ‘at risk’ will not develop psychosis (Salazar de Pablo, Radua, et al. 2021).

The most widely accepted interviews to identify CHR-P are the CAARMS (Yung et al. 2005), and SIPS (Miller et al. 2003), that identify three CHR-P groups, namely Brief and Limited Intermittent Psychotic

Table 3. Main characteristics of comprehensive assessment of At-risk mental state and structured interview for prodromal symptoms interviews.

	SIPS 5.6.1 (cOPS, pOPS)	CAARMS 2015
Subscales/symptoms domains	P1: Unusual Thought Content/Delusional Ideas P2: Suspiciousness/Persecutory Ideas P3: Grandiose Ideas P4: Perceptual Abnormalities/Hallucinations P5: Disorganised Communication	P1: Unusual Thought Content P2: Non-Bizarre Ideas P3: Perceptual Abnormalities P4: Disorganised Speech
Severity	Seven levels (0–6)	Seven levels (0–6)
Frequency	Three levels (1–3)	Seven levels (0–6)
APS		
Severity, frequency, functioning	Severity 3–5 plus Frequency 2	<i>Subthreshold intensity</i> Severity 3–5 (P1/2), 3–4 (P3), 4–5 (P4) plus Frequency 3–6 <i>OR</i> <i>Subthreshold frequency</i> Severity 6 (P1/2/4), 5–6 (P3) plus Frequency 3 <i>AND</i> Both with SOFAS drop $\geq 30\%$ sustained ≥ 1 month within the past year/ <50 last 12 months
Symptoms to rate	Past month, in last 12 months	Last 12 months
Symptoms started	Started or worsened last 12 months, but could have been there even earlier	Up to five years earlier
BLIPS		
Severity, frequency, functioning	Severity 6 plus Frequency 1	Severity 6 (P1/2/4), 5–6 (P3) plus Frequency 4–6 <i>AND</i> SOFAS drop $\geq 30\%$ sustained ≥ 1 month within the past year/ <50 last 12 months
Symptoms to rate	Past three months	Last 12 months
Symptoms started	Past three months	Up to five years earlier
Duration	Not more than three months	Not more than seven days
GRD		
Criteria and functioning	Schizotypal personality disorder <i>OR</i> First-degree relative with psychotic disorder <i>AND</i> GAF drop $\geq 30\%$ over the past month relative to 12 months prior	Schizotypal personality disorder <i>OR</i> First-degree relative with psychotic disorder <i>AND</i> SOFAS drop $\geq 30\%$ sustained ≥ 1 month within the past year/ <50 last 12 months
Psychosis		
Psychosis criteria	Severity 6 plus Frequency 3 <i>OR</i> Symptoms are seriously disorganising and dangerous	Severity 6 (P1/2/4), 5–6 (P3) plus Frequency 4–6
Duration	NA	More than seven days
Exclusion criteria		
Exclusion criteria	Previous diagnosis of psychosis, symptoms are seriously disorganising and dangerous Symptoms are strongly connected with substance abuse	Previous diagnosis of psychosis (CAARMS or other sources) Symptoms strongly connected with hallucinogens, amphetamines, and cocaine (or other known to induce psychosis, excluding cannabinoids)
	Symptoms better explained by other disorder	

Legend. SPS: Attenuated Psychotic Symptoms; BLIPS: Brief Limited Intermittent Psychotic Symptoms; CAARMS: Comprehensive Assessment of At-Risk Mental State; COPS: Criteria of Prodromal Syndromes; GRD: Genetic Risk and Deterioration; POPS: Presence of Psychotic Symptoms; SIPS: Structured Interview for Prodromal Symptoms. Edited from (Miller et al. 2003; Yung et al. 2005; Addington, Woods, et al. 2023).

Symptoms (BLIPS), Attenuated Positive Symptoms (APS), Genetic Risk and Deterioration (GRD) syndrome (Table 3). Briefly, BLIPS is defined by full positive psychotic symptoms that are, however, limited in frequency and duration. APS is defined by severity-subthreshold positive symptoms. GRD have schizotypal personality disorder or a first degree relative with psychosis as well as a recent drop in psychosocial functioning. Both CAARMS and SIPS should be administered to help-seeking subjects, and information gathered from the interview must be integrated with informants' input. Differences exist between CAARMS and SIPS on the maximum duration of subthreshold psychotic symptoms before defining a full-blown psychotic episode (Miller et al. 2003). Also, a

non-negligible portion of CAARMS-defined BLIPS meets full psychosis criteria for SIPS (Miller et al. 2003; Fusar-Poli, Cappucciati, et al. 2016). Moreover, the two interviews assess differently concomitant substance use, as well as functional impairment for APS and BLIPS. Despite these and other differences (Table 3), CAARMS and SIPS have an overall agreement of 86–93% (Fusar-Poli, Cappucciati, et al. 2016) in determining CHR-P status, and the CONVERT tool (Fusar-Poli, Cappucciati, et al. 2016) is freely available to convert scores between the two instruments.

The difference between CHR-P (at-risk status) and brief psychotic disorder (full-blown schizophrenia-spectrum disorder) according to the DSM-5-TR (APA 2022) is

blurred, as the latter includes positive psychotic symptoms lasting from one day to one month (Miller et al. 2003), which overlaps with a subgroup of patients meeting CHR-P BLIPS criteria. Hence, differentiating between CHR-P and brief psychotic disorder is not always possible and at best challenging without using a semi-structured interview.

The study selection flow of the systematic review of novel psychometric tools for measuring CHR-P status is reported in eFigure 2. The systematic review identified four studies (Brady and Larrauri 2023; Addington, Woods, et al. 2024; Wannan et al. 2024; Woods SW et al. 2024) reporting on a newly developed instrument, the Positive Symptoms for CAARMS Harmonised with SIPS (PSYCHS), which integrates CAARMS and SIPS (eTable 3). In the PSYCHS, full harmonisation of CAARMS and SIPS has been achieved for rating positive symptoms severity and determining transition to psychosis, but not for assessing CHR-P subgroups, which still relies on separate SIPS or CAARMS criteria. The harmonisation process is described in more detail in eTable 3.

In CHR-P subjects, transition to frank psychosis can be assessed using either the CAARMS, SIPS, or PSYCHS, all of which require at least one positive psychotic symptom occurring several times a week. However, for determining transition, these measures differ in symptom duration (one week for the CAARMS and PSYCHS, one month for the SIPS) and waive duration and frequency if the symptom is imminently dangerous (PSYCHS) or either seriously disorganising or dangerous (SIPS), or in case a new or increased antipsychotic has been administered (CAARMS and PSYCHS).

In addition to the UHR/CHR-P criteria operationalised by CAARMS and SIPS, a complementary approach to identifying individuals with increased risk of psychosis has been developed based on the assessment of basic symptoms using the Schizophrenia Proneness Instrument—Adult (SPI-A) (Schultze-Lutter et al. 2012) and—Child and Youth (SPI-CY) (Schultze-Lutter et al. 2012). This approach focuses on self-experienced, subtle cognitive and perceptive disturbances, which are often subjectively distressing, preceding and accompanying attenuated or brief psychotic symptoms. However, meta-analytic evidence on the prognostic accuracy of such tools is lacking.

The systematic review with meta-analysis on the prognostic accuracy of a range of psychometric tools to measure CHR-P status showed that they have excellent prognostic accuracy in predicting psychosis in clinical samples at a mean follow-up of 34 months, i.e. $AUC = 0.85$ (95% CI: 0.81–0.88). More in detail, sensitivity was outstanding (0.93, 95% CI: 0.87–0.96), but

specificity was poor (0.58, 95% CI: 0.50–0.66) (Oliver et al. 2022). In the discussion of that systematic review, authors indicated that CHR-P should be assessed in help-seeking, or risk-enriched populations only, because the prevalence of psychosis in the group undergoing CHR-P assessment determines CAARMS prognostic accuracy (Fusar-Poli, Schultze-Lutter, et al. 2016; Fusar-Poli, Sullivan, et al. 2019). Hence, administering CAARMS or SIPS to individuals who are not help-seeking, or outside of clinical services (such as screening in schools), is not useful in determining any risk of psychosis.

3.1.3. Biological correlates of clinical high risk of psychosis

The study selection flow of the meta-umbrella on biological correlates in individuals at CHR-P is reported in eFigure 3 (Table 4). Studies excluded after full-text assessment, with reason for exclusion, are reported in eTable 4. The meta-umbrella review identified one umbrella review reporting on the biological alterations in subjects with CHR-P (Fusar-Poli et al. 2020) (Table 4). Biological alterations in CHR-P individuals resemble those consistently shown in individuals with schizophrenia. Compared with healthy controls, subjects at CHR-P have increased cortisol levels (Chaumette et al. 2016) as well as elevated IL-6 and IL-1beta (Park and Miller 2020).

The study selection flow of meta-analyses and large consortium brain imaging studies is reported in eFigure 4. Studies excluded after full-text assessment, with reason for exclusion, are reported in eTable 5. The umbrella review identified 17 eligible studies (Davis et al. 2014; Dutt et al. 2015; Erickson et al. 2016; Harrisberger et al. 2016; Merritt et al. 2016; Walter et al. 2016; Ding et al. 2019; Wenneberg et al. 2020; Del Fabro et al. 2021; Jalbrzikowski et al. 2021; Baldwin et al. 2022; Luna et al. 2022; Vissink et al. 2022; Zhao Y et al. 2022; Simmonite et al. 2023; Zeng et al. 2023; Allen et al. 2024) reporting on brain imaging findings in subjects with CHR-P, applying different techniques (Table 4). Among these, three studies (Jalbrzikowski et al. 2021; Baldwin et al. 2022; Allen et al. 2024) were from the ENIGMA consortium ($n=2,577$ – $3,169$). These studies reported on structural measures (brain volume, cortical thickness, surface area), functional measures (functional activity), and positron emission tomography or spectroscopy metrics (combined glutamate and glutamine, glutamate). In CHR-P subjects, there is converging evidence of a neuroprogressive process (Davis et al. 2014; Chaumette et al. 2016), evidenced by reduced brain volume, cortical thickness and surface area of the whole brain and specific areas (Jalbrzikowski

Table 4. Biological correlates of clinical high risk for psychosis.

Biological factor	Source	Effect size* vs healthy controls
Inflammation vs HC		
Cortisol (Chaumette et al. 2016)	MA ($k=8$, $n=1,060$)(Chaumette et al. 2016)	Hedge's $g=0.59$ (NA)
IL-6 (Park and Miller 2020)	MA ($k=5$, $n=229$) (Park and Miller 2020)	SMD = 0.31 (95%CI 0.02–0.59)
IL1- β (Park and Miller 2020)	MA ($k=2$, $n=74$) (Park and Miller 2020)	SMD=–0.66 (95%CI –1.27 to –0.05)
Neuroimaging [#]		
Structural		
Overall		
Mean CT (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$)(Jalbrzikowski et al. 2021)	Cohen's $d=-0.18$ (95%CI –0.25 to –0.11)
Estimated intracranial VOL (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$)(Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.20 to –0.06)
Total SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$)(Jalbrzikowski et al. 2021)	Cohen's $d=-0.15$ (95%CI –0.22 to –0.08)
Lower PBSI-SA (Baldwin et al. 2022)	ENIGMA ($n=2,644$)(Baldwin et al. 2022)	$t(2642) = -5.39$, $p < 0.01$
Lower PBSI-CT (Baldwin et al. 2022)	ENIGMA ($n=2,790$)(Baldwin et al. 2022)	$t(2788) = -9.11$, $p < 0.01$
Lower PBSI-SV (Baldwin et al. 2022)	ENIGMA ($n=2,735$)(Baldwin et al. 2022)	$t(2733) = -4.34$, $p < 0.01$
Global CT (Allen et al. 2024)	ENIGMA ($n=2577$)(Allen et al. 2024)	Cohen's $d = <0.22$ CI NA (decreased)
Infranormal global ADS (Allen et al. 2024)	ENIGMA ($n=2577$)(Allen et al. 2024)	$\chi^2 = 12.82$, FDR corrected $p = 6.85 \times 10^{-4}$
Infranormal SV ADS (Allen et al. 2024)	ENIGMA ($n=2577$)(Allen et al. 2024)	$\chi^2 = 5.68$, FDR corrected $p = 0.02$
Infranormal SA ADS (Allen et al. 2024)	ENIGMA ($n=2577$)(Allen et al. 2024)	$\chi^2 = 16.01$, FDR corrected $p = 2.53 \times 10^{-4}$
Specific areas		
Left rostral anterior cingulate CT (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$)(Jalbrzikowski et al. 2021)	Cohen's $d=-0.11$ (95%CI –0.18 to –0.04)
Bilateral posterior cingulate CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$)(Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.2 to –0.06)
Bilateral postcentral CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.12$ (95%CI –0.19 to –0.05)
Bilateral paracentral CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.15$ (95%CI –0.22 to –0.08)
Bilateral precentral CT (Jalbrzikowski et al. 2021) (LR)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.2 to –0.06)
Bilateral precuneus CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.15$ (95%CI –0.22 to –0.08)
Bilateral supramarginal CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.11$ (95%CI –0.18 to –0.04)
Left parahippocampal CT (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.2 to –0.06)
Bilateral insula CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.17$ (95%CI –0.24 to –0.1)
Bilateral medial orbitofrontal CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.2 to –0.06)
Right lateral orbitofrontal CT (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.09$ (95%CI –0.16 to –0.02)
Bilateral rostral middle frontal CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.2 to –0.06)
Bilateral caudal middle frontal CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.12$ (95%CI –0.19 to –0.04)
Bilateral superior frontal CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.11$ (95%CI –0.18 to –0.04)
Bilateral fusiform CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.17$ (95%CI –0.24 to –0.1)
Bilateral superior parietal CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.12$ (95%CI –0.19 to –0.05)
Bilateral inferior parietal CT (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.16$ (95%CI –0.24 to –0.09)
Bilateral inferior temporal CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.15$ (95%CI –0.22 to –0.08)
Bilateral middle temporal CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.18$ (95%CI –0.26 to –0.11)
Right transverse temporal CT (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.11$ (95%CI –0.18 to –0.04)
Bilateral superior temporal CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.15$ (95%CI –0.22 to –0.08)
Bilateral banks of the superior temporal sulcus CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.13$ (95%CI –0.2 to –0.06)
Bilateral lateral occipital CT (Jalbrzikowski et al. 2021) (R)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.16$ (95%CI –0.23 to –0.09)
Bilateral medial prefrontal cortex CT (Zhao Y et al. 2022)	MA ($k=10$ $n=1,390$) (Zhao Y et al. 2022)	($z = -1.01$, $p < 0.001$)
Bilateral lateral ventricles VOL (Jalbrzikowski et al. 2021) (L)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=0.11$ (95%CI 0.04 to 0.18)
Hippocampus VOL (Harrisberger et al. 2016)	MA ($k=3$, $n=155$) (Harrisberger et al. 2016)	Hedge's $g=-0.38$ (95%CI –0.73 to –0.03)
Hippocampus VOL (R) (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.16$ (95%CI –0.23 to –0.08)
Hippocampus VOL (R) (Walter et al. 2016)	MA ($n=1,429$) (Walter et al. 2016)	Hedge's $g=-0.24$, $p=0.0418$
Hippocampus VOL (L) (Vissink et al. 2022)	MA ($k=7$, $n=1,088$) (Vissink et al. 2022)	Hedge's $g=-0.26$, (95% CI –0.49 to –0.02), $p=0.04$
Hippocampus VOL (R) (Vissink et al. 2022)	MA ($k=7$, $n=1,088$) (Vissink et al. 2022)	Hedge's $g=-0.33$ (95% CI –0.60 to –0.07), $p=0.01$
Thalamus VOL (Harrisberger et al. 2016)	MA ($k=3$, $n=155$) (Harrisberger et al. 2016)	Hedge's $g=-0.60$ (95%CI –0.96 to –0.25)**
Thalamus VOL (R) (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=1.039$, (increased)**
Bilateral median cingulate VOL (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=1.034$, (increased)
Right fusiform gyrus VOL (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=1.051$, (increased)
Right gyrus rectus VOL (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=-2.109$, (decreased)
Medial frontal gyrus VOL (Luna et al. 2022)	MA ($k=41$, $n=4,846$) (Luna et al. 2022)	Hedge's $g=-0.28$, $p < 0.001$
Right superior frontal gyrus VOL (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=-2.321$, (decreased)
Left superior frontal gyrus VOL (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=-2.228$, (decreased)
Left superior temporal gyrus VOL (Ding et al. 2019)	MA ($k=14$, $n=1,331$) (Ding et al. 2019)	$z=1.048$, (increased)
Lateral Ventricles VOL (Vissink et al. 2022)	MA ($k=3$, $n=841$) (Vissink et al. 2022)	Hedge's $g=0.17$ (95% CI 0.02 to 0.31), $p=0.02$

(Continued)

Table 4. Continued.

Biological factor	Source	Effect size* vs healthy controls
Cerebrospinal VOL (Vissink et al. 2022)	MA ($k=4$, $n=922$) (Vissink et al. 2022)	Hedge's $g=0.21$ (95% CI 0.08 to 0.35), $p=0.002$
Whole brain VOL (Vissink et al. 2022)	MA ($k=7$, $n=1,237$) (Vissink et al. 2022)	Hedge's $g=-0.14$ (95% CI -0.26 to -0.03), $p=0.02$
Left entorhinal SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.09$ (95%CI -0.16 to -0.02)
Right isthmus cingulate SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=0.09$ (95%CI 0.2 to 0.16)
Left pars opercularis SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.09$ (95%CI -0.16 to -0.02)
Right pericalcarine SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.09$ (95%CI -0.17 to -0.02)
Left supramarginal SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.11$ (95%CI -0.18 to -0.04)
Left rostral anterior cingulate SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.12$ (95%CI -0.19 to -0.04)
Right superior frontal SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.09$ (95%CI -0.16 to -0.02)
Right inferior parietal SA (Jalbrzikowski et al. 2021)	ENIGMA ($n=3,169$) (Jalbrzikowski et al. 2021)	Cohen's $d=-0.10$ (95%CI -0.17 to -0.03)
Functional		
Salience network connectivity (Del Fabro et al. 2021)	MA ($k=16$, $n=1,484$) (Del Fabro et al. 2021)	Hedge's $g=-0.085$, $p=0.012$ FDR corrected= 0.07
Right precuneus (Luna et al. 2022)	MA ($k=55$, $n=3,096$) (Luna et al. 2022)	Hedge's $g=-0.4$, $p<0.001$
Bilateral anterior cingulate cortex (Luna et al. 2022)	MA ($k=55$, $n=3,096$) (Luna et al. 2022)	Hedge's $g=-0.33$, $p<0.001$
Right superior frontal gyrus (Dutt et al. 2015)	MA ($k=11$, $n=NA$) (Dutt et al. 2015)	$p<0.01$ (increased)
Right inferior frontal gyrus (Luna et al. 2022)	MA ($k=55$, $n=3,096$) (Luna et al. 2022)	Hedge's $g=-0.34$, $p<0.001$
Left superior frontal gyrus (Luna et al. 2022)	MA ($k=55$, $n=3,096$) (Luna et al. 2022)	Hedge's $g=-0.33$, $p<0.001$
Left medial frontal gyrus (Dutt et al. 2015)	MA ($k=15$, $n=NA$) (Dutt et al. 2015)	$p<0.01$ (decreased)
Right inferior parietal lobule (Dutt et al. 2015)	MA ($k=15$, $n=NA$) (Dutt et al. 2015)	$p<0.01$ (decreased)
Left superior temporal gyrus (Dutt et al. 2015)	MA ($k=11$, $n=NA$) (Dutt et al. 2015)	$p<0.01$ (increased)
Medial prefrontal cortex and anterior cingulate cortex activation in response to monetary stimuli (Zeng et al. 2023)	MA ($k=13$, $N=744$) (Zeng et al. 2023)	SMD= 1.330, $p<0.001$ (increased)
Left cerebellum and parahippocampal gyrus activation in response to monetary stimuli (Zeng et al. 2023)	MA ($k=13$, $N=744$) (Zeng et al. 2023)	SMD= -2.051 , $p<0.001$ (decreased)
Right supramarginal gyrus activation in response to monetary stimuli (Zeng et al. 2023)	MA ($k=13$, $N=744$) (Zeng et al. 2023)	SMD= -1.775 , $p<0.001$ (decreased)
Right insula and putamen activation in response to monetary stimuli (Zeng et al. 2023)	MA ($k=13$, $N=744$) (Zeng et al. 2023)	SMD= -1.485 , $p<0.001$ (decreased)
Mismatch negativity		
Mismatch negativity (Erickson et al. 2016)	MA ($k=16$, $N=NA$) (Erickson et al. 2016)	Cohen's $d=0.40$ (95%CI 0.23 to 0.58) (increased)
PET/MRS		
Medial frontal Glx (MRS) (Merritt et al. 2016)	MA ($k=8$, $N=386$) (Merritt et al. 2016)	Hedge's $g=0.26$ (95%CI 0.05 to 0.46)
Frontal Glx (MRS) (Wenneberg et al. 2020)	MA ($k=4$, $N=140$) (Wenneberg et al. 2020)	SMD= 0.55 (95% CI 0.21 to 0.89), $p=0.001$ (increased)
Thalamus glutamate (MRS) (Wenneberg et al. 2020)	MA ($k=3$, $N=218$) (Wenneberg et al. 2020)	SMD= -0.5 (95% CI -0.78 to -0.23), $p<0.001$

Legend. ADS: average deviation score; CT: cortical thickness; Glx: combined glutamate and glutamine; IL: interleukin; MA: meta-analysis; MRS: proton magnetic resonance spectroscopy; PBSI: person-based similarity index; PET: positron emission tomography; SMD: standardised mean difference; VR: Variability ratio; *Positive values indicate higher levels in CHR;**, opposite findings from two works on thalamus; # when bilateral, left or right side with largest difference is indicated [(L) or (R)], and reported. Edited from (Davis et al. 2014; Dutt et al. 2015; Chaumette et al. 2016; Erickson et al. 2016; Harrisberger et al. 2016; Merritt et al. 2016; Walter et al. 2016; Ding et al. 2019; Fusar-Poli Paolo et al. 2020; Park and Miller 2020; Wenneberg et al. 2020; Del Fabro et al. 2021; Jalbrzikowski et al. 2021; Baldwin et al. 2022; Luna et al. 2022; Vissink et al. 2022; Zhao Y et al. 2022; Zeng et al. 2023; Allen et al. 2024).

et al. 2021); however, the effect sizes ranges from very small to small (Cohen's $d=0.13$ – 0.22) (Allen et al. 2024). Among specific brain regions, alterations emerged for some areas that were confirmed across more than one metric, that were replicated in more than one study on the same metric, or that had a medium effects size. Compared with healthy controls, CHR-P subjects exhibit prominently altered frontal lobes; reduced volume in bilateral superior frontal gyri (Ding et al. 2019), reduced cortical thickness (Jalbrzikowski et al. 2021), and reduced surface area (Jalbrzikowski et al. 2021), asymmetric altered activation (right increased, left decreased) (Dutt et al. 2015; Luna et al. 2022), and increased combined glutamate plus glutamine levels (Merritt et al. 2016; Wenneberg et al. 2020). Bilateral

medial prefrontal cortex has reduced cortical thickness (Zhao Y et al. 2022) and increased motivational-related activation during reward anticipation (Zeng et al. 2023). Also, the right inferior parietal lobule shows decreased cortical thickness (Jalbrzikowski et al. 2021), surface area (Jalbrzikowski et al. 2021) and function (Dutt et al. 2015). In addition, the left superior temporal gyrus shows increased volume (Ding et al. 2019), reduced cortical thickness (Jalbrzikowski et al. 2021), and increased activation (Dutt et al. 2015). Furthermore, the left anterior cingulate has reduced cortical thickness (Jalbrzikowski et al. 2021), reduced surface area (Jalbrzikowski et al. 2021), and reduced activation in resting state (Luna et al. 2022), whereas there is increased activation in the bilateral anterior cingulate

cortex during reward anticipation (Zeng et al. 2023). Among subcortical structures, a number of studies reported a reduced volume of both the right hippocampus (Harrisberger et al. 2016; Walter et al. 2016; Jalbrzikowski et al. 2021) and the left hippocampus (Harrisberger et al. 2016; Vissink et al. 2022). The largest difference has been reported for the thalamus, which has reduced volume in CHR-P subjects (medium effect size) (Harrisberger et al. 2016), as well as reduced glutamate levels (Wenneberg et al. 2020). Lastly, bilateral lateral ventricles showed increased volume in two studies (Jalbrzikowski et al. 2021; Vissink et al. 2022). Mismatch negativity was increased in CHR-P compared with healthy controls (Erickson et al. 2016). Apart from these areas where brain alterations were confirmed across different reports or measures, all other differences were largely non-significant, not replicated, and virtually all of them had a very small effect size (Cohen's d /Hedge's $g < 0.2$).

3.1.4. Comorbid mental disorders of CHR-P

Subjects meeting CHR-P criteria frequently have poor functioning, or a drop in functioning (at least according to CAARMS), and present with frequent symptoms of or full-blown comorbid mental disorders (Table 5). In a recent meta-analysis (Solmi, Soardo, et al. 2023), that pooled data from 312 observational and interventional studies that reported comorbid mental disorders in almost 35,000 CHR-P subjects, 75.7% of subjects met criteria for at least one non-psychotic disorder (Table 5). The most frequent disorders were

anxiety/mood disorders (60.1%), any mood disorders (43.7%), any depressive disorder/episode (39.3%), any anxiety disorder (33.7%), major depressive disorder (31.1%), any trauma-related disorder (29.4%), any personality disorder (23.3%), any pervasive developmental disorder (around 14.8%), neurotic, stress-related and somatoform disorders (around 14.2%), cannabis use disorder (13%), schizotypal personality disorder (12.5%), attention-deficit/hyperactivity disorder (12.5%), any behavioural disorder (12.5%), pervasive developmental disorder not otherwise specified (12.1%), social anxiety disorder (11.8%), any substance use disorder (11.8%), phobias (11.5%), avoidant personality disorder (10.5%), borderline personality disorder (10.4%), and other disorder in less than 10% of study participants. While the vast majority of these comorbid disorders do not seem to be associated with functioning (i.e. aggravate or mitigate functioning impairment already present with CHR-P status), some of them are (Solmi, Soardo, et al. 2023). Somatoform disorder, alcohol use disorder, and schizotypal personality disorder (in descending order of magnitude) are associated with a more severe impairment of functioning, whilst dysthymia and generalised anxiety disorder (again in descending order of magnitude) with a less severe impairment of functioning. Also, importantly, according to the same meta-analysis (Solmi, Soardo, et al. 2023), comorbid mood disorder, generalised anxiety disorder and agoraphobia are associated with lower odds of transition to psychosis. After meeting CHR-P criteria, up to eight years of follow-up, rates of any non-psychotic disorders decrease somewhat, yet remain high, being still present in >50% of subjects meeting CHR-P criteria at baseline.

Given the high proportion of CHR-P subjects with comorbid mental disorders, the clinical needs of these subjects go beyond the prevention of psychosis.

Table 5. Course and impact of concomitant mental disorders in subjects at CHR-P.

Course of concomitant mental disorders over time in CHR-P subjects
Over 75% of CHR-P subjects have a concomitant DSM/ICD mental disorder
Most frequent concomitant mental disorders at baseline CHR-P assessment are:
Any mood disorder, around 43%
Depressive disorder, around 39%
Anxiety disorders, around 33%
Any trauma-related disorder, around 29%
Personality disorders, around 23%
Up to eight years after meeting CHR-P status criteria, a comorbid mental disorder is still present in more than 50% of subjects
Impact of concomitant mental disorders on functioning in CHR-P subjects
Somatoform disorder, alcohol use disorder, and schizotypal personality disorder are associated with worse functioning impairment (in descending order of magnitude)
Dysthymia and generalised anxiety disorder moderate a less severe impairment of functioning (in descending order of magnitude)
Impact of comorbid mental disorders on transition to psychosis in CHR-P subjects
Comorbid mood disorder, generalised anxiety disorder and agoraphobia lower the odds of transition to psychosis.

Legend. DSM, Diagnostic and Statistical Manual; ICD, International Classification of Diseases. Edited from (Solmi, Soardo, et al. 2023).

3.1.5. Age at onset of psychosis, epidemiology of transition from CHR-P to psychosis, psychosis prediction models, and ethical considerations to inform clinical implementation of psychosis prevention

Regarding age at onset of psychosis, according to the largest meta-analysis conducted so far on the age at onset of mental disorders (Solmi, Radua, et al. 2022), the proportion of individuals with onset of a schizophrenia spectrum disorder before the age of 14, 18, 25 was 3%, 12.3%, 47.85%, supporting that the age eligibility criteria for psychosis prevention programs should be age 14 (Table 6).

Table 6. Epidemiology of transition to psychosis, risk estimates, and ethical considerations.

Epidemiology of transition to psychosis	
Subjects at CHR-P have increased risk of transition to psychosis	The prevalence of schizophrenia is around 1% in the general population. The prevalence of CHR-P is 1.7% and 19.2% in the general population and in clinical samples, respectively. The rate of transition to psychosis in CHR-P subjects is as high as 8% at 6 months, reaching 29% at 4 years, then plateauing and reaching 35% at 10 years from CHR-P baseline assessment, but lower for children and adolescents
Estimating risk of transition to psychosis Tools	The two most employed diagnostic tools to assess early psychosis are CAARMS and SIPS, with good prognostic performance In clinical centres where CAARMS or SIPS/SOPS are not used, an individualised transdiagnostic risk calculator has been recently developed employing electronic health information. This tool can be used not only in CHR-P patients, but also in any other individual with non-psychotic psychiatric disorder.
Population	Assessment of CHR-P status or risk of psychosis should only be assessed in help-seeking non-psychotic (sub) clinical population, as the prognostic accuracy of CAARMS and SIPS/SOPS is poor if applied to the general population.
Validate prognostic/prediction models	Models should be developed, validated internally, and replicated in external samples to ensure generalisability. Models' prognostic/prediction accuracy must be determined through discrimination values (Harrel C index or Area-Under-the Curve, sensitivity, specificity), calibration (regression slope of prognostic index), overall performance (R^2 , Brier Score), in longitudinal cohort studies.
Risk calculators candidates	Multiple risk calculators have been developed, which should be updated with evidence on additional risk factors (see Table 2).
Key ethical principles	
Autonomy	The right for an individual to make their own choice
Beneficence	The principle of acting with the best interest of the other in mind
Non-maleficence	The principle that 'above all, do no harm'
Justice	Fairness and equality among individuals
Explainability/interpretability	Why a clinical prediction model arrives at an output/prediction
Implementation of key ethical principles, and reasons	
Keep a human component in the risk assessment and communication	Promote social interactions, promoting human-to-human interaction in the risk estimate, avoiding social isolation Involve the user in the critical interpretation of risk estimate, to avoid acritical acceptance of automated outputs Allow users to benefit from risk estimates, accepting and preventing the risk of automation distrust deriving from the absence of human-to-human interaction Always ensure accountability, which is complicated in fully automated risk estimates Mitigate digital divide, i.e. gap in access to preventive care for those subjects with limited digital literacy or limited access to digital devices
Ensure validity and representativeness	Ask users if they want to be informed about the risk estimate Only use validated clinical prediction models (see above), to avoid structural bias and over-optimism Ensure that clinical prediction models have been validated in populations representative of users (under- or over-representation of minorities limits generalisability)
Ensure transparency and reproducibility	Use glass-box clinical prediction models with transparent and reproducible algorithms, instead of black-box 'obscure' machine learning protocols
Training of operators	Offer CHR-P assessment tools training to operators Offer clinical prediction model training to operators, so all variables in the clinical prediction model are accurately collected, beyond other sources of incentives that could bias diagnostic codes Train in ethical communication of risk

Legend. Edited from (Fusar-Poli, Rutigliano, Stahl, Davies, Bonoldi, et al. 2017; Fusar-Poli, Rutigliano, Stahl, Davies, De Micheli, et al. 2017; Fusar-Poli et al. 2018; Fusar-Poli, Werbeloff, et al. 2019; Puntis et al. 2021; Salazar de Pablo, Studerus, et al. 2021; Salazar de Pablo, Woods, et al. 2021; Fusar-Poli, Manchia, et al. 2022; Meehan et al. 2022).

A recent meta-analysis pooled data from 130 studies and 9,222 individuals (Salazar de Pablo, Radua, et al. 2021). The cumulative transition risk from CHR-P to psychosis was 8% at 6 months, 14% at 1 year, 17% at 1.5 years, 20% at 2 years, 25% at 2.5 years, 27% at 3 years, 28% at 3.5 years, 29% at 4 years, and 35% at 10 years (Salazar de Pablo, Radua, et al. 2021) (Table 6). Moreover, a lower proportion of female individuals ($\beta = -0.02$; 95% CI: -0.04 to -0.01) and a higher proportion of BLIPS ($\beta = 0.02$; 95% CI: 0.01 – 0.03) were associated with higher transition risk. Also, across CHR-P cohorts, higher age has been identified as a risk factor for transition to psychosis (Fusar-Poli et al. 2012). Indeed, risk for transition to psychosis is lower in children and adolescents fulfilling CHR-P criteria, being 9.5% at 1 year, 12.1% at 2 years and only 16.1% at

≥ 5 years (Lång et al. 2022). The lower conversion rates to psychosis compared to adults are likely due to the fact that attenuated positive symptoms are less specific before adulthood, possibly being associated with internalising, externalising, substance use and personality disorder traits or diagnoses that might also emerge around the same age (Kelleher, Murtagh, et al. 2012; Gerstenberg et al. 2015; Schimmelmann et al. 2015; Gerstenberg et al. 2016). Additionally, even full psychotic symptoms appear to be less specific in youth. The meta-analytically determined median prevalence of psychotic symptoms – predominantly auditory hallucinations – is as high as 17% among children aged 9–12 years and much lower, i.e. 7.5%, among adolescents aged 13–18 years (Kelleher, Connor, et al. 2012) where epidemiologically the risk for psychosis

should be higher (Solmi, Radua, et al. 2022). Nevertheless, when measured in the same study with homogeneous definitions and tools, the duration of untreated psychosis appears to be three times as long in adolescents than adults with first episode psychosis (5.4 ± 3.1 vs 18.7 ± 6.2 months (Stentebjerg-Olesen et al. 2016)), highlighting the need to focus on psychosis prevention in youth too. The risk of transition to psychosis can be measured with two different yet complementary approaches in subjects who are help-seeking or assessed in a clinical context. A first possibility is to administer a clinical interview to assess whether a subject meets CHR-P criteria. CAARMS's area under the curve (AUC) at 2 years is 0.79 (Oliver et al. 2018), with a sensitivity and specificity of 83% and 74% at 6 months (Yung et al. 2005), respectively. SIPS had a sensitivity of 100%, as well as a specificity of 71% at six months (Miller et al. 2003) follow-up. A second approach to quantify the risk of transition to psychosis is to use risk calculators. Risk calculators for psychosis are among the most valid clinical prediction models in psychiatry, and can be used by healthcare professionals, regardless of previous administration of CAARMS or SIPS, since they rely on demographic characteristics and clinical diagnoses (Table 6). The use of calculators might be a more feasible approach in settings or time periods with insufficient staff to administer CAARMS or SIPS. The two approaches can also be combined, as the risk of transition to psychosis is not the same across all individuals with CHR-P. Clinical prediction models are crucial for developing and implementing precision psychiatry, but methodological and ethical guidance should be followed. Regarding the methodological standards for prediction models, a large sample size is needed to have a sufficient number of events (at least 100), and an appropriate events/model variables ratio (ideally at least 20 events per model variable, i.e. event per variable, EPV), to protect from biased results and overfitting (Meehan et al. 2022). Also, the variables/predictors that compose the model should be identified *via* systematic review of the literature, and should be considered all together in multivariable models. Furthermore, after its development within a given sample, each model should be validated internally and externally in new cohorts of individuals (Meehan et al. 2022). The validity of each prediction model should be measured with discrimination metrics, calibration, and overall performance (Table 6) (Fusar-Poli et al. 2018). Finally, the clinical impact of each model should be measured with simulation studies or real-world experimental studies (Meehan et al. 2022). We account for these and other

methodological aspects of prediction typically measured with the Prediction model Risk Of Bias Assessment Tool (PROBAST) (Wolff et al. 2019), updating a previous systematic review focusing on prediction of psychosis. The study selection flow of the updated systematic review (Salazar de Pablo, Studerus, et al. 2021) on prediction and prognosis models with proper internal or external validation specifically focusing on CHR-P status and prediction of psychosis onset, is reported in eFigure 5. Out of 1742 hits, we ultimately identified 40 additional studies since previous reviews (Fusar-Poli, Stringer, et al. 2019; Osborne and Mittal 2019; Zarogianni et al. 2019; Zhang et al. 2019; Bourgin et al. 2020; Collin et al. 2020; Oliver, Wong, et al. 2020; Perkins et al. 2020; Raket et al. 2020; Studerus et al. 2020; Yassin et al. 2020; Dickens et al. 2021; Grent't-Jong et al. 2021; Haining et al. 2021; Hauke et al. 2021; Irving et al. 2021; Koutsouleris et al. 2021; Mongan et al. 2021; Puntis et al. 2021; Worthington et al. 2021; Antonucci et al. 2022; Dwyer et al. 2022; Koutsouleris et al. 2022; Lee et al. 2022; Li Z et al. 2022; Moore et al. 2022; Sullivan et al. 2022; Worthington et al. 2022; Doborjeh et al. 2023; Iftimovici et al. 2023; Loch et al. 2023; Lyu et al. 2023; Mondelli et al. 2023; Argolo et al. 2024; Byrne et al. 2024; Hartmann et al. 2024; Kizilay et al. 2024; Krakowski et al. 2024; Reinen et al. 2024; Sprungli-Toffel et al. 2024; Zhu Y et al. 2024), highlighting an increased research interest in the field. Studies excluded after full-text assessment, with reason for exclusion, are reported in eTable 6. The systematic review found that all prediction models published in the field of CHR-P status and prediction of psychosis onset were at high risk of bias according to PROBAST. The largest source of bias was the analysis domain. A critical factor was that studies tended to include too many variables per number of events, or even completely neglected this aspect, not even reporting information to assess EPV (Fusar-Poli et al. 2018). Another critical factor was the inclusion of a component of the outcome (i.e. positive symptoms) among predictors. Only 11 studies externally validated models in a sample with ≥ 100 events (Fusar-Poli et al. 2018). Finally, only three prediction models (Fusar-Poli, Rutigliano, Stahl, Davies, Bonoldi, et al. 2017; Raket et al. 2020; Krakowski et al. 2024) assessed clinical utility, applying decision-curve analyses, aiming to measure the potential 'net benefit' over routine practice (Fusar-Poli et al. 2018). Hence, despite methodological limitations in the field of mental health, in psychiatry the field of prevention of psychosis is the one where the most progress has been made in terms of clinical prediction. Nevertheless, the

potential implementation of prediction models requires ethical considerations.

Regarding the ethical considerations around risk prediction and communication, a recent review and consensus statement involving multidisciplinary stakeholders led by the European College of Neuropsychopharmacology Prevention of Severe Mental Disorders (PSMD) Cluster and funded by the European Brain Research Area (EBRA) provided a unique ethical insight on how researchers and clinicians should assess and communicate risk calculated with a novel clinical prediction model (Fusar-Poli, Manchia, et al. 2022). Such an ethical framework applies well to assessing and communicating the risk of transition to psychosis in subjects meeting CHR-P criteria. Research and clinical practice should always follow key ethical principles, namely autonomy, beneficence, non-maleficence, justice, and explainability/interpretability. These principles should guide the clinical implementation of precision psychiatry, risk assessment and communication. Briefly, some overarching clinically relevant principles are necessary for an ethical implementation of risk calculations and precision psychiatry in the field of prevention of psychosis (and beyond). These include offering human-to-human interaction to users, only relying on validated clinical prediction models that must be transparent and reproducible and administered by appropriately trained operators. The definition of ethical principles, and the reasons for their clinical implementation are described in more detail in Table 6.

3.1.6. Randomised controlled trials to prevent psychosis

The study selection flow of the systematic review of RCTs in subjects meeting CHR-P status criteria is reported in eFigure 6 (Table 7). Out of initial 1207 hits, we ultimately included 44 RCTs reported across 70 publications (McGorry et al. 2002; Morrison et al. 2004; McGlashan et al. 2006; Nordentoft et al. 2006; Morrison et al. 2007; Ruhrmann et al. 2007; Amminger et al. 2010; Addington et al. 2011; Bechdolf et al. 2011; Yung et al. 2011; Bechdolf et al. 2012; Morrison et al. 2012; van der Gaag et al. 2012; McGorry et al. 2013; Woods SW et al. 2013; Miklowitz et al. 2014; Kantrowitz et al. 2015; Piskulic et al. 2015; Ising et al. 2016; Loewy et al. 2016; Stain et al. 2016; Albert et al. 2017; Bechdolf et al. 2017; Cadenhead K et al. 2017; Choi et al. 2017; McGorry et al. 2017; Woods S et al. 2017; Bhattacharyya et al. 2018; Mossaheb, Papageorgiou, et al. 2018; Mossaheb, Schäfer, et al. 2018; Nelson et al. 2018; Piskulic et al. 2018; TD et al. 2018; Berger et al. 2019; Bolt et al. 2019; Cadenhead KS et al. 2019; Davies, Paloyelis, et al. 2019; Davies, Rutigliano, et al. 2019;

Pozza et al. 2019; Wessels et al. 2019; Wilson et al. 2019; Alqarni et al. 2020; Amminger et al. 2020; Appiah-Kusi et al. 2020; Davies, Wilson, et al. 2020; Glenthøj et al. 2020; Kristensen et al. 2020; Mallawaarachchi et al. 2020; Schmidt A et al. 2020; Glenthøj et al. 2021; Li H et al. 2021; Myin-Germeys et al. 2021; Pozza et al. 2021; Rinne et al. 2021; Tsai et al. 2021; Friedman-Yakoobian et al. 2022; Addington, Liu, et al. 2023; Bechdolf et al. 2023; Davies et al. 2023; McGorry et al. 2023; Tang et al. 2023; Waite et al. 2023; Zhao J et al. 2023; Zhu H et al. 2023; Davies, Bossong et al. 2024; Davies, Martins et al. 2024; Livingston et al. 2024; Qurashi et al. 2024; Wasserthal et al. 2024) with publicly available results, plus 30 RCTs that are still ongoing or for which results are not publicly available. Studies excluded after full-text assessment, with reason for exclusion, are reported in eTable 7. Details of the included RCTs are reported in Table 7, while characteristics of RCTs still ongoing or for which no results are available are described in eTable 8.

Among the RCTs that reported results, eight studies focused on cognitive therapy or CBT or CBT-informed interventions (Morrison et al. 2004; 2007; Addington et al. 2011; Morrison et al. 2012; van der Gaag et al. 2012; Ising et al. 2016; Stain et al. 2016; Pozza et al. 2019, 2021; Addington, Liu, et al. 2023; Waite et al. 2023), 14 on other psychosocial interventions (Nordentoft et al. 2006; Bechdolf et al. 2012; Miklowitz et al. 2014; Piskulic et al. 2015; Loewy et al. 2016; Albert et al. 2017; Choi et al. 2017; Piskulic et al. 2018; TD et al. 2018; Wessels et al. 2019; Glenthøj et al. 2020; Kristensen et al. 2020; Glenthøj et al. 2021; Li H et al. 2021; Myin-Germeys et al. 2021; Rinne et al. 2021; Tsai et al. 2021; Friedman-Yakoobian et al. 2022; Zhao J et al. 2023), 16 on biological interventions (McGlashan et al. 2006; Ruhrmann et al. 2007; Amminger et al. 2010; Woods SW et al. 2013; Kantrowitz et al. 2015; Cadenhead K et al. 2017; Woods S et al. 2017; Bhattacharyya et al. 2018; Mossaheb, Papageorgiou, et al. 2018; Mossaheb, Schäfer, et al. 2018; Cadenhead KS et al. 2019; Davies, Paloyelis, et al. 2019; Davies, Rutigliano, et al. 2019; Wilson et al. 2019; Appiah-Kusi et al. 2020; Davies, Wilson, et al. 2020; Schmidt A et al. 2020; Davies et al. 2023; Tang et al. 2023; Zhu H et al. 2023; Davies, Bossong et al. 2024; Davies, Martins et al. 2024; Livingston et al. 2024; Qurashi et al. 2024), and six on combined (i.e. psychosocial plus biological) interventions (McGorry et al. 2002; Bechdolf et al. 2011; Yung et al. 2011; McGorry et al. 2013; Bechdolf et al. 2017; McGorry et al. 2017; Nelson et al. 2018; Berger et al. 2019; Bolt et al. 2019; Alqarni et al. 2020; Amminger et al. 2020; Mallawaarachchi et al. 2020;

Table 7. Individual randomised controlled trials to prevent psychosis in people at clinical high risk for psychosis.

Author, year/RCT/Rob	Centre	Referrals	CHR-P definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment†	Improve from baseline within group
Cognitive therapy or cognitive-behavioural therapy (Addington et al. 2011) High Rob	PRIME Clinic, CAMH, Toronto, Canada	Primary care (GP), mental health specialists, general population (radio, public transport, newspapers)	SIPS	51 27/ 24	21 14 to 30	SB	Problem-focused CBT (up to 20 sessions) (audiotaped for treatment fidelity) (French and Morrison 2004)	Supportive therapy	6M	Transition , positive, negative, depressive, anxiety symptoms, social functioning, drop-out	None	Problem-focused CBT (positive, anxiety symptoms) Supportive therapy (positive, depressive, anxiety symptoms)
(Addington, Liu, et al. 2023) NCT02234258 Some concerns	University of Calgary, Canada; University of California, San Diego, US; Zucker Hillside Hospital, New York, US	Health care providers, educators, social service agencies and self-referrals	SIPS	152 70/ 82	17,36 17,49 12 to 13	SB	Cognitive-Behavioural Social Skills Training (CBT SST)	Supportive therapy	4,5M	Global social functioning , defeatist beliefs	None	CBT SST (defeatist beliefs, social functioning, social self-efficacy) Supportive therapy (positive, negative, depressive, anxiety symptoms)
(Morrison et al. 2004; 2007) High Rob	NR	Primary care, student counselling services, emergency departments, mental health specialists, voluntary sector agencies	PACE PAINS BPRS	60 37/23	22 16 to 36	SB	Cognitive therapy + monitoring	Monitoring	12M	Transition , positive symptoms, functioning, distress	Cognitive therapy (Transition)	NP
(Morrison et al. 2012) High Rob	Manchester, Birmingham/ Worcestershire, Glasgow, Cambridgeshire, Norfolk, UK	Primary and secondary healthcare professionals	CAARMS	288 144/144	20,74 14 to 35	SB	Cognitive therapy + monitoring	Monitoring	12M	Transition, severity of symptoms, distress , emotional dysfunction, quality of life	Cognitive therapy (severity of symptoms)	NR
(Pozza et al. 2019; 2021) High Rob	Florence, Prato, Italy	Five community mental health centres	CAARMS	58 29/29	25,41 (CBT) 26 (control) 16 to 35	SB	CBT	Individual supportive sessions	7 M	Transition , anxiety symptoms, depressive symptoms	CBT (Transition , depressive symptoms, anxiety symptoms)	CBT (depressive symptoms, anxiety symptoms) Individual supportive sessions (depressive symptoms, anxiety symptoms)
(Stain et al. 2016) ANZCTR 12606000101583 High Rob	Psychological Assistance Service, Newcastle; Centre for Rural and Remote Mental Health, Orange, Australia	Primary healthcare services, self-referrals, community mental health services, community adolescent teams, counselling services, youth-related services	CAARMS SCID K-SADS	57 30/27	16,5 14 to 30	SB	CBT	Non Directive Reflective Listening	18M	Transition , functioning, distress, symptom severity, quality of life	Non Directive Reflective Listening (distress)	CBT (symptom severity) Non Directive Reflective Listening (symptom severity, distress)

(Continued)

Table 7. Continued.

Author, year/RCT/RoB	Centre	Referrals	CHR-P definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment ^a	Improve from baseline within group
(van der Gaag et al. 2012; Ising et al. 2016) ISRCTN21353122 High RoB	Mental Health Centre PsyQ Haaglanden, the Hague, Academic Medical Centre and Mental Health Centre PsyQ, Amsterdam, Mental Health Centre Rivierduinen, Leiden Mental Health Institute Friesland, Friesland, Amsterdam	General practitioners	CAARMS Prodromal Questionnaire	201 97/104	22.9 (experimental) 22.6 (control) 14 to 35	SB	CBT for ultra high risk patients with Treatment as usual	Treatment as usual	24M	Transition , depression, anxiety, quality of life, functioning, beliefs about illness	CBT UHR (Transition)	CBT for ultra-high risk with Treatment as usual (depression, anxiety, distress) Treatment as usual (anxiety, depression)
(Waite et al. 2023) ISRCTN85601537 Low RoB	Oxford Health NHS Foundation Trust, Berkshire Healthcare NHS Foundation Trust, England, UK	Mental health services	CAARMS	40 21/19	16.9 14 to 23	SB	SleepWell therapy with Treatment as usual	Treatment as usual	3M	Insomnia severity , as usual (Insomnia severity), psychotic experiences, depressive, anxiety symptoms	SleepWell therapy+Treatment as usual (Insomnia severity)	NR
Other psychosocial interventions												
(Bechdolf et al. 2012; Wessels et al. 2019) NCT00204087 High RoB	Department of Psychiatry and Psychotherapy in Cologne, Bonn, Düsseldorf, Munich, Germany	Primary care, mental health specialists, counsellors	Eliraos, RAO5	128 63/65	26.0 NA	OL	Integrated psychological intervention (combination of CBT/ST/CRT/ EDU)/A et al. 2010)	Supportive counselling	12M	Transition , treatment response	Integrated psychological intervention (transition)	NP
(Nordentoft et al. 2006) High RoB	Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark (Petersen et al. 2005)	All inpatient and outpatient mental health services in Copenhagen (Copenhagen Hospital Corporation) and Aarhus county	ICD-10 (Schizotypal disorder)	79 42/37	24.9 18 to 45(Petersen et al. 2005)	OL	Integrated treatment (assertive community treatment, individual or group social skills training, EDU in multiple family groups)	Standard treatment	24M	Transition , psychotic, negative, disorganised symptoms	Integrated treatment (Transition , negative symptoms)	NR
(Albert et al. 2017) High RoB	Mental Health Centre Copenhagen, Kildegaardsvej, Denmark	6 Danish OPUS teams (5 in Copenhagen, and one in Aarhus)	ICD-10 (schizotypal disorder)	83 39/44	26.6 18 to 35	SB	Integrated treatment (family treatment, and skill training)	Treatment as usual	6M	Transition , psychotic, negative, disorganised symptoms, substance use, functioning, employment status, cognitive function	None	OPUS Treatment (Negative symptoms, functioning) Treatment as usual (Negative symptoms, functioning)
(Choi et al. 2017) Some concerns	Institute of living in Hartford, CT, and COPE in New York State Psychiatric Institute, Columbia University, US	Mental health specialists	SIPS SOPS	62 31/31	18.35 16 to 24	DB	Processing Speed Training (tablet-based cognitive training with pupillometric neurofeedback)	Placebo training	2M	Cognition (processing, speed) , social functioning, depressive, anxiety symptoms	PST (cognition)	PST (cognition)
(Friedman-Yakoobian et al. 2022) High RoB	NR	Social Media, online advertisements, clinicians, schools, universities	COPS SIPS	38 20/18	19.2 (Intervention) 19.1 (Control) 15 to 26	SB	Cognition for Learning and for Understanding Everyday Social Situations (CLUES)	Enriched Acceptance and Commitment Therapy (EnACT)	9M	Social functioning , psychotic symptoms, cognition	CLUES (social functioning, social cognition)	CLUES (social functioning, social cognition, positive symptoms, visual memory, reaction time) EnACT (positive symptoms, visual memory, reaction time)

(Continued)

Table 7. Continued.

Author, year/RCT/RoB	Centre	Referrals	CHR-P definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment*	Improve from baseline within group
(TD et al. 2018; Gienhøj et al. 2020; Kristensen et al. 2020; Gienhøj et al. 2021)	Mental Health Centre Copenhagen, Denmark	Psychiatric in- and out-patient facilities of the catchment area of Copenhagen	CAARMS	146/73/73	23.93 (Intervention) 23.90 (Control) 18 to 40	SB	Cognitive remediation with treatment as usual	Treatment as usual	6M	Cognitive functioning. clinical symptoms, social and role functioning, white matter organisation	None	NR
NCT02098408 High RoB	Shanghai Mental Health Centre, Suzhou	NR	SIPS	80/40/40	20.51 14 to 45	SB	SMART (Specific Memory Attention Resource and Training) app	Treatment as usual	3M	Cognitive function	SMART (Attention/vigilance)	SMART (Attention/vigilance)
ChiCTR2000031741 High RoB	Guangji Hospital	Mental health specialists, primary care, general population (schools, internet)	SIPS	83	18.2 12 to 30	DB	Auditory training (AT) (laptop-based auditory processing-based training)	Placebo training (computer gaming) (CG)	2M	Cognition (verbal memory). positive, negative, disorganised symptoms, functioning	AT (cognition, disorganised symptoms)	AT (cognition, positive, negative, disorganised symptoms, functioning)
(Loewy et al. 2016) NCT00655239 Some concerns	Psychiatry Department, San Francisco, US											CG (positive, negative, disorganised symptoms, functioning)
(Miklowitz et al. 2014; Rime et al. 2021)	NAPLS-2 consortium: Atlanta, Cambridge, Los Angeles, San Diego, Chapel Hill, New Haven, New York, US; Calgary, Canada	Health care providers, educators, social service agencies, general population (schools, internet) ¹⁰⁸	SIPS	129/66/63	17.4 12 to 32	NR	Family-focused treatment for individuals at CHR	Family EDU (Enhanced care)	6M	Positive symptoms. negative symptoms, functioning, family interaction, depression	Family-focused treatment (Positive symptoms)	Family focused therapy (Positive symptoms, negative symptoms, functioning)
NCT01907282 High RoB												Family EDU (Enhanced Care) (Neative symptoms, functioning)
(Reininghaus et al. 2019) NTR4252 High RoB	INTERACT trial: 5 regions in Belgium and the Netherlands	Treating clinicians	CAARMS	148/71/77	25 15 to 65	SB	Acceptance and Commitment Therapy in Daily Life (ACT-DL)	Standard care	12M	Psychotic distress. social functioning, symptom severity	ACT-DL (psychotic distress, negative symptoms, global functioning)	NR
(Piskulic et al. 2015) Some concerns	At Risk for Mental Illness Research group Calgary, Canada	Health care providers, educators, social service agencies, general population (schools, internet)	SIPS	32/18/14	19.72 (Intervention) 17.5 (Control) 14 to 35	SB	Auditory processing CRT (Brain Fitness Program)	Placebo (video games)	9M	Cognition. functioning, positive, negative symptoms,	None	Placebo (cognition) CRT (cognition, functioning)
(Piskulic et al. 2018) High RoB	At Risk for Mental Illness Research group, Calgary, Canada	Mental health agencies, school counselling services, community general population (outreach campaigns)	SOPS	12/7/5	19.0 (Median, Intervention) 20.0 (Median, control) 14 to 25	SB	CRT+ Motivational interviewing	CRT only	2M	Attrition rates	NR	NR
(Tsai et al. 2021) High RoB	China Medical University Hospital, Taiwan	NR	Chinese Version of Schizotypal Personality Questionnaire-Brief (CSPQ-8) Chinese Mandarin State and Trait Anxiety Form- Y (CMSTAL-Y)	92/46/46	21.34 20 to 35	NR	Health-awareness-strengthening lifestyle program (HASL)	Waitlist control	0.5M	Health promotion lifestyle, nutrition, physical exercise, quality of life, anxiety	HASL (health promotion lifestyle, nutrition, quality of life, anxiety)	HASL (self-actualization aspects of health promotion lifestyle, anxiety)

(Continued)

Table 7. Continued.

Author, year/RCT/RoB	Centre	Referrals	CHRP definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment*	Improve from baseline within group
(Zhao J et al. 2023) ChiCTR200039623 Low RoB	Beijing Anding Hospital, China	Referral from treating psychiatrists, Self-referral	SIPS	57 28/29	25.5 18 to 35	SB	EMDR	Waiting list	3M	PTSD symptoms , positive, anxiety, depressive symptoms, suicidal ideation	EMDR (PTSD symptoms , positive, anxiety, depressive symptoms, suicidal ideation)	EMDR (PTSD symptoms , positive, anxiety, depressive symptoms, suicidal ideation)
Biological interventions												
(Amminger et al. 2010; Mossaheb, Papageorgiou, et al. 2018; Mossaheb, Schafer, et al. 2018) NCT00396643 Low RoB	Psychosis detection unit, Vienna General Hospital, Austria	Mental health specialists, counsellors	PANSS, clinical interview accounting for CAARMS frequency criteria, and GRD definition	81 41/40	16.4 13 to 25	DB	ω -3 PUFAs (1.2 grams daily) + NBI (9 sessions of pharmacological (AD, BDZ), psychological, psychosocial intervention including case-management with social support)	Placebo + NBI (9 sessions of pharmacological (AD, BDZ), psychological, psychosocial intervention including case-management with social support)	3M	Transition , positive, negative, general, depressive symptoms, functioning, drop-out, lipid profile	ω -3 PUFAs (transition , positive, negative, general symptoms, and functioning)	NR
(Gadenhead K et al. 2017; Gadenhead KS et al. 2019) NCT01429454 Low RoB	NAPLS Consortium	Mental health specialists, schools, colleges primary care	SIPS	127	18.69 12-30	DB	ω -3 PUFAs (700 mg EPA, 480 mg DHA)	Placebo	6M	Transition , cardiometabolic, dietary Omega 3 fatty acids and oxidative stress indices	None	ω -3 PUFAs (positive, functioning)
(Davies et al. 2023; Davies C. et al. 2024) ISRCTN4632781 High RoB	Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK	NR	CAARMS	52 33/ 19	22.7 23.9 /24.1 18 to 35	DB	Single oral dose of 600mg of Cannabidiol (CBD)	Placebo	0.03M (one day)	Hippocampal blood flow ⁴⁹	Single oral dose of 600 mg of Cannabidiol (CBD) (hippocampal blood flow, hippocampal glutamate)	NP
(Davies Cathy et al. 2024) ISRCTN48799530 Some concerns	Outreach and support in South-London (OASIS) service, London, UK; Maudsley NHS Foundation Trust, London, UK	NR	CAARMS	50 33/ 17	23.2 24.2 18 to 35	DB	40IU intranasal oxytocin (two parallel [CHRP vs healthy controls] crossover design)	Placebo (two parallel [CHRP vs healthy controls] crossover design)	0.07M (2 days)	Functional brain network topology , (including network organisation in subcortical and cortical regions)	40IU intranasal oxytocin (functional brain network topology)	NP
(Bhattacharyya et al. 2018; Appiah-Kusi et al. 2020; Davies, Wilson, et al. 2020) ISRCTN4632781 Low RoB	King's College, London loPPN, UK	Early intervention service	CAARMS	52 16/17	22.43 NA	DB	Cannabidiol (600 mg)	Placebo ⁵	0	fMRI BOLD signal during encoding, recall and recollection , cannabidiol, cortisol, activity of the medial temporal lobe and striatum during fear processing	Cannabidiol (encoding, recall)	NP
(Wilson et al. 2019) Low RoB	Kings College London, London UK Clinical Research Facility	Early intervention service	CAARMS	33	NR 18 to 35	DB	Cannabidiol (600 mg)	Placebo, Healthy Control (Not CHR, no CBD administered)	NA (cross-sectional)	Behavioural performance (5 domains: mean monetary reward, accuracy, reaction time, false-starts, any trial responses)	CHR-CBD (Reaction time, false starts)	NP
(Davies, Paboyelis, et al. 2019; Rutigliano, et al. 2019; Schmidt A et al. 2020) Low RoB	NR	Two early detection services: The OASIS and Tower Hamlets Early Detection Service	CAARMS	30	NR 18 to 35	DB	Intranasal oxytocin (40IU)	Placebo	0	Global cerebral blood flow , hippocampal cerebral blood flow, choline in ACC, cognitive and social empathy	Intranasal oxytocin (hippocampal cerebral blood flow)	NP

(Continued)

Table 7. Continued.

Author, year/RCT/RoB	Centre	Referrals	CHRP definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment ^a	Improve from baseline within group
(Kantrowitz et al. 2015) NCT00826202 Low RoB	Nathan Kline Institute, Yale, Zucker Hillside Hospital, and New York State Psychiatric Institute, US	Mental health specialists, primary care	SOPS	44 20/24	19.5 13 to 35	DB	D-serine	Placebo	4M	Negative symptoms, positive symptoms, cognition, sleep	D-serine (negative symptoms)	D-serine (negative symptoms)
(Livingston et al. 2024) NCT06190483 Low RoB	Outreach and Support in South London (OASIS), South London and Maudsley NHS Foundation Trust	NR	CAARMS	66 24/ 22	25.3 18 to 32	DB	5 mg of oral diazepam (crossover design)	Placebo (crossover design)	0.5M	Hippocampal regional cerebral blood flow [rCBF]	Diazepam (Hippocampal regional cerebral blood flow [rCBF])	NP
(Qurashi et al. 2024) NCT02569307 Low RoB	Abasi Shaheed Hospital, Karachi Pakistan; Civil hospital Karachi, Karachi, Pakistan; Karwn e Hayat, Karachi Pakistan; Colleges and Universities, Karachi Pakistan; General Practitioners Karachi Pakistan; Institute of Behavioural Sciences, Karachi Pakistan	Self-referrals	CAARMS	326 82/ 82/ 82/ 80	24 16 to 25	DB	1. Minocycline 2. omega-3 fatty acids 3. minocycline+ omega-3 fatty acids	Double placebo	6M	Transition to psychosis, positive, depressive symptoms, social and role functioning	None	omega-3 fatty acids (positive, depressive symptoms [among non-transitioners]) minocycline+ omega-3 fatty acids (positive, depressive symptoms [among non-transitioners])
(McGlashan et al. 2006) Low RoB	PRIME clinics: Yale, North Carolina/ Chapel Hill, US; Calgary, Toronto, Canada.	Clinicians, general population (advertisements)	SIPS	60 31/29	17.7 12 to 45	DB	Olanzapine (5–15mg)	Placebo	12M	Transition, positive, negative, general, depressive, manic symptoms, functioning, drop-out	None	Olanzapine (total, positive symptoms, functioning) (functioning)
(Ruhmann et al. 2007) High RoB	Departments of Psychiatry, Cologne, Bonn, Dusseldorf, Munich, Germany	Psychologists, psychiatrists, general practitioners, school or university counselling services, self-referrals	ERIAS ERI-BAPPSS	124 65/59	25.6 18–36	OL	Needs-focused intervention+amisulpride (50–800 mg/day)	Needs-focused intervention only	24M	Positive symptoms, negative, depressive, basic symptoms, functioning	Needs-focused intervention + amisulpride (positive symptoms, negative symptoms, basic symptoms, functioning)	Needs-focused intervention + amisulpride (positive symptoms, negative symptoms, basic symptoms, functioning) (positive symptoms, negative symptoms, depressive symptoms) Needs-focused intervention only (depressive symptoms)
(Tang et al. 2023) ChiCTR-16009566 High RoB	Shanghai Mental Health Centre, China	Shanghai At-Risk for Psychosis Program (SHARP)	SIPS SOPS	65 31/ 27	19 15 to 45	DB	TMS	Sham TMS	0.5M	Visual spatial learning (VSL), cognitive functioning, transition to psychosis at 12 M	TMS VSL performance, transition to psychosis at 12M)	TMS VSL performance and precision)
(Woods SW et al. 2013) NCT0026874 NCT00291226 Low RoB	PRIME Research Clinic, Yale University, New Haven, USA	Community education efforts	COPS SOPS	8 4/4	15.3 (Intervention) 16.5 (Control) 15 to 17	DB	Glycine (0.8 g/kg/d)	Placebo	3M	SOPS total score, positive, negative, disorganisation, general symptoms, depressive symptom severity, cognition	Glycine (Depressive symptoms)	Glycine (SOPS total, positive, negative, disorganisation, general symptoms, depressive symptoms)

(Continued)

Table 7. Continued.

Author, year/RCT/RoB	Centre	Referrals	CHR-P definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment*	Improve from baseline within group
(Woods S et al. 2017) Low RoB	Atlanta, Los Angeles, San Diego, San Francisco, Glen Oaks, Detroit, Worcester, Boston, New Haven, Chapel Hill, US; Calgary, Canada	Clinician referral	SIPS SOPS	51 24/27	22.3 16 to 40	DB	Ziprasidone (20–160mg/d)	Placebo	6M	Transition , positive symptoms	Ziprasidone (Positive symptoms)	NR
(Zhu H et al. 2023) ChiCTR-IOR-17013513 High RoB	Beijing Anding Hospital, China	NR	SIPS	80 37/ 40	19.76 16 to 30	DB	Shi-Zhen-An-Shen Herbal Formula Granule (SZAS-HFG) + placebo for aripiprazole	Aripiprazole + placebo for SZAS-HFG	3M	Positive symptoms, cognitive functioning, general functioning	Shi-Zhen-An-Shen Herbal Formula Granule (SZAS-HFG) + placebo for aripiprazole (general functioning)	NR
Combined (psychosocial plus pharmacological) interventions												
(Bechdolf et al. 2011; 2017; 2023) of = 631fa13b1e f64d766dbf185 e6d89de17 Some concerns	6 sites in Germany (University of Cologne; Rheinische Friedrich-Wilhelm University; Heinrich-Heine University; Ludwig-Maximilian-Universität; Charité-Universitätsmedizin, Berlin; Campus Charité- Mitte, Berlin; University of Göttingen; University of Aachen)	Mental health professionals or self-referrals	SIPS SOPS SPIA	280 129/ 96/ 55	24.4 18 to 49	DB aripiprazole SB CBT	1. CBT 2. Aripiprazole + clinical management	Placebo + Clinical management	12 M	Transition to psychosocial , time to transition, psychopathological symptoms, psychosocial functioning, safety, side effects	None	All arms (positive and disorganisation symptoms, basic symptoms [COGDIS], psychosocial functioning, and depression)
(McGorry et al. 2002) High RoB	PACE clinic, Melbourne, Australia	Mental health specialists, primary care, general population (schools)	CAARMS	59 31/28	20 14 to 30	SB	Specific Prevention Intervention (NBI) + risperidone [1–2mg] + CBT ^{†,26)}	NBI (pharmacological (AD, BDZ), psychological, psychosocial interventions including case-management with social support)	6M	Transition	SPI (transition)	NR
(Yung et al. 2011; McGorry et al. 2013) ACTRN01260 5000247673 Low RoB	PACE Clinic, Melbourne, Australia	NR	CAARMS	115 43/44/28	18.1 14–30	DB	Risperidone (0.5–2mg/day) + CBT	CBT + placebo, supportive therapy + placebo	12M	Transition , psychiatric symptoms, psychosocial functioning, quality of life	None	Risperidone (0.5–2 mg/day) + CBT (negative symptoms, psychosocial functioning) CBT + Placebo (negative symptoms, psychosocial functioning) Supportive therapy + Placebo (negative symptoms, psychosocial functioning)

(Continued)

Table 7. Continued.

Author, year/RCT/RoB	Centre	Referrals	CHR-P definition	N	Age	Blinding	Intervention	Control	Duration*	Primary and other outcomes	Superior treatment*	Improve from baseline within group
(McGorry et al. 2017; Nelson et al. 2018; Berger et al. 2019; Bolt et al. 2019; Alcañal et al. 2020; Amminger et al. 2020; Mallawaarachchi et al. 2020) 12608000475347 Low RoB	Melbourne, Sydney, Australia; Vienna, Austria; Copenhagen, Denmark; Hong Kong; Jena, Germany; Amsterdam, Netherlands; Singapore; Basel, Zurich, Switzerland;	Mental health specialists	CAARMS	304 153/151	19.1 13 to 40	DB	ω -3 PUFAs (1.4 grams daily) + CBCM	Placebo + CBCM	6M	Transition: total, negative, depressive, manic symptoms, functioning, erythrocyte lipid species	Placebo (functioning)	NR
(McGorry et al. 2023) NCT02751632 Low RoB	Personal Assessment and Crisis Evaluation (PACE) clinic; 4 headspace centres	NR	CAARMS	342 Step 1: 342 Step 2: 281 Step 3: 138	12 to 25	DB	Multiple assignment randomised trial (SMART) consisting of three steps: Step 1: Support and problem solving (SPS) (1.5months); Step 2: SPS vs CBCM (4.5 months); Step 3: CBCM+Antidepressant Medication vs CBCM + Placebo (6 months)	Monitoring	12M	Social and role functioning, general psychopathology, negative, depressive, positive symptoms, quality of life, cognitive biases	None	NR
(Wassersherl et al. 2024) NCT03149107 Low RoB	11 sites in Germany (University Hospital of Bonn; University Hospital of Cologne; University of Oldenburg; University of Heidelberg; Regensburg; RWTH Aachen University; Charité Universitätsmedizin; Ludwig Maximilian University of Munich; University of Tübingen; Vivantes Klinikum Am Urban; LVR-Clinik Bonn)	Self-referred in early detection facilities, health care providers	SIPS SPI-A	48 23/24	24.9 15 to 45	DB SB	1. N-acetylcysteine (NAC) 2. Integrated Preventive Psychological Intervention (IPIPI)	1. Placebo (PLC) for NAC 2. Psychological Stress Management (PSM) for IPIPI	6.5M	Transition to psychosis, social functioning, social cognition, neurocognitive capabilities	None	None

Legend: AD: antidepressants; BDZ: benzodiazepines; BPRS: Brief Psychiatric Rating Scale; CAARMS: Comprehensive Assessment of At-Risk Mental State; CAMH: Centre for Addiction and Mental Health; CBCM: Cognitive Behavioural Case Management; CBT: cognitive behavioural therapy; COPE: Centre of Prevention and Evaluation; (CICR): computerised cognitive-remediation therapy; DB: double-blind; EMDR: eye movement desensitisation and reprocessing; EDU: psychoeducation; EHRs: Early Recognition Inventory; ER-BAPPSS: Early Recognition Inventory; Basic and Positive Psychotic Spectrum Symptoms score; GRD: Genetic risk and Deterioration Syndrome; IRAOS: Retrospective Assessment of the Onset of Schizophrenia; M: months; NBI: needs-based interventions; NP: not pertinent; OL: open label; PACE: Personal Assessment and Crisis Evaluation; PANSS: Positive And Negative Symptoms Scale; PRIME: Prevention Through Risk Identification, Management, and Education; PUFAs: polyunsaturated fatty acids; PTSD: post-traumatic stress disorder; RoB: risk of bias; SB: single-blind; SIPS: Structured Interview for Prodromal Symptoms; SOPS: Scale Of Prodromal Symptoms; SPIA: Schizophrenia Proneness Instrument, Adult version; ST: skills training; T: time points; TMS: transcranial magnetic stimulation; W: weeks* : duration of randomised treatments; rounded to months; #: only outcomes where the intervention was statistically significantly superior to control were considered; §: also included healthy control group, not reported as not pertinent. Edited from (McGorry et al. 2002; Morrison et al. 2004; McGlashan et al. 2006; Nordentoft et al. 2006; Morrison et al. 2007; Ruhrmann et al. 2010; Addington et al. 2011; Yung et al. 2011; Bechdolf et al. 2012; Morrison et al. 2012; van der Gaag et al. 2012; McGorry et al. 2013; Woods SW et al. 2013; Miklowitz et al. 2014; Kantrowitz et al. 2015; Ising et al. 2016; Loewy et al. 2016; Berger et al. 2019; Bolt et al. 2018; Piskulic et al. 2018; TD et al. 2018; Berger et al. 2019; Cadenhead KS et al. 2019; Davies, Paloyelis, et al. 2019; Pozza et al. 2019; Wessels et al. 2019; Bhattacharyya et al. 2018; Mossaheh, Papageorgiou, et al. 2018; Mossaheh, Schäfer, et al. 2020; Appiah-Kusi et al. 2020; Glenthøj et al. 2020; Kristensen et al. 2020; Mallawaarachchi et al. 2020; Schmidt A et al. 2020; Glenthøj et al. 2021; Li H et al. 2021; Myin-Germeys et al. 2021; Pozza et al. 2021; Rinne et al. 2021; Tsai et al. 2021; Friedman-Yakobian et al. 2022; Addington, Liu, et al. 2023; Bechdolf et al. 2023; Davies et al. 2023; Tang et al. 2023; Zhao J et al. 2023; Waite et al. 2023; McGorry et al. 2023; Davies, Bossong et al. 2024; Livingston et al. 2024; Qurashi et al. 2024; Wassersherl et al. 2024).

Bechdolf et al. 2023; McGorry et al. 2023; Wasserthal et al. 2024). The results are descriptively reported in Table 7 for both primary and secondary outcomes. Eight RCTs compared CBT with a control intervention, focusing on transition to psychosis as an outcome in six (Morrison et al. 2004; 2007; Addington et al. 2011; Morrison et al. 2012; van der Gaag et al. 2012; Ising et al. 2016; Stain et al. 2016; Pozza et al. 2019, 2021) of these. In only three (Morrison et al. 2004; 2007; van der Gaag et al. 2012; Ising et al. 2016; Pozza et al. 2019, 2021) of these six RCTs CBT outperformed the control group in reducing the transition rate. Of the 14 RCTs on other psychosocial interventions, only integrated psychological intervention outperformed the control group in two RCTs regarding transition to psychosis (Nordentoft et al. 2006; Bechdolf et al. 2012; Wessels et al. 2019), and one more recent RCT found no superiority for this intervention (Albert et al. 2017). Of the RCTs testing biological and combined interventions, ω -3 PUFAs outperformed placebo on transition in one RCT (Amminger et al. 2010; Mossaheb, Papageorgiou, et al. 2018; Mossaheb, Schäfer, et al. 2018), but no difference emerged in three subsequent RCTs (Cadenhead K et al. 2017; McGorry et al. 2017; Nelson et al. 2018; Berger et al. 2019; Bolt et al. 2019; Cadenhead KS et al. 2019; Alqarni et al. 2020; Amminger et al. 2020; Mallawaarachchi et al. 2020; Qurashi et al. 2024). Of the five RCTs testing combined interventions, needs-based interventions plus low-dose risperidone and CBT outperformed needs-based intervention alone on transition in an earlier RCT (McGorry et al. 2002); however, four more recent RCTs found no superiority for any combined intervention over control conditions (Bechdolf et al. 2011; Yung et al. 2011; McGorry et al. 2013; Bechdolf et al. 2017; McGorry et al. 2017; Nelson et al. 2018; Berger et al. 2019; Bolt et al. 2019; Alqarni et al. 2020; Amminger et al. 2020; Mallawaarachchi et al. 2020; Bechdolf et al. 2023; McGorry et al. 2023; Wasserthal et al. 2024). No other psychosocial or biological or combined interventions was superior to other interventions on transition to psychosis in CHR-P subjects.

3.1.7. Meta-analyses and network meta-analyses of randomised controlled trials

The study selection flow of the umbrella review of (network) meta-analyses of RCTs in subjects meeting CHR-P status criteria, is reported in eFigure 7 (Table 8). Out of initial 350 hits, we ultimately included 11 (network) meta-analyses (Preti and Cella 2010; Stafford et al. 2013; van der Gaag et al. 2013; Hutton and Taylor

2014; Davies, Cipriani, et al. 2018; Davies, Radua, et al. 2018; Bosnjak Kuharic et al. 2019; Fusar-Poli, Radua, et al. 2021; Mei et al. 2021; Fusar-Poli, Radua, et al. 2022; Zheng et al. 2022). Studies excluded after full-text assessment, with reason for exclusion, are reported in eTable 9.

Details on outcomes, sample size, interventions, and results of included (network) meta-analyses are reported in Table 8.

Out of 11 publications, nine only conducted pairwise meta-analyses (Preti and Cella 2010; Stafford et al. 2013; van der Gaag et al. 2013; Hutton and Taylor 2014; Bosnjak Kuharic et al. 2019; Fusar-Poli, Radua, et al. 2021; Mei et al. 2021; Fusar-Poli, Radua, et al. 2022; Zheng et al. 2022), and two conducted a network meta-analysis (Davies, Cipriani, et al. 2018; Davies, Radua, et al. 2018). All (network) meta-analyses considered a mix of psychosocial and pharmacological interventions.

Among the two network meta-analyses, as primary outcomes, one considered psychotic symptoms (Davies, Radua, et al. 2018), and one considered transition to psychosis (Davies, Cipriani, et al. 2018). No significant result emerged for transition to psychosis. Ziprasidone as augmentation of needs-based intervention (NBI) outperformed family CBT with/without risperidone in one network meta-analysis (Davies, Radua, et al. 2018) regarding attenuated psychotic symptoms.

Regarding transition to psychosis, in pairwise meta-analyses, all interventions pooled together outperformed TAU in three meta-analyses (Preti and Cella 2010; van der Gaag et al. 2013; Mei et al. 2021). Antipsychotics outperformed TAU in one meta-analysis (van der Gaag et al. 2013). CBT outperformed supportive therapy in one meta-analysis (Stafford et al. 2013), and CBT plus supportive therapy outperformed supportive therapy alone in one meta-analysis (Bosnjak Kuharic et al. 2019). CBT-informed treatment outperformed other treatments in three meta-analyses (Hutton and Taylor 2014; Mei et al. 2021; Zheng et al. 2022). Importantly, significant results regarding CBT on transition to psychosis were not confirmed in any network meta-analysis (see above), nor in two additional meta-analyses (Fusar-Poli, Radua, et al. 2021; 2022). Regarding other outcomes, CBT also outperformed supportive therapy on psychotic symptoms in one meta-analysis (Hutton and Taylor 2014). No difference emerged from other outcomes (Hutton and Taylor 2014; Mei et al. 2021; Zheng et al. 2022). Differences in the included studies across eligible meta-analyses might explain (part of) the differences in results, are described in Table 8.

Table 8. Network and pairwise meta-analyses on randomised controlled trials aiming to prevent psychosis in people at clinical high risk of psychosis (expanded from (Fusar-Poli, Davies, et al. 2019)).

Author, year	Source	Primary outcome, other outcomes	RCT-N	Interventions	Significant findings of primary analyses, random-effects model
(Preti and Cella 2010)	MA	Transition	5-180	CBT, CBT+RIS, IPI, monitoring, NBI, OLA, Om3, Pbo, TAU	Transition: all interventions pooled together No other significant findings
(Stafford et al. 2013)	MA	Transition	11-1,246	CBT, CBT+Pbo, CBT+RIS, CBT+SUP, IPI, NBI, NBI+AMI, OLA, Om3, Pbo, SUP, SUP+Pbo, TAU	Transition: i) CBT>SUP at 6–12 months (RR = 0.54, 95%CI = 0.34–0.86), 12+ months (RR = 0.63, 95%CI = 0.40–0.99), ii) CBT+RIS>SUP at 6 months (RR = 0.35, 95%CI = 0.13–0.95) No other significant findings
(van der Gaag et al. 2013)	MA	Transition	10-NA	CBT, CBT+RIS, OLA, IPI, Pbo, TAU, antipsychotics	Transition: i) all interventions pooled together, ii) Antipsychotics (RR = 0.55, 95%CI=NA, $p=0.029$). No other significant findings
(Hutton and Taylor 2014)	MA	Transition, APS, functioning, distress, QoL	6-800	CBT, CBT+monitoring, CBT+Pbo, CBT+RIS, IPI, monitoring, SUP, SUP+Pbo	Transition: CBT-informed>others at 12 months (RR = 0.45, 95%CI = 0.28–0.73), at 18–24 months (RR = 0.41, 95%CI = 0.23–0.72). APS: CBT-informed>others at 12 months ($g=-0.25$, 95%CI –0.46to – 0.03) No other significant findings
(Davies, Cipriani, et al. 2018)	NMA	Transition, acceptability	16-2,035	NBI, CBT-F + RIS+NBI, CBT-F + NBI, CBT-F + CBT-V + NBI, Dser + NBI, IPI, FFT+NBI, OLA+NBI, Om3 + NBI, ZIP+NBI	No significant findings
(Davies, Radua, et al. 2018)	NMA	APS, acceptability	14-1,707	NBI, ARI+NBI, CBT-F + NBI, CBT-F + RIS+NBI, Dser + NBI, FFT+NBI, IPI, OLA+NBI, Om3 + NBI, ZIP+NBI	APS: i) ZIP+NBI>NBI (SMD=–1.10, 95%CI=–2.04to – 0.15), >CBT-F (SMD=–1.03, 95%CI=–2.05to – 0.01), >CBT-F + RIS+NBI (SMD=–1.18, 95%CI –2.29to – 0.07) at 6 months. Acceptability: NBI+ARI>NBI+OLA (OR = 3.73, 95%CI = 1.01–13.81) No other significant findings
(Bosnjak Kuharic et al. 2019)	MA	Transition	20-2,151	NBI, Pbo, SUP, aminoacids, AMI+NBI, CBT, CBT + NBI + RIS, CBT + Pbo, CBT + RIS, CBT + SUP, CT, EC, FT, IPI, OLA + SUP, Om3, SUP, SUP + Pbo, TAU	Transition: CBT+SUP>SUP, transition 18 months (RR = 0.45, 95%CI = 0.23–0.89)* No other significant findings
(Mei et al. 2021)*	MA	Transition, APS, negative symptoms, depressive symptoms, anxiety symptoms, distress, QoL, functioning	26-2,351	CBD, CBCM+Pbo, CBT, CBT+monitoring, CBT+RIS, CBT+TAU, COMP, CRT, CRT+TAU, Dser, EC, FFT, FT, Gly, IPI, monitoring, NBI, NDRL+TAU, OLA+SUP, Om3, Om3 + CBCM, Pbo, SUP, SUP+Pbo, TAU, ZIP	Transition: All interventions pooled together CBT>others at EoT (RR = 0.55, 95%CI = 0.31–0.99), 12 months (RR = 0.52, 95%CI = 0.33–0.82), 18+ months (RR = 0.60, 95%CI = 0.42–0.84)* APS: All interventions pooled together No other significant findings
(Fusar-Poli, Radua, et al. 2021)**	MA	Transition	7-NA	CBT, CBT+monitoring, CBT+Pbo, CBT+TAU, monitoring, NDRL+TAU, SUP, SUP+Pbo, TAU	No significant findings **
(Zheng et al. 2022)*	MA	Transition, APS, depressive symptoms, distress, functioning, QoL	10-1,128	CBT, CBT+RIS, CBT+NBI, NBI	Transition: CBT>NBI 6–12 (RR = 0.44, 95%CI = 0.30–0.64), 12–24 (RR = 0.46, 95%CI = 0.30–0.69), 24+ (RR = 0.58, 0.35–0.95) months No other significant findings
(Fusar-Poli, Radua, et al. 2022)***	MA	Transition	9-NA	CBT, CBT+RIS, CBT+NBI, NBI	No significant findings***

Legend. Acceptability: all-cause discontinuation; AMI: amisulpride; APS: attenuated psychotic symptoms; ARI: aripiprazole; CBCM: CBCM, cognitive-behavioural case management; CBT: cognitive behavioural therapy; CBT-F: French & Morrison CBT protocol; CBT-V: van der Gaag CBT protocol; CI: confidence interval; COMP: computer games; CT: cognitive training; Dser: D-serine; EC: enhanced care; FFT: family-focused therapy; FT: family treatment; Gly: glycine; IPI: integrated psychological interventions; MA: meta-analysis; NBI: needs-based interventions (including placebo); NDRL: non directive reflective listening; NMA: network meta-analysis; OLA: olanzapine; Om3: omega-3 fatty acids; Pbo: placebo; QoL: quality of life; RCT: randomised controlled trial; RIS: risperidone; RR: risk ratio; SUP: supportive; TAU: treatment as usual; Total RCT/n: overall number of RCTs and subjects included in the meta-analysis or network meta-analysis across any outcome; ZIP: ziprasidone. Bold outcome was primary outcome of review; *: GRADE=very low; *: excluding PREVENT, and including RCT with high risk of bias; **: excluding RCT with high risk of bias, and including PREVENT trial; ***: excluding RCT with high risk of bias, one Chinese RCT with high risk of bias, and including PREVENT trial; *: excluding PREVENT, including three RCTs with high risk of bias. Edited from (Preti and Cella 2010; Stafford et al. 2013; van der Gaag et al. 2013; Hutton and Taylor 2014; Schmidt SJ et al. 2015; Davies, Cipriani, et al. 2018; Davies, Radua, et al. 2018; Devoe et al. 2018; Bosnjak Kuharic et al. 2019; Devoe et al. 2019b, 2019a, 2020; Fusar-Poli, Radua, et al. 2021; Mei et al. 2021; Fusar-Poli, Radua, et al. 2022; Zheng et al. 2022).

3.1.8. Studies comparing psychosis prevention services with other services, and cost-effectiveness of psychosis prevention services

We updated a systematic review (Sizer et al. 2022) on studies comparing psychosis prevention services with other services (Table 9). The study selection flow of the update of that systematic review is reported in eFigure 8. Studies excluded after full-text assessment,

with reason for exclusion, are reported in eTable 10. Three cohort studies were reported in the original systematic review (Sizer et al. 2022), comparing 78 subjects with FEP after meeting CHR-P criteria in prevention services (CHR-P-T) versus 253 subjects not being assessed in psychosis prevention services and directly presenting with FEP (FEP-D) (Table 9). One study set in Taiwan showed no difference on cognitive

Table 9. Studies comparing psychosis prevention services with other services, and cost-effectiveness of psychosis prevention services.

Author, year Country	N Months	Design Model Intervention/service	Outcomes	Findings
Psychosis prevention service-focused studies (Sizer et al. 2022)				
(Yoviene Sykes et al. 2020) US	97 12M	Cohort Mean or frequency comparisons FEP seen in UHR service vs FEP not seen	Any hospitalisation, number of hospitalisations, length of stay, any emergency room visit, repeat diagnosis of psychosis or continued antipsychotic prescription, DUP	UHR service superior in DUP UHR had more emergency visits. No difference in any hospitalisation, number of hospitalisations, length of hospital stay, repeat diagnosis of psychosis.
(Valmaggia et al. 2015) UK	190 12M	Cohort Mean or frequency comparisons FEP seen in UHR service vs FEP not seen	Any hospitalisation, total involuntary admissions, length of hospital stay, DUP	UHR service superior on any hospitalisation, involuntary admissions, DUP. No difference in length of hospital stay No difference in any cognitive function
(Liu et al. 2015) Taiwan	67 12M	Cohort Mean or frequency comparisons FEP seen in UHR service vs FEP not seen	WCST, WAIS-III, TMT, verbal fluency test, Weschler Memory test	
(Fusar-Poli P. et al. 2020)	1561 24M	Cohort Mean or frequency comparisons FEP seen in UHR service vs FEP not seen	Treatment with antipsychotic, informal hospitalisation, compulsory hospitalisation, treatment with clozapine, and length in hospital stay	UHR service inferior in antipsychotic medication (at 3, 6, and 24 months, not 12 months), informal and involuntary hospital admission (at all time points), and length in hospital stay (at all time points). No difference in clozapine
Cost-effectiveness				
(Ising et al. 2015) NL	196 18M	RCT Incremental cost-effectiveness ratio with nonparametric bootstrapping TAU + CBT vs TAU	Transition, QALY. Intervention, medical, travel, loss of productivity costs.	Cost-effectiveness: CBT avoided 89.5% v. 76.2% transition to psychosis, lower cost by US\$844 (£551) per prevented psychosis, 63.7% probability of being more cost effective. Cost-utility: CBT had similar QALY 0.60 v. 0.57, 52.3% probability of being the superior treatment.
(Ising et al. 2017) NL	196 48M	RCT Incremental cost-effectiveness ratio with nonparametric bootstrapping TAU + CBT vs TAU	Transition, QALY. Intervention, medical, travel, loss of productivity costs.	Cost-effectiveness: CBT avoided transition to psychosis (with a risk difference of 0.122; $b = 1.324$, $SEb = 0.017$, $z = 7.99$, $p < 0.001$), lower cost by US\$ 577 per participant, 83% probability of being more cost effective. Cost-utility: CBT had similar QALY 2.63 vs 2.46, 75% probability of being superior treatment, and 92% probability of being cost-effective at €20 000 threshold per QALY.
(Ologundudu et al. 2023) CA	1000 15year	Cohort (simulated) Decision modelling, Markov model Standard treat all CHR-P strategy vs Risk stratification treatment strategy (i.e. CHR-P with $\geq 20\%$ risk of transition only)	Transition, QALY.	Treating only CHR-P individuals with a risk of $\geq 20\%$ resulted in lower costs (\$1,398) and fewer quality-adjusted life-years (0.055 QALYs) per person compared to a strategy of treating every CHR-P individual. The incremental cost-effectiveness ratio (ICER) for the 'treat all' approach was \$25,448 per QALY, indicating that treating all individuals may be a cost-effective strategy.

(Continued)

Table 9. Continued.

Author, year Country	N Months	Design Model Intervention/service	Outcomes	Findings
(Phillips et al. 2009) AU	59 36M	RCT Mean costs comparison SPI vs NBI	Transition to psychosis. Outpatient, pharmacological, inpatient costs.	Lower transition to psychosis, but no difference in costs
(Perez et al. 2015) UK	104 centres 24M	Cluster RCT Decision analytic modelling Primary care practices (clusters) assigned to: i) 2 year low-intensity intervention, guidelines, postal campaign; ii) high-intensity intervention, liaising mental health professional; iii) practice as usual	Number of referrals, true positive referral (UHR or FEP). Incremental cost per additional true positive identified	Total cost per true-positive referral in the 2 year follow-up was £26 785 in high-intensity practices, £27 840 in low-intensity practices, and £30 007 in PAU practices. The high-intensive intervention, which improved liaison between primary and secondary care for people presenting early signs of psychosis, was found to be both clinically and cost effective.
(Valmaggia et al. 2009) UK	114 24M	Cohort Decision modelling Psychosis prevention service (OASIS) vs early intervention service	Services use and pharmacological treatment following referral and employment	Over the initial 12 months from presentation, the costs of the OASIS intervention were £1872 higher than TAU. However, after 24 months they were £961 less than TAU.
(Wijnen et al. 2020) NL	2,514 120M	Cohort (simulated) PsyMod, Markov model CBT vs care as usual	Service use, treatment and utilities	CBTuh resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant incremental cost-effectiveness ratio) with a reduction in 5-year healthcare costs of €1,002,166.
(Campion et al. 2019) UK	857/year 120M	Cohort (model) Knapp model Psychosis prevention service (OASIS) vs standard care	National health service costs, productivity costs	Reach all new CHR-P cases each year would need extra costs of £1 904 396 in first year (from increased service costs), but free up resources of £19.7m over 10 years with an estimated 10-year cost of implementation gap for each 1 year cohort of £18.9m
(Brimblecombe et al. 2017) UK	20 36M	Cohort Pre vs post Psychosis prevention service, within-subject pre-post comparison	Service use, crime, employment costs	Mental health improved or stayed the same, employment rates improved, total cost difference of £621 425
(Jin et al. 2021) UK	200,000 Lifetime	Cohort (simulated) Cost-utility analysis, discrete-event simulation CBT UHR 100% vs 41.01%	Lifetime costs, QALY	Cost-effective above willingness-to-pay £20 000 and £30 000 threshold per QALY
(Jin et al. 2020) UK	69,800 Lifetime	Cohort (simulated) Cost-utility analysis, discrete-event simulation TAU + CBT vs TAU	Clinical benefits, clinical harms, costs, cost savings	Cost-effective above willingness-to-pay £20 000 threshold per QALY

Legend. CBT: cognitive behavioural therapy; DUP: duration of untreated psychosis; FEP: first-episode psychosis; NBI: supportive and as needed psychotherapy; OASIS: Outreach and Support in South London; SPI: specific preventive intervention, including pharmacological treatment with antipsychotics and psychological treatment; TRS: treatment-resistant schizophrenia; UHR: ultra-high risk of psychosis; WCST: Wisconsin Card Sorting Test; WAIS-III: Wechsler Adult Intelligence Scale-3rd Edition; TMT: Trail Making Tests. Edited from (Phillips et al. 2009; Valmaggia et al. 2009; Ising et al. 2015; Liu et al. 2015; Perez et al. 2015; Valmaggia et al. 2015; Brimblecombe et al. 2017; Ising et al. 2017; Campion et al. 2019; Fusar-Poli P. et al. 2020; Jin et al. 2020; Wijnen et al. 2020; Yoviene Sykes et al. 2020; Jin et al. 2021; Sizer et al. 2022; Ologundudu et al. 2023).

functioning, suggesting that the access to CHR-P and related help-seeking behaviour before FEP might not be driven by cognitive symptoms (Liu et al. 2015). Regarding outcomes after FEP, one study set in UK showed that CHR-P-T subjects had fewer hospitalisations, fewer involuntary admissions, and shorter duration of untreated illness (Valmaggia et al. 2015). This latter finding was confirmed in one US study (Yoviene Sykes et al. 2020). However, no differences emerged on the length of hospital stay in both the UK and US, and in the US no differences emerged for hospitalisations. We identified one additional study (Fusar-Poli P.

et al. 2020) set in UK showing that CHR-P-T subjects were more likely to receive antipsychotic medication (at 3, 6, and 24 months, not at 12 months), be admitted to hospital both informally and on a compulsory basis, and spend more time in hospital compared to FEP-D subjects, highlighting severe clinical outcomes for CHR-P-T. No differences were observed in the likelihood of receiving clozapine.

Regarding cost-effectiveness, the study selection flow of the systematic review of cohort and cost-effectiveness studies regarding psychosis prevention services is reported in eFigure 9. Studies excluded after full-text assessment,

with reason for exclusion, are reported in eTable 11. From initial 2956 hits we ultimately included 11 studies (Phillips et al. 2009; Valmaggia et al. 2009; Ising et al. 2015; Perez et al. 2015; Brimblecombe et al. 2017; Ising et al. 2017; Campion et al. 2019; Jin et al. 2020; Wijnen et al. 2020; Jin et al. 2021; Ologundudu et al. 2023). Details and results of included studies are reported in Table 9. Six studies were set in UK, three in the Netherlands, one in Australia, and one in Canada. Five studies used data that originated from a single RCT comparing CBT with TAU, and simulated cost-effectiveness models of CBT confirming its cost-effectiveness (Ising et al. 2015; 2017; Jin et al. 2020; Wijnen et al. 2020; Jin et al. 2021). One study measured actual costs associated with specific preventive intervention (SPI) versus need-based intervention (NBI), instead showing no difference in costs (Phillips et al. 2009). Another study found that high-intensive interventions strengthening liaison between primary and secondary care for people presenting with early signs of psychosis was cost-effective (Phillips et al. 2009). Two other studies used real-world data from the OASIS psychosis prevention service, London, UK, showing its cost-effectiveness versus standard care (Valmaggia et al. 2009; Campion et al. 2019). One further study measured the costs before versus after receiving an intervention in a psychosis prevention service, again showing cost effectiveness (Brimblecombe et al. 2017). Finally, a simulation study demonstrated that providing treatment to all CHR-P individuals, regardless of their transition risk as assessed by the North American Prodrome Longitudinal Study risk calculator, led to higher quality-adjusted life-years (QALYs) compared to a risk-stratified approach and was found to be cost-effective (Ologundudu et al. 2023).

3.2. Grading, guidelines, and recommendations

3.2.1. Grading of evidence

The criteria used to grade the level of evidence, and formulate guidelines are available in Tables 1 and 10.

Grading of evidence and guidelines for prevention of psychosis at intervention- and service-levels are available in Table 11. Table 11 is limited to those interventions with ≥ 1 study showing the intervention or the service to be superior to the control group on transition to psychosis.

3.2.2. Recommendations

Considering the evidence and its grading an initial list of 12 recommendations was circulated to authors. Scores were $\geq 4/5$ in $\geq 80\%$ of respondents for all 12 recommendations. The recommendations are listed in Table 12 and reported below together with the

consensus rates from authors, grouped by service organisation, assessment and risk communication, and intervention level.

Three recommendations were made at service organisation level:

1. Psychosis indicated prevention services might be implemented in close collaboration with early intervention services for psychosis to minimise duration of untreated illness. 90.7% agreed 4 or 5/5.
2. To prevent psychosis, at the mental health service level, intake age criteria should be between 14 to 35. 87.5% agreed 4 or 5/5.
3. To prevent psychosis, mental health services should allow access to persons with cannabis use disorder. 96.9% agreed 4 or 5/5.

Six recommendations were made at the assessment and risk communication level:

1. To identify CHR-P, mental health services staff should be trained to administering and rating CAARMS, SIPS, or future validated interviews such as PSYCHS in clinical settings. 84.4% agreed 4 or 5/5.
2. To identify CHR-P, mental health services staff should use CAARMS, SIPS, or PSYCHS in the future in clinical settings. 84.4% agreed 4 or 5/5.
3. To estimate risk of psychosis, mental health services staff should be trained in using and interpreting psychosis risk calculators in clinical settings. 81.3% agreed 4 or 5/5.
4. To communicate the risk of psychosis, mental health services staff should be trained in communicating the estimate of risk of psychosis in clinical settings. 84.4% agreed 4 or 5/5.
5. To estimate and communicate the risk of psychosis, mental health services staff should use only validated risk calculators, keeping a human-to-human interaction with client. 81.3% agreed 4 or 5/5.
6. To provide comprehensive care, mental health services staff should assess the presence of comorbid mental disorders also in those meeting CHR-P criteria. 100% agreed 4 or 5/5.

Three recommendations were made at intervention level:

1. To prevent psychosis, mental health services staff should offer treatment to reduce use or achieve abstinence of cannabis use (if present). 90.7% agreed 4 or 5/5.

Table 10. World federation of societies of biological Psychiatry grading system for levels of evidence.

Evidence effective/ Grade	Explanation	Evidence not effective/ Grade	Explanation
Strong/ A	At least two independent RCTs with a low risk of bias show efficacy (superiority to placebo, or in the case of psychotherapy studies, superiority to a 'active psychological placebo' in a study with adequate blinding), OR superiority to/equivalent efficacy compared with an established comparator treatment in a 3-arm study with placebo control or in a well-powered non-inferiority trial (only applicable if such a standard treatment exists) with a low risk of bias, AND No negative RCTs with a low risk of bias exist. If there are contradicting results from RCTs, the majority of RCTs AND/OR a meta-analysis with low risk of bias shows efficacy. If there are more than one 'A' treatment options, the decision should be based on head-to-head comparisons or meta-analyses showing superiority of one of the treatments	Strong/ -A	At least two independent, adequately powered RCTs with low risk of bias as detailed on the left show NO efficacy AND no positive RCTs with a low risk of bias exist If there are contradicting results from RCTs, however, the majority of RCTs AND/OR a meta-analysis with very low risk of bias shows NO efficacy
Limited/ B	RCT with a moderate risk of bias showing superiority to placebo (or in the case of psychotherapy studies, superiority to a 'active psychological placebo') OR a randomised controlled comparison with a standard treatment without placebo control with a sample size sufficient for a non-inferiority trial with a moderate risk of bias, AND No negative studies exist OR Meta-Analyses with a moderate risk of bias that shows efficacy	Limited/ -B	1 RCT with a moderate risk of bias showing NO superiority to placebo (or in the case of psychotherapy studies, NO superiority to a 'active psychological placebo') OR LESS efficacy than a standard treatment in an RCT without placebo control with a moderate risk of bias AND No positive studies exist OR Meta-Analyses with a moderate risk of bias that show NO efficacy
Low/ C1	One or more prospective open studies (with a minimum of 10 evaluable patients per group) using a control group, but no randomisation, or using no control group, show efficacy. OR one or more well-conducted case control or cohort studies (with a minimum of 10 evaluable patients) with a moderate probability that the relationship is causal show efficacy OR RCTs AND/OR meta-analyses with a high risk of bias show efficacy	Low/ -C1	One or more prospective open studies (with a minimum of 10 evaluable patients) using a control group, but no randomisation, or using no control group, show NO efficacy. OR One or more well-conducted case control or cohort studies (with a minimum of 10 evaluable patients) with a moderate probability that the relationship is causal shows NO efficacy OR RCTs AND/OR meta-Analyses with a high risk of bias that show NO efficacy
Low/ C2	Non-analytic studies, e.g. case reports or case series with less than 10 evaluable patients show efficacy in the majority of cases	Low/ -C2	Non-analytic studies, e.g. case reports or case series with less than 10 evaluable patients show NO efficacy in the majority of cases
Low/ C3	Expert opinions not based on any published data reporting efficacy	Low/ -C3	Expert opinions not based on any published data reporting NO efficacy
No evidence	No sufficient evidence to advise for or against the use of the intervention	No evidence	No sufficient evidence to advise for or against the use of the intervention

Edited from (Hasan et al. 2019).

2. To provide comprehensive care, mental health services staff should offer evidence-based treatment for comorbid mental disorders also in those meeting CHR-P criteria. 100% agreed 4 or 5/5.
3. To prevent psychosis, mental health services staff should offer treatment for CHR-P status based on patient preference, clinician/centre experience, and following the 'first do no harm' principle. 93.8% agreed 4 or 5/5.

4. Discussion

These guidelines update previous guidelines, in light of updated evidence (NICE 2014; Schmidt SJ et al. 2015; Addington et al. 2017), integrating a lived experience and clinical experience-informed a-priori-defined lens that is representative of the clinical and ethical matters related with the indicated prevention of psychosis. All specific interventions including CBT, other psychosocial interventions, biological interventions and combined

Table 11. Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry and EPI Canada, on interventions with at least one positive randomised controlled trial on transition to psychosis in clinical high risk of psychosis subjects, or at least one study showing cost-effectiveness.

Intervention	LoE primary outcome	LoE key and other secondary outcomes	Acceptability	Recommendation
Cognitive therapy or CBT for psychosis ($k=7$)	No recommendations RCT: 3 superior, high RoB 3 negative, high RoB MA RCT: 6MA superior, high RoB 2MA negative, some RoB NMA RCT: 1 negative, high RoB	No recommendations RCT: 3 superior (depressive, anxiety, insomnia symptoms), high/low RoB 7 negative, high/low RoB 1 inferior (distress), high RoB MA: 1 superior, high RoB 2 negative, high RoB NMA: 1 inferior, high RoB	GOOD 5 cost effective	No recommendation
Integrated treatment ($k=2$)	No recommendations RCT: 2 superior, high RoB 1 negative, high RoB MA RCT: 3 negative, high RoB 3 inferior, high RoB NMA RCT: 1 negative, high RoB	No recommendations RCT: 1 superior (negative symptoms), high RoB 2 negative, high RoB MA: 2 negative, high RoB NMA: 1 negative, high RoB	NR	No recommendation
Risperidone (including SPI) ($k=2$)	No recommendations RCT: 1 superior, high RoB 1 negative, low RoB MA RCT: 5 superior, high RoB 3 negative, high RoB NMA RCT: 1 negative, high RoB	No recommendations RCT: 1 negative, low RoB 1 NA MA: 2 negative, high RoB NMA: 1 inferior, high RoB	POOR Not cost effective (SPI)	No recommendation
$\omega-3$ PUFAs ($k=3$)	No recommendations RCT: 1 superior, low RoB 3 negative, low RoB MA RCT: 3 negative, high RoB 2 inferior, high RoB NMA RCT: 1 negative, high RoB	No recommendations RCT: 1 positive (positive, negative, general symptoms, functioning), low RoB 2 negative, low RoB 1 inferior (functioning), low RoB MA: 3 negative, high RoB NMA: 1 negative, high RoB	NR	No recommendation
Psychosis prevention service / Any intervention	B MA RCT: 3 positive pooling different interventions, and no superior intervention in NMA	C1 Cohort: 1 cohort: mental health improved or stayed the same, fewer hospitalisations, involuntary admission. 2 cohort: DUP shortened 2 negative: length of hospital stay 1 negative: number of hospitalisations 1 negative: clozapine 1 inferior: informal and involuntary hospital admission, and length in hospital stay	GOOD 3 cost-effective	Limited recommendation

Legend. CBT: cognitive-behavioural therapy; LoE: level of evidence; MA: meta-analysis; NA: did not assess; NMA: network meta-analysis; NR: no studies reported; RCT: randomised controlled trial; RoB: risk of bias; SPI: specific prevention intervention.

interventions, had conflicting findings at the individual RCT and meta-analytic level, precluding any possibility of recommending specific interventions for the prevention of psychosis. Some psychological interventions, such as CBT, have been tested more extensively than others and are therefore more likely to be widely available. Evidence on CBT has been mixed, with some studies supporting its superiority to treatment as usual and

others not, including a meta-analysis published after our search (Minichino et al. 2025). Notably, specific interventions pooled together outperformed treatment as usual in several separate meta-analyses (Phillips et al. 2009; Preti and Cella 2010; van der Gaag et al. 2013). Moreover, observational evidence showed that psychosis prevention services improved several outcomes compared with other services (Valmaggia et al. 2015; Yoviene

Table 12. Clinical recommendations for the prevention of psychosis.

Recommendations	Evidence
Service organisation	
Psychosis indicated prevention services might be implemented in close collaboration with early intervention services for psychosis to minimise duration of untreated illness	Observational
To prevent psychosis, at the mental health service level, intake age criteria should be between 14 to 35.	Observational
To prevent psychosis, mental health services should allow access to persons with cannabis use disorder.	Observational
Assessment and risk communication	
To identify CHR-P, mental health services staff should be trained to administering and rating CAARMS, SIPS, or future validated interviews such as PSYCHS* in clinical settings.	Observational
To identify CHR-P, mental health services staff should use CAARMS, SIPS, PSYCHS* in clinical settings.	Observational
To estimate risk of psychosis, mental health services staff should be trained in using and interpreting psychosis risk calculators in clinical settings.	Consensus only
To estimate and communicate the risk of psychosis, mental health services staff should be trained in communicating the estimate of risk of psychosis in clinical settings.	Consensus only
To estimate and communicate the risk of psychosis, mental health services staff should use only validated risk calculators, keeping a human-to-human interaction with client.	Consensus only
To provide comprehensive care, mental health services staff should assess the presence of comorbid mental disorders also in those meeting CHR-P criteria.	Observational
Intervention	
To prevent psychosis, mental health services staff should offer treatment aiming to abstinence from cannabis use (if present).	Observational
To provide comprehensive care, mental health services staff should offer evidence-based treatment for comorbid mental disorders also in those meeting CHR-P criteria.	Observational
To prevent psychosis and provide comprehensive care, mental health services staff should offer treatment for CHR-P status based on patient preference, clinician/centre experience, and following the “first do no harm” principle.	Randomised controlled trials

Legend. *: based on future evidence of psychometric properties; CAARMS: Comprehensive Assessment of At-Risk Mental State; CHR-P: clinical high-risk for psychosis; PSYCHS: Positive SYmptoms for CAARMS Harmonised with SIPS; SIPS, Structured Interview for Prodromal Symptoms.

Sykes et al. 2020), and that prevention services, and CBT in particular, were cost-effective (Valmaggia et al. 2009; Ising et al. 2015; Perez et al. 2015; Brimblecombe et al. 2017; Ising et al. 2017; Campion et al. 2019; Jin et al. 2020; Wijnen et al. 2020; Jin et al. 2021). However, given the lack of consistent findings across individual RCTs, and different meta-analyses, these guidelines can make ‘limited’ recommendations to implement psychosis prevention services, and cannot recommend one specific intervention in individuals at CHR-P among many that have been previously tested.

While RCTs for schizophrenia select a potentially biased sample that is not necessarily representative of the general population (Taipale et al. 2022), there is no evidence of selection/sampling bias in RCTs of individuals at CHR-P for prevention of psychosis, as rates of transition to psychosis do not differ between cohort studies and RCTs (Salazar de Pablo, Davies, et al. 2021). Hence, findings from RCTs included in this review probably can be extended to real-world services. Psychosis prevention services are mainly designed to provide primary indicated prevention in those meeting CHR-P criteria. However, beyond indicated prevention, psychosis prevention services also implement several primary public health prevention strategies (e.g. universal and selective interventions) globally (Estradé et al. 2022). A systematic review including 66 publications on 13 standalone, 40 integrated, three network, and six regional or international surveys of CHR-P services across Europe, Asia, Oceania, Africa, North and South America, providing

care to >28 million people, showed that CHR-P services already target social and cultural (16 initiatives), economic (seven initiatives), demographic (six initiatives), environmental events (four initiatives) and neighbourhood (three initiatives) Sustainable Development Goal determinants of mental disorders developed by United Nations Member States (Estradé et al. 2022), indicating that CHR-P services deliver a wide range of public health initiatives aimed at prevention and the promotion of mental well-being, extending beyond the indicated prevention of psychosis. We believe that given the heterogeneous clinical practice across psychosis prevention services, pooling all interventions reflects a diverse portfolio of interventions that are different in quality and superior in intensity from treatment as usual delivered in ‘regular’ mental health services, which primarily focus on more advanced stages of persistent and severe mental disorders. However, there is the need for more research on individualised and adapted implementation of psychosis prevention services according to given cultural, environmental and resource parameters.

The specific assessment and intervention model to be administered within each psychosis prevention service should be informed by the clinical presentation of each patient, and should be informed by evidence on CHR-P assessment tools, risk factors for psychosis, psychosis risk modelling, concomitant mental disorders, and, importantly, ethical considerations. Some clinical recommendations were nevertheless made based on the evidence review and consensus.

Mental health professionals working in psychosis prevention services should be trained in using the CAARMS or SIPS/SOPS to assess/determine CHR-P status. Recently a novel tool for CHR-P assessment is being tested - i.e. the PSYCHS (Woods SW et al. 2024) – to overcome limitations of CAARMS or SIPS/SOPS, and to provide one unique tool, which should be ideally be adopted once evidence is available regarding its psychometric properties and clinical usability (Brady and Larrauri 2023). It is important that the service organisation accounts for the need of administering such tools, which can be time-consuming but that are needed to define CHR-P. Moreover, abbreviated versions of CHR-P tools are now available such as the Mini-CAARMS (Stefana et al. 2025), reducing administration time.

Communicating risk estimates in medicine is complex. Risk of transition to psychosis can be calculated, yet this should be done exclusively using multivariable, validated, transparent and reproducible clinical prediction models. Moreover, risk models should always be applied in the context of a human-to-human interaction and by mental health professionals that are trained in clinical prediction model interpretation and communication. Overall, communication with patients and families about psychosis risk should include encouraging patients to state their preferences regarding the communication of medical information, respecting requests not to receive certain information, and tailoring disclosure to the individual's needs and expectations (Woods SW et al. 2021), consistently with ethical guidance from the American Medical Association (AMA n.d.). Any communication to patients regarding their risk should be conducted by staff trained in communicating risk, which they should be accountable for.

Cannabis use is a risk factor for schizophrenia, and other mental disorders (Myran, Harrison, et al. 2023; Myran, Pugliese, et al. 2023; Myran et al. 2024; Myran, Pugliese, Harrison, et al. 2025; Myran, Pugliese, McDonald, et al. 2025). It has been estimated that the population attributable fraction of cannabis with respect to schizophrenia spectrum disorders is 9.73% (95% CI = 4.50–17.30%) (Dragioti et al. 2022). The risk is particularly elevated in young males, and progressively increases from persons with cannabis use disorder to cannabis-induced psychosis (Myran, Harrison, et al. 2023). Considering the age at onset of psychosis, and other mental disorders (Solmi, Radua, et al. 2022), young adults should be informed regarding the risk of cannabis. Unfortunately, the literacy regarding the risk of

psychosis associated with use of cannabis is very low (Goodman and Hammond 2022).

Several treatments have been tested for the treatment of cannabis use disorder. Evidence suggests that combining CBT, motivational enhancement therapy (which seeks to enhance motivation to change), and contingency management (which uses operant conditioning to reinforce a target behaviour) is effective in reducing frequency and quantity of use. However, improvements in sustained abstinence remain limited. In this context, testing novel pharmacological agents represents a promising avenue to enhance the effects of existing psychosocial treatments (Sherman and McRae-Clark 2016).

To prevent psychosis and avert adverse developmental effects of presenting symptoms, comorbidities and functional disabilities, psychosis prevention services should not leave out patients younger than 18. The peak age at onset of schizophrenia is 20.5 years, and a reasonable age intake criterion is age 14 to 35 also considering feasibility and resource allocation, as well as specificities of younger populations who frequently need care for different conditions (Solmi, Radua, et al. 2022). Indeed, the high rates of comorbid mental disorders in CHR-P call for a transdiagnostic mental health assessment. Individuals meeting CHR-P criteria should be assessed for and receive evidence-based treatment for concomitant mental disorders targeting also an improvement of functioning. The choice of specific interventions offered to individuals at CHR-P should be based on the person's autonomy and informed shared decision-making and consent process, on a 'first do no harm' non-maleficence principle, and on clinical expertise of a multi-professional mental health team. Regarding comorbid disorders, we could not recommend specific interventions to improve outcomes in CHR-P youth with specific comorbid mental health disorders due to the lack of meta-analytic evidence. Moreover, non-psychotic symptoms (e.g. depressive and anxiety symptoms) have not shown improvement in experimental interventions compared to control conditions in 'generic' samples (i.e. samples not stratified by comorbid mental disorders) of CHR-P individuals. Hence the treatment of comorbid mental disorder should follow evidence-based guidelines for each disorder.

Given that young people with mental health conditions tend to face substantial delays in accessing treatment (McGorry et al. 2024), it is essential to foster continuity of care and strengthen referral pathways, for example by promoting connections with emerging

youth-oriented primary care transdiagnostic services (McGorry et al. 2022).

However, risk estimates need to be communicated in even more cautious and balanced ways in younger subjects. The question whether psychosis prevention services or transdiagnostic mental health services should be implemented remains currently unanswered (Solmi, Soardo, et al. 2023).

Future research should address several aspects that could complement the evidence that informed these guidelines. First, clinicians, ethics experts, subjects with lived experience and their families should work together in co-designing a standardised approach to communicate risk of psychosis. Second, more research needs to be conducted regarding the impact of cannabis strength (i.e. THC content), frequency and quantity of use, on the risk of psychosis and on the outcome of psychosis (after onset) in subjects with or without CHR-P. Third, additional treatments should be conducted to prevent psychosis in CHR-P, testing novel biological pharmacological, non-pharmacological (e.g. brain stimulation), lifestyle (e.g. exercise, diet, smoking cessation), digital or psychosocial interventions. Future multi-arm, adaptive RCTs or implementation science approaches may represent a future direction in the field. Fourth, RCTs are needed to test candidate interventions to prevent psychosis in subjects with cannabis use disorder. Fifth, data from previous RCTs to prevent psychosis in CHR-P should be shared in collaborative efforts to analyse individual patient data to identify subgroups of patients that might benefit from a specific type of treatment. Sixth, while implementing cluster RCTs comparing psychosis prevention service versus transdiagnostic mental health prevention services would pose feasibility barriers, (simulation) studies leveraging data from existing services, and/or Delphi studies collecting the input of persons with lived experience in co-designing prevention services are needed. Seventh, our recommendations were not informed by neuroimaging and biomarker findings, as they are not yet informative for guiding real-world clinical care at scale (Rambaud et al. 2022) due to their small effect sizes, limited replication, lack of evidence testing their clinical utility, and poor scalability. Nevertheless, machine learning approaches and biomarker research may hold promise in advancing knowledge on heterogeneity among youth at CHR-P (Koutsouleris et al. 2021). Future studies employing multimodal and promptly available, scalable parameters may leverage neuroimaging data alongside behavioural and symptom data

to refine prognostic precision in this population, in line with ongoing large-scale international initiatives such as the Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) program (Brady and Larrauri 2023; Wannan et al. 2024). Eighth, additional studies testing the prognostic accuracy and broader clinical utility of interviews measuring basic symptoms, potentially at even earlier stages than attenuated psychotic symptoms, accounting for language- and context-specific considerations, should be conducted (Schultze-Lutter et al. 2012). Ninth, research focusing on both psychosis prevention services and transdiagnostic prevention services is still limited. To date, tools to assess bipolar at-risk status are being developed (Salazar de Pablo et al. 2025; Stefanelli et al. 2025), as well as even broader approaches such as the clinical high at risk mental state (CHARMS) (McGorry et al. 2018; Destrée et al. 2024), and transdiagnostic prediction models are emerging (Arribas et al. 2026), yet no comparative study has analysed the clinical utility of a transdiagnostic versus a psychosis-focused prevention approach. Tenth, future research could focus on therapeutic monitoring of pharmacological treatment in CHR-P subjects who receive a pharmacological (non-antipsychotic) treatment for comorbid non-psychotic mental disorders. Such research could help develop and examine tools to optimise treatment personalisation. This is in line with recent research advances on therapeutic monitoring of antipsychotic medications in individuals with full-blown psychotic disorders (Hart et al. 2024; Schoretsanitis et al. 2024).

These guidelines have several limitations related with the restrictions of the currently available data, and of previous evidence synthesis efforts. For instance, the recommendation to target cannabis use was not based on evidence demonstrating that a reduction in cannabis use results in lower psychosis transition rates. It was based on the convincing evidence of cannabis as a modifiable risk factor for psychosis. Moreover, prevention in specific populations, such as first-degree relatives of persons with schizophrenia not meeting criteria for CHR-P, individuals with 22q11 syndrome, or those who have not been assessed with CHR-P tools or that do not have cannabis use disorder go beyond the aims and scope of these guidelines.

Nevertheless, we the current guidelines provide context, content, tools and specific guidance that is useful for researchers, clinicians, health care administrators and other interest who aim at reducing the risk for individuals to develop psychosis.

Acknowledgements

MS is supported by Clinical Research Chair in Evidence-Based Mental Health, from the Faculty of Medicine, University of Ottawa, Canada. MB is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator grant (1156072 and 2017131). TB is supported by funding from the Ministry of University and Research under the call Progetti di Rilevante Interesse Nazionale (PRIN) 2022 (project number 202245X547). JS is supported by a FRQS Senior Clinician-Scientist Award. Alison Yung is supported by an NHMRC leadership fellowship #2026339.

Author contributions

Conceptualisation: MS; Methodology: MS, CUC, AFC, TB, GLB; Writing - Original draft: MS, GLB, TB; Visualisation: MS, GLB, RG, TB; Investigation: MS, GLB, TB, RG; Supervision: MS, CUC, AFC; Project administration: MS; Writing - review & Editing: all authors

Disclosure statement

Consultant: AbbVie, Alkermes, Angelini, Autobahn, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink Global, Merck, Mindpax, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Neurosterix, NeuShen, Neusignal Therapeutics, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recognify Life Science, Recordati, Relmada, Response Pharmaceutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Terran, Tolmar, Vertex, Viatrix and Xenon Pharmaceuticals. Grant/research support: Boehringer-Ingelheim, Janssen and Takeda. Honoraria/speakers or advisory boards: AbbVie, Alkermes, Allergan, Angelini, BMS, Boehringer Ingelheim, Bristol-Meyers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatrix. Stock holder/stock options: Cardio Diagnostics, Kuleon Biosciences, LB Pharmaceuticals, MedLink Global, Mindpax, Quantic, Terran. Other financial or material support: expert testimony for Janssen, Lundbeck, Neurocrine, and Otsuka; Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva; royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran. Fusar-Poli has received research fees from Lundbeck and honoraria from Lundbeck, Angelini, Menarini and Boehringer Ingelheim outside the current study. McGorry was a Founding Director of the board and now Patron of headspace (Australia) and is Executive Director of Orygen, Australia's National Centre of Excellence in Youth Mental Health. Orygen is the lead agency for five headspace centres across northwest Melbourne. He has received past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli

Lilly, Novartis, and Pfizer, and honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca, Roche, Bristol Myers Squibb, and Lundbeck. He has received grant funding from the Colonial Foundation, the National Health and Medical Research Council (NHMRC) of Australia, the Australian Research Council, the National Association for Research on Schizophrenia and Depression, The Stanley Foundation, the National Institutes of Health (NIH), the Wellcome Trust, and the Australian and Victorian governments. He has been granted patents for the prevention of psychotic disorders using omega-3 polyunsaturated fatty acids in Australia and in the United States (AU 2015203289, 2017; US 9884034, 2018), with an additional claim in the United States (US 15/844444) and a pending patent application in Canada (CA 2773031). Shah received funding from salary awards from the Fonds de recherche du Quebec Sante. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, MedinCell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatrix, outside the submitted work. Woods has received research funding from Auspex, Pfizer, and Teva, served as a consultant for Boehringer-Ingelheim and Merck, received royalties from Oxford University Press, and been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. Solmi has received honoraria/has been a consultant for AbbVie, Angelini, Bausch Health, Boehringer Ingelheim, Lundbeck, Otsuka, Teva. Yatham reports personal fees from Canadian Network for Mood & Anxiety Treatments, Gedeon Richter, Sanofi, Intracellular Therapies, Merck, and GSK; grants and personal fees from DSP and Abbvie; and, other financial activities from CANMAT and Alkermes. Margolese reports membership on advisory board or speakers' bureaus or consultant: Abbvie, Bausch Health, BI, HLS, Janssen, Newron, Otsuka, Lundbeck, Teva; funded grants, research, or clinical trials: AIFred, Neuron, SyneuRx; Volunteer/Advocacy: President, EPI Canada 2025-2027. Other authors have no conflict of interest to disclose. Stain: consultant for TIPS centre for clinical research in psychosis, Stavanger, Norway.

ORCID

Marco Solmi  <http://orcid.org/0000-0003-4877-7233>
 Gabriele Lo Buglio  <http://orcid.org/0000-0003-2425-8383>
 Howard C. Margolese  <http://orcid.org/0000-0002-3912-0566>
 Liang-Jen Wang  <http://orcid.org/0000-0002-5320-1151>
 Scott W. Woods  <http://orcid.org/0000-0002-3103-5228>
 Michael Berk  <http://orcid.org/0000-0002-5554-6946>

References

- NICE 2014. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline.
- A B, V P, S G, J G. 2010. Cognitive behavioural therapy in people at risk of psychosis. Huber.

- Addington J, Addington D, Abidi S, Raedler T, Remington G. 2017. Canadian treatment guidelines for individuals at clinical high risk of psychosis. *Can J Psychiatry*. 62(9):656–661. <https://doi.org/10.1177/0706743717719895>
- Addington J et al. 2011. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. *Schizophr Res*. 125(1):54–61. <https://doi.org/10.1016/j.schres.2010.10.015>
- Addington J et al. 2023. Cognitive-behavioral social skills training: outcome of a randomized controlled trial for youth at risk of psychosis. *Schizophr Bull Open*. 4(1):sgad020. <https://doi.org/10.1093/schizbullopen/sgad020>
- Addington J, Woods SW, Yung AR, Calkins ME, Fusar-Poli P. 2024. Harmonizing the structured interview for psychosis-risk syndromes (SIPS) and the comprehensive assessment of at-risk mental states (CAARMS): an initial approach. *Early Interv Psychiatry*. 18(4):248–254. <https://doi.org/10.1111/eip.13401>
- Albert N et al. 2017. Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5-year follow-up of the OPUS II study. *Schizophr Res*. 182:24–30. <https://doi.org/10.1016/j.schres.2016.10.013>
- Allen P et al. 2024. Normative modeling of brain morphometry in clinical high risk for psychosis. *JAMA Psychiatry*. 81(1):77. <https://doi.org/10.1001/jamapsychiatry.2023.3850>
- Alqarni A et al. 2020. Supplementation with the omega-3 long chain polyunsaturated fatty acids: changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. *Schizophr Res*. 226:52–60. <https://doi.org/10.1016/j.schres.2019.08.033>
- AMA. n.d. AMA principles of medical ethics. <https://www.ama-assn.org/system/files/2019-06/code-of-medical-ethics-chapter-2.pdf>
- Amminger GP et al. 2020. The NEURAPRO biomarker analysis: long-chain omega-3 fatty acids improve 6-month and 12-month outcomes in youths at ultra-high risk for psychosis. *Biol Psychiatry*. 87(3):243–252. <https://doi.org/10.1016/j.biopsych.2019.08.030>
- Amminger GP et al. 2010. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. *Arch Gen Psychiatry*. 67(2):146–154. <https://doi.org/10.1001/archgenpsychiatry.2009.192>
- Antonucci LA et al. 2022. Using combined environmental-clinical classification models to predict role functioning outcome in clinical high-risk states for psychosis and recent-onset depression. *Br J Psychiatry*. 220(4):229–245. <https://doi.org/10.1192/bjp.2022.16>
- APA. 2022. Diagnostic and statistical manual of mental disorders. 5th ed. Text Revision (DSM-5-TR).
- Appiah-Kusi E et al. 2020. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. *Psychopharmacology*. 237(4):1121–1130. <https://doi.org/10.1007/s00213-019-05442-6>
- Arango C et al. 2018. Preventive strategies for mental health. *Lancet Psychiatry*. 5(7):591–604. [https://doi.org/10.1016/S2215-0366\(18\)30057-9](https://doi.org/10.1016/S2215-0366(18)30057-9)
- Arango C et al. 2021. Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. *World Psychiatry*. 20(3):417–436. <https://doi.org/10.1002/wps.20894>
- Argolo F et al. 2024. Natural language processing in at-risk mental states: enhancing the assessment of thought disorders and psychotic traits with semantic dynamics and graph theory. *Braz J Psychiatry*. 46:e20233419. <https://doi.org/10.47626/1516-4446-2023-3419>
- Arribas M et al. 2026. Joint detection of risk for psychotic disorders or bipolar disorders in clinical practice in the UK: development and validation of a clinical prediction model. *Lancet Psychiatry*. 13(1):14–23. [https://doi.org/10.1016/S2215-0366\(25\)00307-4](https://doi.org/10.1016/S2215-0366(25)00307-4)
- Baldwin H et al. 2022. Neuroanatomical heterogeneity and homogeneity in individuals at clinical high risk for psychosis. *Transl Psychiatry*. 12(1):297. <https://doi.org/10.1038/s41398-022-02057-y>
- Bechdolf A et al. 2023. Prevention of first-episode psychosis in people at clinical high risk: a randomized controlled, multicentre trial comparing cognitive-behavioral therapy and clinical management plus low-dose aripiprazole or placebo (PREVENT). *Schizophr Bull*. 49(4):1055–1066. <https://doi.org/10.1093/schbul/sbad029>
- Bechdolf A et al. 2017. 108. PREVENT: a randomized controlled trial for the prevention of first-episode psychosis comparing cognitive-behavior therapy (CBT), clinical management, and aripiprazole combined and clinical management and placebo combined. *Schizophr Bull*. p. S56–S57.
- Bechdolf A et al. 2011. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. *Schizophr Bull*. 37(Suppl 2):S111–S121. <https://doi.org/10.1093/schbul/sbr083>
- Bechdolf A et al. 2012. Preventing progression to first-episode psychosis in early initial prodromal states. *Br J Psychiatry*. 200(1):22–29. <https://doi.org/10.1192/bjp.bp.109.066357>
- Belbasis L et al. 2018. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. *Acta Psychiatr Scand*. 137(2):88–97. <https://doi.org/10.1111/acps.12847>
- Benrimoh D et al. 2024. On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis. *Mol Psychiatry*. 29(5):1361–1381. <https://doi.org/10.1038/s41380-024-02415-w>
- Berger M et al. 2019. Relationship between polyunsaturated fatty acids and psychopathology in the NEURAPRO clinical trial. *Front Psychiatry*. 10:393. <https://doi.org/10.3389/fpsy.2019.00393>
- Bhattacharyya S et al. 2018. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. *JAMA Psychiatry*. 75(11):1107–1117. <https://doi.org/10.1001/jamapsychiatry.2018.2309>
- Bolt LK et al. 2019. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: findings from the NEURAPRO randomized clinical trial. *Schizophr Res*. 206:67–74. <https://doi.org/10.1016/j.schres.2018.12.013>
- Bortolato B et al. 2017. Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. *Bipolar Disord*. 19(2):84–96. <https://doi.org/10.1111/bdi.12490>
- Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L. 2019. Interventions for prodromal stage of psychosis.

- Cochrane Database Syst Rev. 2019(11). <https://doi.org/10.1002/14651858.CD012236.pub2>
- Bourgin J et al. 2020. Predicting the individual risk of psychosis conversion in at-risk mental state (ARMS): a multivariate model reveals the influence of nonpsychotic prodromal symptoms. *Eur Child Adolesc Psychiatry*. 29(11):1525–1535. <https://doi.org/10.1007/s00787-019-01461-y>
- Brady LS, Larrauri CA, AMP SCZ Steering Committee. 2023. Accelerating Medicines Partnership(®) Schizophrenia (AMP(®) SCZ): developing tools to enable early intervention in the psychosis high risk state. *World Psychiatry*. 22(1):42–43. <https://doi.org/10.1002/wps.21038>
- Brimblecombe N et al. 2017. The role of youth mental health services in the treatment of young people with serious mental illness: 2-year outcomes and economic implications. *Early Interv Psychiatry*. 11(5):393–400. <https://doi.org/10.1111/eip.12261>
- Byrne JF et al. 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: a multi-cohort model development study. *Schizophr Bull*. 50(3):579–588. <https://doi.org/10.1093/schbul/sbad184>
- Cadenhead K et al. 2017. 23. omega-3 fatty acid versus placebo in a clinical high-risk sample from the north american prodrome longitudinal studies (NAPLS) consortium. *Schizophr Bull*. 43(suppl_1):S16–S16. <https://doi.org/10.1093/schbul/sbx021.042>
- Cadenhead KS et al. 2019. Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: findings from the North American Prodrome Longitudinal Studies Consortium. *Schizophr Res*. 204:96–103. <https://doi.org/10.1016/j.schres.2018.09.022>
- Campion J, Taylor MJ, McDaid D, Park AL, Shiers D. 2019. Applying economic models to estimate local economic benefits of improved coverage of early intervention for psychosis. *Early Interv Psychiatry*. 13(6):1424–1430. <https://doi.org/10.1111/eip.12787>
- Chaumette B et al. 2016. Salivary cortisol in early psychosis: new findings and meta-analysis. *Psychoneuroendocrinology*. 63:262–270. <https://doi.org/10.1016/j.psyneuen.2015.10.007>
- Choi J et al. 2017. Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. *Psychiatr Rehabil J*. 40(1):33–42. <https://doi.org/10.1037/prj0000217>
- Collin G et al. 2020. Brain functional connectivity data enhance prediction of clinical outcome in youth at risk for psychosis. *Neuroimage Clin*. 26:102108. <https://doi.org/10.1016/j.nicl.2019.102108>
- Correll CU et al. 2018. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. *JAMA Psychiatry*. 75(6):555–565. <https://doi.org/10.1001/jamapsychiatry.2018.0623>
- Correll CU, Rubio JM, Kane JM. 2018. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? *World Psychiatry*. 17(2):149–160. <https://doi.org/10.1002/wps.20516>
- Correll CU et al. 2022. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. *World Psychiatry*. 21(2):248–271. <https://doi.org/10.1002/wps.20994>
- Correll CU et al. 2017. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. *World Psychiatry*. 16(2):163–180. <https://doi.org/10.1002/wps.20420>
- Davies C et al. 2023. Hippocampal glutamate, resting perfusion and the effects of cannabidiol in psychosis risk. *Schizophr Bull Open*. 4(1):sgad022. <https://doi.org/10.1093/schizbullopen/sgad022>
- Davies C et al. 2024. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol. *Psychol Med*. 54(5):993–1003. <https://doi.org/10.1017/S0033291723002775>
- Davies C et al. 2018. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. *World Psychiatry*. 17(2):196–209. <https://doi.org/10.1002/wps.20526>
- Davies C et al. 2024. Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin. *Mol Psychiatry*. 29(5):1241–1252. <https://doi.org/10.1101/2023.03.17.23286528>
- Davies C et al. 2019. Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. *Neuropsychopharmacology*. 44(7):1300–1309. <https://doi.org/10.1038/s41386-018-0311-6>
- Davies C et al. 2018. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. *Front Psychiatry*. 9:187. <https://doi.org/10.3389/fpsy.2018.00187>
- Davies C et al. 2019. Neurochemical effects of oxytocin in people at clinical high risk for psychosis. *Eur Neuropsychopharmacol*. 29(5):601–615. <https://doi.org/10.1016/j.euroneuro.2019.03.008>
- Davies C et al. 2020. Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. *Lancet Psychiatry*. 7(5):399–410. [https://doi.org/10.1016/S2215-0366\(20\)30057-2](https://doi.org/10.1016/S2215-0366(20)30057-2)
- Davies C et al. 2020. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. *Transl Psychiatry*. 10(1):311. <https://doi.org/10.1038/s41398-020-0862-2>
- Davis J, Moylan S, Harvey BH, Maes M, Berk M. 2014. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. *Aust N Z J Psychiatry*. 48(6):512–529. <https://doi.org/10.1177/0004867414533012>
- Del Fabro L et al. 2021. Functional brain network dysfunctions in subjects at high-risk for psychosis: a meta-analysis of resting-state functional connectivity. *Neurosci Biobehav Rev*. 128:90–101. <https://doi.org/10.1016/j.neubiorev.2021.06.020>
- Destrée L et al. 2024. Transdiagnostic risk identification: a validation study of the Clinical High At Risk Mental State (CHARMS) criteria. *Psychiatry Res*. 333:115745. <https://doi.org/10.1016/j.psychres.2024.115745>
- Devoe DJ, Farris MS, Townes P, Addington J. 2019a. Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis. *Early Interv Psychiatry*. 13(1):3–17. <https://doi.org/10.1111/eip.12677>
- Devoe DJ, Farris MS, Townes P, Addington J. 2019b. Interventions and social functioning in youth at risk of psychosis: a

- systematic review and meta-analysis. *Early Interv Psychiatry*. 13(2):169–180. <https://doi.org/10.1111/eip.12689>
- Devoe DJ, Farris MS, Townes P, Addington J. 2020. Interventions and transition in youth at risk of psychosis: a systematic review and meta-analyses. *J Clin Psychiatry*. 81(3):17r12053. <https://doi.org/10.4088/JCP.17r12053>
- Devoe DJ, Peterson A, Addington J. 2018. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. *Schizophr Bull*. 44(4):807–823. <https://doi.org/10.1093/schbul/sbx139>
- Dickens AM et al. 2021. Dysregulated lipid metabolism precedes onset of psychosis. *Biol Psychiatry*. 89(3):288–297. <https://doi.org/10.1016/j.biopsych.2020.07.012>
- Ding Y et al. 2019. Brain structural abnormalities as potential markers for detecting individuals with ultra-high risk for psychosis: a systematic review and meta-analysis. *Schizophr Res*. 209:22–31. <https://doi.org/10.1016/j.schres.2019.05.015>
- Doborjeh Z et al. 2023. Investigation of social and cognitive predictors in non-transition ultra-high-risk individuals for psychosis using spiking neural networks. *Schizophrenia (Heidelb)*. 9(1):10. <https://doi.org/10.1038/s41537-023-00335-2>
- Dragioti E et al. 2022. Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. *Mol Psychiatry*. 27(8):3510–3519. <https://doi.org/10.1038/s41380-022-01586-8>
- Dragioti E et al. 2019. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. *JAMA Psychiatry*. 76(12):1241–1255. <https://doi.org/10.1001/jamapsychiatry.2019.2859>
- Dutt A et al. 2015. Exploring neural dysfunction in 'clinical high risk' for psychosis: a quantitative review of fMRI studies. *J Psychiatr Res*. 61:122–134. <https://doi.org/10.1016/j.jpsychires.2014.08.018>
- Dwyer DB et al. 2022. Clinical, brain, and multilevel clustering in early psychosis and affective stages. *JAMA Psychiatry*. 79(7): 677–689. <https://doi.org/10.1001/jamapsychiatry.2022.1163>
- Erickson MA, Ruffle A, Gold JM. 2016. A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. *Biol Psychiatry*. 79(12):980–987. <https://doi.org/10.1016/j.biopsych.2015.08.025>
- Estradé A et al. 2022. Public health primary prevention implemented by clinical high-risk services for psychosis. *Transl Psychiatry*. 12(1):43. <https://doi.org/10.1038/s41398-022-01805-4>
- Firth J et al. 2020. A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. *World Psychiatry*. 19(3):360–380. <https://doi.org/10.1002/wps.20773>
- French P, Morrison A. 2004. Early detection and cognitive therapy for people at high risk of developing psychosis: a treatment approach. Wiley.
- Friedman-Yakoobian MS, Parrish EM, Eack SM, Keshavan MS. 2022. Neurocognitive and social cognitive training for youth at clinical high risk (CHR) for psychosis: a randomized controlled feasibility trial. *Schizophr Res*. 243:302–306. <https://doi.org/10.1016/j.schres.2020.09.005>
- Fusar-Poli P et al. 2012. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry*. 69(3):220–229. <https://doi.org/10.1001/archgenpsychiatry.2011.1472>
- Fusar-Poli P et al. 2016. Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS. *Psychiatry J*. 2016:7146341–7146311. <https://doi.org/10.1155/2016/7146341>
- Fusar-Poli P et al. 2021. Preventive psychiatry: a blueprint for improving the mental health of young people. *World Psychiatry*. 20(2):200–221. <https://doi.org/10.1002/wps.20869>
- Fusar-Poli P et al. 2019. Preventive treatments for psychosis: umbrella review (just the evidence). *Front Psychiatry*. 10:764. <https://doi.org/10.3389/fpsy.2019.00764>
- Fusar-Poli P et al. 2020. Real-world clinical outcomes two years after transition to psychosis in individuals at clinical high risk: electronic health record cohort study. *Schizophr Bull*. 46(5):1114–1125. <https://doi.org/10.1093/schbul/sbaa040>
- Fusar-Poli P, Hijazi Z, Stahl D, Steyerberg EW. 2018. The science of prognosis in psychiatry: a review. *JAMA Psychiatry*. 75(12):1289–1297. <https://doi.org/10.1001/jamapsychiatry.2018.2530>
- Fusar-Poli P et al. 2022. Ethical considerations for precision psychiatry: a roadmap for research and clinical practice. *Eur Neuropsychopharmacol*. 63:17–34. <https://doi.org/10.1016/j.euroneuro.2022.08.001>
- Fusar-Poli P, Radua J. 2018. Ten simple rules for conducting umbrella reviews. *Evid Based Ment Health*. 21(3):95–100. <https://doi.org/10.1136/ebmental-2018-300014>
- Fusar-Poli P, Radua J, Davies C, Jauhar S. 2022. Overoptimistic literature and methodological biases favoring cognitive behavioral therapy for the prevention of psychosis. *Schizophr Bull*. 48(1):1–3. <https://doi.org/10.1093/schbul/sbab129>
- Fusar-Poli P, Radua J, Jauhar S. 2021. Lack of robust meta-analytic evidence to favour cognitive behavioural therapy for prevention of psychosis. *World Psychiatry*. 20(3):443–444. <https://doi.org/10.1002/wps.20896>
- Fusar-Poli P et al. 2017. Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis. *JAMA Psychiatry*. 74(5):493–500. <https://doi.org/10.1001/jamapsychiatry.2017.0284>
- Fusar-Poli P et al. 2017. Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. *Eur Psychiatry*. 42:49–54. <https://doi.org/10.1016/j.eurpsy.2016.11.010>
- Fusar-Poli P et al. 2020. Prevention of psychosis: advances in detection, prognosis, and intervention. *JAMA Psychiatry*. 77(7): 755–765. <https://doi.org/10.1001/jamapsychiatry.2019.4779>
- Fusar-Poli P et al. 2016. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. *Schizophr Bull*. 42(3):732–743. <https://doi.org/10.1093/schbul/sbv162>
- Fusar-Poli P et al. 2019. Transdiagnostic psychiatry: a systematic review. *World Psychiatry*. 18(2):192–207. <https://doi.org/10.1002/wps.20631>
- Fusar-Poli P et al. 2019. Clinical-learning versus machine-learning for transdiagnostic prediction of psychosis onset in individuals at-risk. *Transl Psychiatry*. 9(1):259. <https://doi.org/10.1038/s41398-019-0600-9>
- Fusar-Poli P, Sullivan SA, Shah JL, Uhlhaas PJ. 2019. Improving the detection of individuals at clinical risk for psychosis in the community, primary and secondary care: an integrated evidence-based approach. *Front Psychiatry*. 10:774. <https://doi.org/10.3389/fpsy.2019.00774>
- Fusar-Poli P et al. 2019. Transdiagnostic risk calculator for the automatic detection of individuals at risk and the

- prediction of psychosis: second replication in an independent national health service trust. *Schizophr Bull.* 45(3):562–570. <https://doi.org/10.1093/schbul/sby070>
- Gao X et al. 2022. Unsaturated fatty acids in mental disorders: an umbrella review of meta-analyses. *Adv Nutr.* 13(6):2217–2236. <https://doi.org/10.1093/advances/nmac084>
- Gates M et al. 2022. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. *BMJ.* 378:e070849. <https://doi.org/10.1136/bmj-2022-070849>
- Gerstenberg M et al. 2015. Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. *J Clin Psychiatry.* 76(11):e1449–1458–e1458. <https://doi.org/10.4088/JCP.14m09435>
- Gerstenberg M et al. 2016. Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. *Psychol Med.* 46(5):1069–1078. <https://doi.org/10.1017/S0033291715002627>
- Glenthøj LB, Kristensen TD, Wenneberg C, Hjorthøj C, Nordentoft M. 2021. Predictors of remission from the ultra-high risk state for psychosis. *Early Interv Psychiatry.* 15(1):104–112. <https://doi.org/10.1111/eip.12917>
- Glenthøj LB et al. 2020. Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: results of the FOCUS randomised clinical trial. *Schizophr Res.* 224:151–158. <https://doi.org/10.1016/j.schres.2020.08.016>
- Goodman S, Hammond D. 2022. Perceptions of the health risks of cannabis: estimates from national surveys in Canada and the United States, 2018–2019. *Health Educ Res.* 37(2):61–78. <https://doi.org/10.1093/her/cyac006>
- Grent-t-Jong T et al. 2021. 40-Hz auditory steady-state responses characterize circuit dysfunctions and predict clinical outcomes in clinical high-risk for psychosis participants: a magnetoencephalography study. *Biol Psychiatry.* 90(6):419–429. <https://doi.org/10.1016/j.biopsych.2021.03.018>
- Gurusamy J, Gandhi S, Damodharan D, Ganesan V, Palaniappan M. 2018. Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: a systematic review. *Asian J Psychiatr.* 36:73–85. <https://doi.org/10.1016/j.ajp.2018.06.018>
- Haining K et al. 2021. The relationship between cognitive deficits and impaired short-term functional outcome in clinical high-risk for psychosis participants: a machine learning and modelling approach. *Schizophr Res.* 231:24–31. <https://doi.org/10.1016/j.schres.2021.02.019>
- Harrisberger F et al. 2016. Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. *NPJ Schizophr.* 2(1):16033. <https://doi.org/10.1038/npjschz.2016.33>
- Hart XM et al. 2024. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics. *World J Biol Psychiatry.* 25(9):451–536. <https://doi.org/10.1080/15622975.2024.2366235>
- Hartmann S et al. 2024. Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohort. *World Psychiatry.* 23(3):400–410. <https://doi.org/10.1002/wps.21240>
- Hasan A et al. 2019. WFSBP guidelines on how to grade treatment evidence for clinical guideline development. *World J Biol Psychiatry.* 20(1):2–16. <https://doi.org/10.1080/15622975.2018.1557346>
- Hauke DJ et al. 2021. Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. *Transl Psychiatry.* 11(1):312. <https://doi.org/10.1038/s41398-021-01409-4>
- Hogg B et al. 2023. Psychological trauma as a transdiagnostic risk factor for mental disorder: an umbrella meta-analysis. *Eur Arch Psychiatry Clin Neurosci.* 273(2):397–410. <https://doi.org/10.1007/s00406-022-01495-5>
- Howes OD et al. 2021. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. *World Psychiatry.* 20(1):75–95. <https://doi.org/10.1002/wps.20822>
- Hutton P, Taylor PJ. 2014. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. *Psychol Med.* 44(3):449–468. <https://doi.org/10.1017/S0033291713000354>
- Iftimovici A, Group IC-pS. et al. 2023. Asynchronous neural maturation predicts transition to psychosis. *Psychiatry Clin Neurosci.* <https://doi.org/10.1111/pcn.13612>
- Ioannidis JP. 2009. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. *CMAJ.* 181(8):488–493. <https://doi.org/10.1503/cmaj.081086>
- Irving J et al. 2021. Using natural language processing on electronic health records to enhance detection and prediction of psychosis risk. *Schizophr Bull.* 47(2):405–414. <https://doi.org/10.1093/schbul/sbaa126>
- Ising HK et al. 2016. Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the dutch early detection intervention evaluation (EDIE-NL) Trial. *Schizophr Bull.* 42(5):1243–1252. <https://doi.org/10.1093/schbul/sbw018>
- Ising HK et al. 2017. Four-year cost-effectiveness of cognitive behavior therapy for preventing first-episode psychosis: the dutch early detection intervention evaluation (EDIE-NL) trial. *Schizophr Bull.* 43(2):365–374. <https://doi.org/10.1093/schbul/sbw084>
- Ising HK et al. 2015. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. *Psychol Med.* 45(7):1435–1446. <https://doi.org/10.1017/S0033291714002530>
- Jalbrzikowski M et al. 2021. Association of structural magnetic resonance imaging measures with psychosis onset in individuals at clinical high risk for developing psychosis: an ENIGMA working group mega-analysis. *JAMA Psychiatry.* 78(7):753–766. <https://doi.org/10.1001/jamapsychiatry.2021.0638>
- Jin H, Tappenden P, MacCabe JH, Robinson S, Byford S. 2020. Evaluation of the cost-effectiveness of services for schizophrenia in the UK across the entire care pathway in a single whole-disease model. *JAMA Netw Open.* 3(5):e205888. <https://doi.org/10.1001/jamanetworkopen.2020.5888>
- Jin H et al. 2021. Cost and health impacts of adherence to the national institute for health and care excellence schizophrenia guideline recommendations. *Br J Psychiatry.* 218(4):224–229. <https://doi.org/10.1192/bjp.2020.241>
- Kahn RS et al. 2015. Schizophrenia. *Nat Rev Dis Primers.* 1(1):15067. <https://doi.org/10.1038/nrdp.2015.67>

- Kantrowitz JT et al. 2015. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. *Lancet Psychiatry*. 2(5):403–412. [https://doi.org/10.1016/S2215-0366\(15\)00098-X](https://doi.org/10.1016/S2215-0366(15)00098-X)
- Kelleher I et al. 2012. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. *Psychol Med*. 42(9):1857–1863. <https://doi.org/10.1017/S0033291711002960>
- Kelleher I et al. 2012. Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. *Schizophr Bull*. 38(2):239–246. <https://doi.org/10.1093/schbul/sbr164>
- Kim JY et al. 2019. Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. *Lancet Psychiatry*. 6(7):590–600. [https://doi.org/10.1016/S2215-0366\(19\)30181-6](https://doi.org/10.1016/S2215-0366(19)30181-6)
- Kizilay E et al. 2024. Automated linguistic analysis in youth at clinical high risk for psychosis. *Schizophr Res*. 274:121–128. <https://doi.org/10.1016/j.schres.2024.09.009>
- Kotlicka-Antczak M et al. 2020. Worldwide implementation of clinical services for the prevention of psychosis: the IEPA early intervention in mental health survey. *Early Interv Psychiatry*. 14(6):741–750. <https://doi.org/10.1111/eip.12950>
- Koutsouleris N et al. 2021. Multimodal machine learning workflows for prediction of psychosis in patients with clinical high-risk syndromes and recent-onset depression. *JAMA Psychiatry*. 78(2):195–209. <https://doi.org/10.1001/jamapsychiatry.2020.3604>
- Koutsouleris N et al. 2022. Exploring links between psychosis and frontotemporal dementia using multimodal machine learning: dementia praecox revisited. *JAMA Psychiatry*. 79(9):907–919. <https://doi.org/10.1001/jamapsychiatry.2022.2075>
- Krakowski K, Oliver D, Arribas M, Stahl D, Fusar-Poli P. 2024. Dynamic and transdiagnostic risk calculator based on natural language processing for the prediction of psychosis in secondary mental health care: development and internal-external validation cohort study. *Biol Psychiatry*. 96(7):604–614. <https://doi.org/10.1016/j.biopsych.2024.05.022>
- Kristensen TD et al. 2020. No effects of cognitive remediation on cerebral white matter in individuals at ultra-high risk for psychosis-A randomized clinical trial. *Front Psychiatry*. 11:873. <https://doi.org/10.3389/fpsy.2020.00873>
- Lång U et al. 2022. Systematic review and meta-analysis: psychosis risk in children and adolescents with an at-risk mental state. *J Am Acad Child Adolesc Psychiatry*. 61(5):615–625. <https://doi.org/10.1016/j.jaac.2021.07.593>
- Lee TY et al. 2022. Prediction of psychosis: model development and internal validation of a personalized risk calculator. *Psychol Med*. 52(13):2632–2640. <https://doi.org/10.1017/S0033291720004675>
- Li H et al. 2021. Enhancing attention and memory of individuals at clinical high risk for psychosis with mHealth technology. *Asian J Psychiatr*. 58:102587. <https://doi.org/10.1016/j.ajp.2021.102587>
- Li Z et al. 2022. Plasma metabolic alterations and potential biomarkers in individuals at clinical high risk for psychosis. *Schizophr Res*. 239:19–28. <https://doi.org/10.1016/j.schres.2021.11.011>
- Liu CC et al. 2015. Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis. *Schizophr Res*. 164(1-3):40–46. <https://doi.org/10.1016/j.schres.2015.03.006>
- Livingston NR et al. 2024. Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis. *Neuropsychopharmacology*. 49(9):1448–1458. <https://doi.org/10.1038/s41386-024-01864-9>
- Loch AA et al. 2023. Detecting at-risk mental states for psychosis (ARMS) using machine learning ensembles and facial features. *Schizophr Res*. 258:45–52. <https://doi.org/10.1016/j.schres.2023.07.011>
- Loewy R et al. 2016. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. *Schizophr Bull*. 42 Suppl 1(Suppl 1):S118–S126. <https://doi.org/10.1093/schbul/sbw009>
- Luna LP et al. 2022. A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 117:110540. <https://doi.org/10.1016/j.pnpbp.2022.110540>
- Lyu H et al. 2023. Eye movement abnormalities can distinguish first-episode schizophrenia, chronic schizophrenia, and prodromal patients from healthy controls. *Schizophr Bull Open*. 4(1):sgac076. <https://doi.org/10.1093/schiz-bullopen/sgac076>
- Mallawaarachchi SR et al. 2020. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: secondary analysis of findings from the NEURAPRO randomized clinical trial. *Schizophr Res*. 218:48–54. <https://doi.org/10.1016/j.schres.2020.03.008>
- McCutcheon RA et al. 2025. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. *Lancet Psychiatry*. 12(5):384–394. [https://doi.org/10.1016/S2215-0366\(25\)00031-8](https://doi.org/10.1016/S2215-0366(25)00031-8)
- McGlashan TH et al. 2006. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. *Am J Psychiatry*. 163(5):790–799. <https://doi.org/10.1176/ajp.2006.163.5.790>
- McGorry PD, Hartmann JA, Spooner R, Nelson B. 2018. Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry. *World Psychiatry*. 17(2):133–142. <https://doi.org/10.1002/wps.20514>
- McGorry PD et al. 2023. A Sequential adaptive intervention strategy targeting remission and functional recovery in young people at ultrahigh risk of psychosis: the staged treatment in early psychosis (STEP) sequential multiple assignment randomized trial. *JAMA Psychiatry*. 80(9):875–885. <https://doi.org/10.1001/jamapsychiatry.2023.1947>
- McGorry PD et al. 2022. Designing and scaling up integrated youth mental health care. *World Psychiatry*. 21(1):61–76. <https://doi.org/10.1002/wps.20938>
- McGorry PD et al. 2024. The lancet psychiatry commission on youth mental health. *Lancet Psychiatry*. 11(9):731–774. [https://doi.org/10.1016/S2215-0366\(24\)00163-9](https://doi.org/10.1016/S2215-0366(24)00163-9)
- McGorry PD et al. 2017. Effect of ω -3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. *JAMA Psychiatry*. 74(1):19–27. <https://doi.org/10.1001/jamapsychiatry.2016.2902>
- McGorry PD et al. 2013. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. *J Clin Psychiatry*. 74(4):349–356. <https://doi.org/10.4088/JCP.12m07785>

- McGorry PD et al. 2002. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry*. 59(10):921–928. <https://doi.org/10.1001/archpsyc.59.10.921>
- Meehan AJ et al. 2022. Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges. *Mol Psychiatry*. 27(6):2700–2708. <https://doi.org/10.1038/s41380-022-01528-4>
- Mei C et al. 2021. Preventive interventions for individuals at ultra high risk for psychosis: an updated and extended meta-analysis. *Clin Psychol Rev*. 86:102005. <https://doi.org/10.1016/j.cpr.2021.102005>
- Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. 2016. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. *JAMA Psychiatry*. 73(7):665–674. <https://doi.org/10.1001/jamapsychiatry.2016.0442>
- Miklowitz DJ et al. 2014. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. *J Am Acad Child Adolesc Psychiatry*. 53(8):848–858. <https://doi.org/10.1016/j.jaac.2014.04.020>
- Miller TJ et al. 2003. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull*. 29(4):703–715. <https://doi.org/10.1093/oxfordjournals.schbul.a007040>
- Minichino A et al. 2025. Preventing psychosis in people at clinical high risk: an updated meta-analysis by the world psychiatric association preventive psychiatry section. *Mol Psychiatry*. 30(6):2773–2782. <https://doi.org/10.1038/s41380-025-02902-8>
- Mondelli V et al. 2023. Serum immune markers and transition to psychosis in individuals at clinical high risk. *Brain Behav Immun*. 110:290–296. <https://doi.org/10.1016/j.bbi.2023.03.014>
- Mongan D et al. 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. *JAMA Psychiatry*. 78(1):77–90. <https://doi.org/10.1001/jamapsychiatry.2020.2459>
- Moore TM et al. 2022. Development of a probability calculator for psychosis risk in children, adolescents, and young adults. *Psychol Med*. 52(14):3159–3167. <https://doi.org/10.1017/S0033291720005231>
- Morrison AP et al. 2007. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. *Schizophr Bull*. 33(3):682–687. <https://doi.org/10.1093/schbul/sbl042>
- Morrison AP et al. 2012. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. *BMJ*. 344(apr05 1):e2233–e2233. <https://doi.org/10.1136/bmj.e2233>
- Morrison AP et al. 2004. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. *Br J Psychiatry*. 185(4):291–297. <https://doi.org/10.1192/bjp.185.4.291>
- Mossaheb N et al. 2018. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids. *Early Interv Psychiatry*. 12(1):30–36. <https://doi.org/10.1111/eip.12275>
- Mossaheb N et al. 2018. Predictors of longer-term outcome in the Vienna omega-3 high-risk study. *Schizophr Res*. 193:168–172. <https://doi.org/10.1016/j.schres.2017.08.010>
- Myin-Germeys I et al. 2021. Efficacy of Acceptance and Commitment Therapy in Daily Life in Early Psychosis: Results from the Multi-Center INTERACT Randomized Controlled Trial. *Psychother Psychosom*. 2022;91(6):411–423. <https://doi.org/10.1159/000522274>
- Myran DT et al. 2023. Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis. *JAMA Psychiatry*. 80(11):1169–1174. <https://doi.org/10.1001/jamapsychiatry.2023.3582>
- Myran DT et al. 2024. Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study. *EClinicalMedicine*. 69:102455. <https://doi.org/10.1016/j.eclinm.2024.102455>
- Myran DT et al. 2025. Changes in incident schizophrenia diagnoses associated with cannabis use disorder after cannabis legalization. *JAMA Netw Open*. 8(2):e2457868. <https://doi.org/10.1001/jamanetworkopen.2024.57868>
- Myran DT et al. 2025. Cannabis use disorder emergency department visits and hospitalizations and 5-year mortality. *JAMA Netw Open*. 8(2):e2457852. <https://doi.org/10.1001/jamanetworkopen.2024.57852>
- Myran DT et al. 2023. Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis. *Mol Psychiatry*. 28(10):4251–4260. <https://doi.org/10.1038/s41380-023-02185-x>
- Nelson B et al. 2018. NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course. *NPJ Schizophr*. 4(1):11. <https://doi.org/10.1038/s41537-018-0052-x>
- Nordentoft M et al. 2006. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. *Schizophr Res*. 83(1):29–40. <https://doi.org/10.1016/j.schres.2006.01.002>
- Oliver D et al. 2022. Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. *Mol Psychiatry*. 27(9):3670–3678. <https://doi.org/10.1038/s41380-022-01611-w>
- Oliver D et al. 2018. Meta-analytical prognostic accuracy of the Comprehensive Assessment of at Risk Mental States (CAARMS): the need for refined prediction. *Eur Psychiatry*. 49:62–68. <https://doi.org/10.1016/j.eurpsy.2017.10.001>
- Oliver D et al. 2020. What causes the onset of psychosis in individuals at clinical high risk? a meta-analysis of risk and protective factors. *Schizophr Bull*. 46(1):110–120. <https://doi.org/10.1093/schbul/sbz039>
- Oliver D et al. 2020. Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients. *Transl Psychiatry*. 10(1):364. <https://doi.org/10.1038/s41398-020-01032-9>
- Ologundudu OM et al. 2023. Risk stratification for treating people at ultra-high risk for psychosis: a cost-effectiveness analysis. *Schizophr Res*. 261:225–233. <https://doi.org/10.1016/j.schres.2023.09.015>

- Osborne KJ, Mittal VA. 2019. External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample. *Psychiatry Res.* 279:9–14. <https://doi.org/10.1016/j.psychres.2019.06.034>
- Page MJ et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed)*. 74(9):790–799. <https://doi.org/10.1016/j.rec.2021.07.010>
- Park S, Miller BJ. 2020. Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. *Schizophr Res.* 226:5–12. <https://doi.org/10.1016/j.schres.2019.03.012>
- Perez J et al. 2015. Clinical effectiveness and cost-effectiveness of tailored intensive liaison between primary and secondary care to identify individuals at risk of a first psychotic illness (the LEGs study): a cluster-randomised controlled trial. *Lancet Psychiatry*. 2(11):984–993. [https://doi.org/10.1016/s2215-0366\(15\)00157-1](https://doi.org/10.1016/s2215-0366(15)00157-1)
- Perkins DO et al. 2020. Polygenic risk score contribution to psychosis prediction in a target population of persons at clinical high risk. *Am J Psychiatry*. 177(2):155–163. <https://doi.org/10.1176/appi.ajp.2019.18060721>
- Petersen L et al. 2005. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. *BMJ*. 331(7517):602. <https://doi.org/10.1136/bmj.38565.415000.E01>
- Phillips LJ et al. 2009. Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. *Early Interv Psychiatry*. 3(1):28–34. <https://doi.org/10.1111/j.1751-7893.2008.00106.x>
- Piskulic D, Barbato M, Liu L, Addington J. 2015. Pilot study of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. *Psychiatry Res.* 225(1-2):93–98. <https://doi.org/10.1016/j.psychres.2014.10.021>
- Piskulic D, Romanowska S, Addington J. 2018. Pilot study of cognitive remediation and motivational interviewing in youth at risk of serious mental illness. *Early Interv Psychiatry*. 12(6):1193–1197. <https://doi.org/10.1111/eip.12520>
- Pozza A, Domenichetti S, Dèttore D. 2019. Terapia cognitivo-comportamentale per giovani ad alto rischio di un primo episodio di psicosi: un trial randomizzato controllato. *Riv Psichiatr*. 54(4):150–159. <https://doi.org/10.1708/3202.31797>
- Pozza A, Domenichetti S, Dèttore D. 2021. Cognitive behavioural therapy for help-seeking adolescents and young adults with at-risk-mental state: effects on subclinical positive symptoms. *Early Interv Psychiatry*. 15(3):513–524. <https://doi.org/10.1111/eip.12974>
- Preti A, Cella M. 2010. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. *Schizophr Res.* 123(1):30–36. <https://doi.org/10.1016/j.schres.2010.07.026>
- Puntis S, Oliver D, Fusar-Poli P. 2021. Third external replication of an individualised transdiagnostic prediction model for the automatic detection of individuals at risk of psychosis using electronic health records. *Schizophr Res.* 228:403–409. <https://doi.org/10.1016/j.schres.2021.01.005>
- Qurashi I et al. 2024. A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: the NAYAB study. *Brain Behav Immun*. 115:609–616. <https://doi.org/10.1016/j.bbi.2023.10.025>
- Radua J et al. 2018. What causes psychosis? an umbrella review of risk and protective factors. *World Psychiatry*. 17(1):49–66. <https://doi.org/10.1002/wps.20490>
- Raket LL et al. 2020. Dynamic ElecTronic hEalth reCord deTectioN (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study. *Lancet Digit Health*. 2(5):e229–e239. [https://doi.org/10.1016/S2589-7500\(20\)30024-8](https://doi.org/10.1016/S2589-7500(20)30024-8)
- Rambaud V, Marzo A, Chaumette B. 2022. Oxidative stress and emergence of psychosis. *Antioxidants (Basel)*. 11(10):1870. <https://doi.org/10.3390/antiox11101870>
- Reinen JM et al. 2024. Multimodal fusion of brain signals for robust prediction of psychosis transition. *Schizophrenia (Heidelb)*. 10(1):54. <https://doi.org/10.1038/s41537-024-00464-2>
- Reininghaus U et al. 2019. Efficacy of acceptance and commitment therapy in daily life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial. *Trials*. 20(1):769. <https://doi.org/10.1186/s13063-019-3912-4>
- Rinne GR, O'Brien MP, Miklowitz DJ, Addington JM, Cannon TD. 2021. Depression, family interaction and family intervention in adolescents at clinical-high risk for psychosis. *Early Interv Psychiatry*. 15(2):360–366. <https://doi.org/10.1111/eip.12954>
- Rosson S et al. 2022. Brain stimulation and other biological non-pharmacological interventions in mental disorders: an umbrella review. *Neurosci Biobehav Rev*. 139:104743. <https://doi.org/10.1016/j.neubiorev.2022.104743>
- Ruhrmann S et al. 2007. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. *Br J Psychiatry Suppl*. 51:S88–S95. <https://doi.org/10.1192/bjp.191.51.s88>
- Salazar de Pablo G et al. 2021. Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis. *Eur Psychiatry*. 64(1):e51. <https://doi.org/10.1192/j.eurpsy.2021.2222>
- Salazar de Pablo G et al. 2026. Development and validation of a prognostic model and risk calculator for the estimation of bipolar-spectrum disorder risk in hospitalised adolescents with non-psychotic/non-bipolar mental disorders. *Mol Psychiatry*. 31(3):1333–1342. <https://doi.org/10.1038/s41380-025-03244-1>
- Salazar de Pablo G et al. 2021. Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis. *JAMA Psychiatry*. 78(9):970–978. <https://doi.org/10.1001/jamapsychiatry.2021.0830>
- Salazar de Pablo G et al. 2021. Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. *Schizophr Bull*. 47(2):284–297. <https://doi.org/10.1093/schbul/sbaa120>
- Salazar de Pablo G, Woods SW, Drymonitou G, de Diego H, Fusar-Poli P. 2021. Prevalence of individuals at clinical high-risk of psychosis in the general population and clinical samples: systematic review and meta-analysis. *Brain Sci*. 11(11):1544. <https://doi.org/10.3390/brainsci11111544>
- Schimmelmann BG, Michel C, Martz-Irngartinger A, Linder C, Schultze-Lutter F. 2015. Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: findings from

- the BEAR and BEARS-kid studies. *World Psychiatry*. 14(2):189–197. <https://doi.org/10.1002/wps.20216>
- Schmidt A et al. 2020. Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis. *Transl Psychiatry*. 10(1):203. <https://doi.org/10.1038/s41398-020-00885-4>
- Schmidt SJ et al. 2015. EPA guidance on the early intervention in clinical high risk states of psychoses. *Eur Psychiatry*. 30(3):388–404. <https://doi.org/10.1016/j.eurpsy.2015.01.013>
- Schoresanitis G et al. 2024. The European psychiatric association (EPA) - early career psychiatrists committee survey on trainees' and early-career psychiatrists' attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. *World J Biol Psychiatry*. 25(6):342–351. <https://doi.org/10.1080/15622975.2024.2367138>
- Schultze-Lutter F et al. 2012. Basic symptoms and the prediction of first-episode psychosis. *Curr Pharm Des*. 18(4):351–357. <https://doi.org/10.2174/138161212799316064>
- Shah JL et al. 2017. Is the clinical high-risk state a valid concept? retrospective examination in a first-episode psychosis sample. *Psychiatr Serv*. 68(10):1046–1052. <https://doi.org/10.1176/appi.ps.201600304>
- Sherman BJ, McRae-Clark AL. 2016. Treatment of cannabis use disorder: current science and future outlook. *Pharmacotherapy*. 36(5):511–535. <https://doi.org/10.1002/phar.1747>
- Simmonite M, Steeby CJ, Taylor SF. 2023. Medial frontal cortex gaba concentrations in psychosis spectrum and mood disorders: a meta-analysis of proton magnetic resonance spectroscopy studies. *Biol Psychiatry*. 93(2):125–136. <https://doi.org/10.1016/j.biopsych.2022.08.004>
- Sizer H et al. 2022. Outcomes for first-episode psychosis after entry via an at-risk mental state clinic compared to direct entry to a first episode of psychosis service: a systematic review and meta-analysis. *Schizophr Res*. 240:214–219. <https://doi.org/10.1016/j.schres.2021.12.019>
- Solmi M et al. 2021. Risk and protective factors for alcohol and tobacco related disorders: an umbrella review of observational studies. *Neurosci Biobehav Rev*. 121:20–28. <https://doi.org/10.1016/j.neubiorev.2020.11.010>
- Solmi M et al. 2023. Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. *Mol Psychiatry*. 28(1):354–368. <https://doi.org/10.1038/s41380-022-01727-z>
- Solmi M et al. 2023. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. *BMJ*. 382:e072348. <https://doi.org/10.1136/bmj-2022-072348>
- Solmi M et al. 2021. Risk and protective factors for mental disorders with onset in childhood/adolescence: an umbrella review of published meta-analyses of observational longitudinal studies. *Neurosci Biobehav Rev*. 120:565–573. <https://doi.org/10.1016/j.neubiorev.2020.09.002>
- Solmi M et al. 2021. Risk and protective factors for personality disorders: an umbrella review of published meta-analyses of case-control and cohort studies. *Front Psychiatry*. 12:679379. <https://doi.org/10.3389/fpsy.2021.679379>
- Solmi M et al. 2021. Risk and protective factors for cannabis, cocaine, and opioid use disorders: an umbrella review of meta-analyses of observational studies. *Neurosci Biobehav Rev*. 126:243–251. <https://doi.org/10.1016/j.neubiorev.2021.03.014>
- Solmi M et al. 2021. Disparities in screening and treatment of cardiovascular diseases in patients with mental disorders across the world: systematic review and meta-analysis of 47 observational studies. *Am J Psychiatry*. 178(9):793–803. <https://doi.org/10.1176/appi.ajp.2021.21010031>
- Solmi M et al. 2020. Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. *Lancet Psychiatry*. 7(1):52–63. [https://doi.org/10.1016/S2215-0366\(19\)30414-6](https://doi.org/10.1016/S2215-0366(19)30414-6)
- Solmi M et al. 2017. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. *Ther Clin Risk Manag*. 13:757–777. <https://doi.org/10.2147/TCRM.S117321>
- Solmi M et al. 2022. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Mol Psychiatry*. 27(1):281–295. <https://doi.org/10.1038/s41380-021-01161-7>
- Solmi M et al. 2021. Risk factors for eating disorders: an umbrella review of published meta-analyses. *Braz J Psychiatry*. 43(3):314–323. <https://doi.org/10.1590/1516-4446-2020-1099>
- Solmi M et al. 2023. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. *Mol Psychiatry*. 28(12):5319–5327. <https://doi.org/10.1038/s41380-023-02138-4>
- Solmi M et al. 2023. Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment. *Mol Psychiatry*. 28(6):2291–2300. <https://doi.org/10.1038/s41380-023-02029-8>
- Solmi M et al. 2020. Factors associated with loneliness: an umbrella review of observational studies. *J Affect Disord*. 271:131–138. <https://doi.org/10.1016/j.jad.2020.03.075>
- Sprungli-Toffel E et al. 2024. Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disorders. *Span J Psychiatry Ment Health*. 18(2):133–140. <https://doi.org/10.1016/j.sjpmh.2024.09.001>
- Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. 2013. Early interventions to prevent psychosis: systematic review and meta-analysis. *BMJ*. 346(jan18 1):f185–f185. <https://doi.org/10.1136/bmj.f185>
- Stain HJ et al. 2016. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPT) trial. *Schizophr Res*. 176(2-3):212–219. <https://doi.org/10.1016/j.schres.2016.08.008>
- Stefana A et al. 2025. The mini-CAARMS: development and validation of a short version of the comprehensive assessment of at risk mental states to facilitate preventive psychiatry. *Schizophr Bull*. <https://doi.org/10.1093/schbul/sbaf146>
- Stefanelli R et al. 2025. The semi-structured interview for bipolar at-risk states (SIBARS): psychometric properties and validation. *J Affect Disord*. 387:119529. <https://doi.org/10.1016/j.jad.2025.119529>
- Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU, Jeppesen P. 2016. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in

- children and adolescents: a systematic review. *J Child Adolesc Psychopharmacol.* 26(5):410–427. <https://doi.org/10.1089/cap.2015.0097>
- Stubbs B et al. 2016. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. *BMC Med.* 14(1):189. <https://doi.org/10.1186/s12916-016-0734-z>
- Stubbs B et al. 2018. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). *Eur Psychiatry.* 54:124–144. <https://doi.org/10.1016/j.eurpsy.2018.07.004>
- Studerus E, Beck K, Fusar-Poli P, Riecher-Rossler A. 2020. Development and validation of a dynamic risk prediction model to forecast psychosis onset in patients at clinical high risk. *Schizophr Bull.* 46(2):252–260. <https://doi.org/10.1093/schbul/sbz059>
- Sullivan SA et al. 2022. Developing and internally validating a prognostic model (P Risk) to improve the prediction of psychosis in a primary care population using electronic health records: the MAPPED study. *Schizophr Res.* 246:241–249. <https://doi.org/10.1016/j.schres.2022.06.031>
- Taipale H et al. 2022. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. *JAMA Psychiatry.* 79(3):210–218. <https://doi.org/10.1001/jama-psychiatry.2021.3990>
- Tang Y et al. 2023. Visuospatial learning selectively enhanced by personalized transcranial magnetic stimulation over parieto-hippocampal network among patients at clinical high-risk for psychosis. *Schizophr Bull.* 49(4):923–932. <https://doi.org/10.1093/schbul/sbad015>
- Td K, Rcw M JJ, JR, Lb G CW, BF, MN, By G, Bh E. 2018. White matter organization and cognition in patients at ultra-high risk for psychosis: preliminary results from the FOCUS-trial. *Early Interv Psychiatry.* 12.
- Tsai CL et al. 2021. Effects of the health-awareness-strengthening lifestyle program in a randomized trial of young adults with an at-risk mental state. *Int J Environ Res Public Health.* 18(4):1959. <https://doi.org/10.3390/ijerph18041959>
- Valmaggia LR et al. 2015. Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. *Br J Psychiatry.* 207(2):130–134. <https://doi.org/10.1192/bjp.bp.114.150623>
- Valmaggia LR et al. 2009. Economic impact of early intervention in people at high risk of psychosis. *Psychol Med.* 39(10):1617–1626. <https://doi.org/10.1017/S0033291709005613>
- van der Gaag M et al. 2012. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. *Schizophr Bull.* 38(6):1180–1188. <https://doi.org/10.1093/schbul/sbs105>
- van der Gaag M et al. 2013. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. *Schizophr Res.* 149(1-3):56–62. <https://doi.org/10.1016/j.schres.2013.07.004>
- Vissink CE et al. 2022. Structural brain volumes of individuals at clinical high risk for psychosis: a meta-analysis. *Biol Psychiatry Glob Open Sci.* 2(2):147–152. <https://doi.org/10.1016/j.bpsgos.2021.09.002>
- Waite F et al. 2023. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial. *Lancet Psychiatry.* 10(9):706–718. [https://doi.org/10.1016/S2215-0366\(23\)00203-1](https://doi.org/10.1016/S2215-0366(23)00203-1)
- Walter A et al. 2016. Hippocampal volume in subjects at clinical high-risk for psychosis: a systematic review and meta-analysis. *Neurosci Biobehav Rev.* 71:680–690. <https://doi.org/10.1016/j.neubiorev.2016.10.007>
- Wannan CMJ et al. 2024. Accelerating medicines partnership(r) schizophrenia (AMP(R) SCZ): rationale and study design of the largest global prospective cohort study of clinical high risk for psychosis. *Schizophr Bull.* 50(3):496–512. <https://doi.org/10.1093/schbul/sbae011>
- Wasserthal S et al. 2024. N-acetylcysteine and a specialized preventive intervention for individuals at high risk for psychosis: a randomized double-blind multicenter trial. *Schizophr Bull Open.* 5(1):sgae005. <https://doi.org/10.1093/schizbullopen/sgae005>
- Wenneberg C et al. 2020. Cerebral glutamate and GABA levels in high-risk of psychosis states: a focused review and meta-analysis of (1)H-MRS studies. *Schizophr Res.* 215:38–48. <https://doi.org/10.1016/j.schres.2019.10.050>
- Wessels H et al. 2019. Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis. *Early Interv Psychiatry.* 13(1):120–127. <https://doi.org/10.1111/eip.12460>
- Wijnen BFM et al. 2020. Designing and testing of a health-economic markov model for prevention and treatment of early psychosis. *Expert Rev Pharmacoecon Outcomes Res.* 20(3): 269–279. <https://doi.org/10.1080/14737167.2019.1632194>
- Wilson R et al. 2019. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. *Transl Psychiatry.* 9(1):203. <https://doi.org/10.1038/s41398-019-0534-2>
- Wolff RF, P. et al. 2019. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. *Ann Intern Med.* 170(1):51–58. <https://doi.org/10.7326/M18-1376>
- Woods S et al. 2017. 112. Effects of ziprasidone versus placebo in patients at clinical high risk for psychosis. *Schizophr Bull.* p. S58.
- Woods SW, 3rd et al. 2021. Counterpoint. Early intervention for psychosis risk syndromes: minimizing risk and maximizing benefit. *Schizophr Res.* 227:10–17. <https://doi.org/10.1016/j.schres.2020.04.020>
- Woods SW et al. 2024. Development of the PSYCHS: positive SYmptoms and Diagnostic Criteria for the CAARMS harmonized with the SIPS. *Early Interv Psychiatry.* 18(4):255–272. <https://doi.org/10.1111/eip.13457>
- Woods SW et al. 2013. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. *Eur Neuropsychopharmacol.* 23(8):931–940. <https://doi.org/10.1016/j.euroneuro.2012.09.008>
- Worthington MA et al. 2022. Individualized prediction of prodromal symptom remission for youth at clinical high risk for psychosis. *Schizophr Bull.* 48(2):395–404. <https://doi.org/10.1093/schbul/sbab115>
- Worthington MA et al. 2021. Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis. *Schizophr Res.* 227:95–100. <https://doi.org/10.1016/j.schres.2020.09.022>

- Yassin W et al. 2020. Machine-learning classification using neuroimaging data in schizophrenia, autism, ultra-high risk and first-episode psychosis. *Transl Psychiatry*. 10(1):278. <https://doi.org/10.1038/s41398-020-00965-5>
- Yoviene Sykes LA et al. 2020. Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. *Schizophr Res*. 216:184–191. <https://doi.org/10.1016/j.schres.2019.12.002>
- Yung AR et al. 2011. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. *J Clin Psychiatry*. 72(4):430–440. <https://doi.org/10.4088/JCP.08m04979ora>
- Yung AR et al. 2005. Mapping the onset of psychosis: the Comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry*. 39(11-12):964–971. <https://doi.org/10.1080/j.1440-1614.2005.01714.x>
- Zarogianni E et al. 2019. Individualized prediction of psychosis in subjects with an at-risk mental state. *Schizophr Res*. 214:18–23. <https://doi.org/10.1016/j.schres.2017.08.061>
- Zeng J et al. 2023. A meta-analysis of neural correlates of reward anticipation in individuals at clinical risk for schizophrenia. *Int J Neuropsychopharmacol*. 26(4):280–293. <https://doi.org/10.1093/ijnp/pyad009>
- Zhang T et al. 2019. Prediction of psychosis in prodrome: development and validation of a simple, personalized risk calculator. *Psychol Med*. 49(12):1990–1998. <https://doi.org/10.1017/S0033291718002738>
- Zhao J et al. 2023. EMDR versus waiting list in individuals at clinical high risk for psychosis with post-traumatic stress symptoms: a randomized controlled trial. *Schizophr Res*. 256:1–7. <https://doi.org/10.1016/j.schres.2023.04.003>
- Zhao Y et al. 2022. Cortical thickness abnormalities at different stages of the illness course in schizophrenia: a systematic review and meta-analysis. *JAMA Psychiatry*. 79(6):560–570. <https://doi.org/10.1001/jamapsychiatry.2022.0799>
- Zheng Y et al. 2022. Cognitive behavioral therapy for prodromal stage of psychosis-outcomes for transition, functioning, distress, and quality of life: a systematic review and meta-analysis. *Schizophr Bull*. 48(1):8–19. <https://doi.org/10.1093/schbul/sbab044>
- Zhu H et al. 2023. Effect of Shi-Zhen-An-Shen herbal formula granule in the treatment of young people at ultra-high risk for psychosis: a pilot study. *Front Psychiatry*. 14:1160452. <https://doi.org/10.3389/fpsy.2023.1160452>
- Zhu Y et al. 2024. Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk. *Mol Psychiatry*. 29(5):1465–1477. <https://doi.org/10.1038/s41380-024-02426-7>